-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FqqDqQjktPT2TZQX2j6PXcoQq+HYU0XM11F8c4GOXqI6nnRIvc9awKc9S2IMGLDg
 ug4WkO5pVH9LHYBchNh6rw==

<SEC-DOCUMENT>0000014272-01-500006.txt : 20010409
<SEC-HEADER>0000014272-01-500006.hdr.sgml : 20010409
ACCESSION NUMBER:		0000014272-01-500006
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20001231
FILED AS OF DATE:		20010402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		1588817

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>r10k1231.htm
<TEXT>

<HTML>
<HEAD>
<TITLE>PART I</TITLE>
</HEAD>
<BODY>
<P ALIGN="CENTER"><font color="#000000"><B><FONT SIZE=5>SECURITIES AND EXCHANGE
  COMMISSION</font></b></font></P>
<FONT SIZE=2>
<P ALIGN="CENTER"><font color="#000000">WASHINGTON, D.C. 20549</font></P>
<P ALIGN="CENTER"></P>
</FONT><B><FONT SIZE=5>
<P ALIGN="CENTER"><font color="#000000">FORM 10-K</font></P>
</font></B><FONT SIZE=2>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER"><font color="#000000">[X] ANNUAL REPORT PURSUANT TO SECTION
  13 OR 15(d) OF THE</font></P>
<P ALIGN="CENTER"><font color="#000000">SECURITIES EXCHANGE ACT OF 1934 </font></P>
<P ALIGN="CENTER"></P>
</FONT><B><FONT SIZE=5>
<P ALIGN="CENTER"><font color="#000000">For the fiscal year ended December 31,
  2000</font></P>
</font></B><FONT SIZE=2>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER"><font color="#000000">Commission File Number 1-1136</font></P>
<P ALIGN="CENTER"></P>
</FONT><B><FONT SIZE=5>
<P ALIGN="CENTER"><font color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></P>
</font></B><FONT SIZE=2>
<P ALIGN="CENTER"><font color="#000000">(Exact name of registrant as specified
  in its charter)</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=642>
  <TR>
    <TD WIDTH="55%" VALIGN="TOP"> <B><FONT SIZE=3>
      <P ALIGN="CENTER">Delaware
      </font></B></TD>
    <TD WIDTH="45%" VALIGN="TOP"> <B><FONT SIZE=3>
      <P ALIGN="CENTER">22-079-0350
      </font></B></TD>
  </TR>
  <TR>
    <TD WIDTH="55%" VALIGN="TOP"> <FONT SIZE=3>
      <P ALIGN="CENTER">(State or other jurisdiction of</P>
      <P ALIGN="CENTER">incorporation or organization)
      </FONT></TD>
    <TD WIDTH="45%" VALIGN="TOP"> <FONT SIZE=3>
      <P ALIGN="CENTER">(IRS Employer Identification No.)</P>
      <B>
      <P ALIGN="CENTER">
      </B></FONT></TD>
  </TR>
</TABLE>
<FONT SIZE=2>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER"><font color="#000000">345 Park Avenue, New York, N.Y. 10154</font></P>
<P ALIGN="CENTER"><font color="#000000">(Address of principal executive offices)</font></P>
<P ALIGN="CENTER"><font color="#000000">Telephone: (212) 546-4000</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Securities registered pursuant to Section
  12(b) of the Act:</font></P>
<P ALIGN="JUSTIFY"></P>
</FONT>
<P ALIGN="CENTER">
<CENTER>
  <TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=556>
    <TR bgcolor="" align="none">
      <TD WIDTH="49%" VALIGN="TOP" height="41" align="none"><b><U><FONT SIZE=2>
        <P><font size="3">Title of each class </font>
        </font></U></b></TD>
      <TD WIDTH="51%" VALIGN="TOP" height="41"><b><FONT SIZE=3>
        <P><u>Name of each exchange on which registered</u></P>
        </FONT></b></TD>
    </TR>
    <TR bgcolor="">
      <TD WIDTH="49%" VALIGN="TOP" HEIGHT=37 align="none"> <FONT SIZE=2>
        <P ALIGN="JUSTIFY">Common Stock, $.10 Par Value
        </FONT></TD>
      <TD WIDTH="51%" VALIGN="TOP" HEIGHT=37> <FONT SIZE=2>
        <P ALIGN="JUSTIFY">New York Stock Exchange</P>
        <P ALIGN="JUSTIFY">Pacific Exchange, Inc.
        </FONT></TD>
    </TR>
    <TR bgcolor="">
      <TD WIDTH="49%" VALIGN="TOP" HEIGHT=10 align="none">
        <P></P>
      </TD>
      <TD WIDTH="51%" VALIGN="TOP" HEIGHT=10>
        <P></P>
      </TD>
    </TR>
    <TR bgcolor="">
      <TD WIDTH="49%" VALIGN="TOP" align="none"> <FONT SIZE=2>
        <P ALIGN="JUSTIFY">$2 Convertible Preferred Stock, $1 Par Value
        </FONT></TD>
      <TD WIDTH="51%" VALIGN="TOP"> <FONT SIZE=2>
        <P ALIGN="JUSTIFY">New York Stock Exchange</P>
        <P ALIGN="JUSTIFY">Pacific Exchange, Inc.
        </FONT></TD>
    </TR>
  </TABLE>
</CENTER>
<p></P>
<FONT SIZE=2>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Securities registered pursuant to Section
  12(g) of the Act: None</font></P>
<P ALIGN="JUSTIFY"></P>
<B>
<P ALIGN="JUSTIFY"><font color="#000000">Indicate by check mark if disclosure
  of delinquent filers pursuant to Item 405 of Regulation S-K is not contained
  herein, and will not be contained, to the best of the registrant's knowledge,
  in definitive proxy or information statements incorporated by reference in Part
  III of this Form 10-K or any amendment to this Form 10-K. [X]</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Indicate by check mark whether the registrant
  (1) has filed all reports required to be filed by Section 13 or 15(d) of the
  Securities Exchange Act of 1934 during the preceding 12 months (or for such
  shorter period that the registrant was required to file such reports), and (2)
  has been subject to such filing requirements for the past 90 days. Yes [X] No
  [ ]</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">The aggregate market value of voting
  stock held by non-affiliates of the registrant as of February 28, 2001 was $123,348,473,200.
  At February 28, 2001, there were 1,948,495,117 shares of common stock outstanding.</font></P>
</B><U>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER"><font color="#000000">Documents incorporated by reference</font></P>
</U><B>
<P ALIGN="CENTER"></P>
</B>
<P ALIGN="JUSTIFY"><font color="#000000">Proxy Statement for Annual Meeting of
  Stockholders on Mary 1, 2001 Part III</font></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><B><U>
<P></P>
<P ALIGN="CENTER"><font color="#000000">PART I</font></P>
</u></B>
<P><font color="#000000">Item 1. BUSINESS</font></P>
<U>
<P><font color="#000000">DESCRIPTION OF BRISTOL-MYERS SQUIBB COMPANY</font></P>
</U> <U>
<P><font color="#000000">General:</font></P>
</U>
<P ALIGN="JUSTIFY"><font color="#000000">Bristol-Myers Squibb Company ("Bristol-Myers
  Squibb" or the "Company") was incorporated under the laws of the State of Delaware
  in August 1933 under the name Bristol-Myers Company as successor to a New York
  business started in 1887. In 1989, the Bristol-Myers Company changed its name
  to Bristol-Myers Squibb Company, as a result of a merger. The Company, through
  its divisions and subsidiaries, is a major producer and distributor in one significant
  business segment - medicines. Operations of the Nutritional and ConvaTec businesses
  are not material to the financial statements. In general, the business of the
  Company is not seasonal.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">On September 28, 2000, the Company announced
  the planned divestiture of its Clairol and Zimmer businesses in 2001. The Company
  announced on February 22, 2001 its intention to separate the Zimmer business
  in a tax-free spin-off to shareholders. Completion is expected by the end of
  the third quarter of 2001. Accordingly, the operations of these businesses have
  been reflected as discontinued operations in the financial statements.</font></P>
<FONT SIZE=2>
<P ALIGN="JUSTIFY"></P>
</FONT>
<P ALIGN="JUSTIFY"><font color="#000000">Sales of selected products and product
  categories from continuing operations are as follows:<br>
  </font></P>
<P ALIGN="JUSTIFY"></P>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=630>
  <TR bgcolor="" align="none">
    <TD WIDTH="59%" VALIGN="TOP" align="none">&nbsp;</TD>
    <TD WIDTH="14%" VALIGN="TOP"><b> <U>
      <P ALIGN="RIGHT">2000
      </U></b></TD>
    <TD WIDTH="14%" VALIGN="TOP"><b> <U>
      <P ALIGN="RIGHT">1999
      </U></b></TD>
    <TD WIDTH="14%" VALIGN="TOP"><b> <U>
      <P ALIGN="RIGHT">1998
      </U></b></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=13 align="none"><i>
      <P></P>
      </i></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=13>
      <P></P>
    </TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=13>
      <P></P>
    </TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=13>
      <P></P>
    </TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">PRAVACHOL*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18>
      <P ALIGN="RIGHT">$1,817
    </TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18>
      <P ALIGN="RIGHT">$1,704
    </TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">$1,643
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">GLUCOPHAGE
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,732
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,317
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">862
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">TAXOL*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,592
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,481
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,206
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Oncology Therapeutics Network
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,080
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">894
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">657
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">PLAVIX
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">903
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">547
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">144
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">BUSPAR*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">709
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">605
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">531
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">PARAPLATIN*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">690
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">600
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">525
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">ZERIT*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">618
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">605
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">551
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">MONOPRIL*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">442
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">424
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">380
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">CEFZIL*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">391
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">402
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">358
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">AVAPRO
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">381
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">255
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">123
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">SERZONE*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">360
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">332
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">257
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">CAPOTEN*/CAPOZIDE*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">356
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">484
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">636
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">EXCEDRIN*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">233
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">240
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">241
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" HEIGHT=18 align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">VIDEX*
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">202
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">205
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP" HEIGHT=18> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">162
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Infant formulas
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP">
      <P ALIGN="RIGHT">1,212
    </TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,233
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">1,203
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Ostomy
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">428
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">449
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">464
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="59%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Wound Care
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">232
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">238
      </FONT></TD>
    <TD WIDTH="14%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="RIGHT">239
      </FONT></TD>
  </TR>
</TABLE>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></P>
<P ALIGN="center"><font color="#000000">2<font size="1"> </font></font></P>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=90%>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP">
      <P ALIGN="JUSTIFY">PRAVACHOL*</P>
    </TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">pravastatin sodium, an HMG Co-A reductase inhibitor indicated
        for primary hypercholestermia. Patents expire in the U.S. in October 2005
        and in international markets from 2000 through 2010.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">GLUCOPHAGE
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">metformin, an oral anti-diabetes agent for type 2 non-insulin-dependent
        diabetes. Hatch-Waxman exclusivity expired in September 2000; however,
        no generic competition existed at the end of the year.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P>TAXOL*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP">
      <P ALIGN="JUSTIFY"><FONT FACE="CG Times">p</font>aclitaxel, used in the
        treatment of refractory ovarian cancer, first-line treatment of ovarian
        cancer in combination with cisplatin, second-line treatment of AIDS- related
        Kaposi's Sarcoma, treatment of metastatic breast cancer after failure
        of combination chemotherapy, adjuvant treatment of node positive breast
        cancer and in the treatment of non-small cell lung carcinoma with cisplatin.
        Reference is also made to Item 3 Legal Proceedings in Part 1 of this Form
        10-K Annual Report and to Note 17 Litigation in Part 2, Item 8, of this
        Form 10-K Annual Report.
    </TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP" HEIGHT=42> <FONT FACE="CG Times">
      <P>Oncology Therapeutics Network
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP" HEIGHT=42> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">a specialty distributor of anti-cancer medicines and
        related products.</P>
      <P ALIGN="JUSTIFY">
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">PLAVIX
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">clopidogrel, a platelet inhibitor, co-developed and jointly
        marketed with Sanofi-Synthelabo.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">BUSPAR*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">buspirone, a novel anti-anxiety agent for persistent
        anxiety with or without accompanying depressive symptoms. The US anxiolytic
        use patent expired on May 22, 2000. The Food and Drug Administration granted
        the company an additional six months exclusivity based on its performance
        of pediatric studies. Patents outside of the US expired in 1999. Reference
        is made to the discussion on BUSPAR* in Item 7 in Part 2 of this Form
        10-K Annual Report.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">PARAPLATIN*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">carboplatin, a chemotherapeutic agent used in the treatment
        of ovarian cancer. Patent expired in France in June 2000 and expires in
        the US in April 2004.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">ZERIT*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">stavudine, used in the treatment of persons with advanced
        HIV disease. Patent expires in the US in June 2008 and internationally
        from 2007 through 2011.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">MONOPRIL*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">fosinopril sodium, a second-generation ACE inhibitor
        with once-a-day dosing indicated for the treatment of hypertension. Composition
        of matter US patent expires in December 2002 and in international markets
        from 2001 through 2008.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY"></P>
      <P ALIGN="JUSTIFY">CEFZIL*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">cefprozil, an oral cephalosporin used in the treatment
        of respiratory infections and sinusitis. US patent expires in December
        2005 and in international markets from 2003 through 2008.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">AVAPRO
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">irbesartan, an angiotensin II receptor antagonist indicated
        for the treatment of hypertension, CO-developed and jointly marketed with
        Sanofi-Synthelabo.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">SERZONE*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">nefazodone, an antidepressant treatment. Patent expires
        in the US in March 2003 and internationally from 2002 through 2010.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">CAPOTEN*/<BR>
        CAPOZIDE*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">captopril, an angiotensin converting enzyme (ACE) inhibitor.
        Patents have expired in the US and in all significant international markets.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">EXCEDRIN*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">an analgesic with acetaminophen and caffeine. EXCEDRIN*
        Migraine is indicated for the treatment of the full migraine syndrome.
      </FONT></TD>
  </TR>
  <TR>
    <TD WIDTH="24%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">VIDEX*
      </FONT></TD>
    <TD WIDTH="76%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">didanosine, an antiretroviral drug used in the treatment
        of adult and pediatric patients with advanced human immunodeficiency virus
        (HIV) infection. Patent expires in the US in August 2006 and internationally
        from 2006 through 2009.
      </FONT></TD>
  </TR>
</TABLE>
<FONT FACE="CG Times">
<P ALIGN="JUSTIFY"><font color="#000000">* Indicates brand names of products which
  are registered trademarks owned by the Company.</font></P>
</FONT><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font><font size="2" color="#000000">
</font><FONT SIZE=2>
<P ALIGN="JUSTIFY"></P>
</FONT><FONT FACE="CG Times">
<P ALIGN="center"><font color="#000000">3</font></P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">SOURCES AND AVAILABILITY OF RAW MATERIALS</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">In general, Bristol-Myers Squibb purchases
  its principal raw materials and supplies in the open market. Substantially all
  such materials are obtainable from a number of sources so that the loss of any
  one source of supply would not have a material adverse effect on the Company.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">PATENTS, TRADEMARKS AND LICENSES</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">The Company owns or is licensed under
  a number of patents in the United States and foreign countries covering products,
  and has also developed many brand names and trademarks for products. The Company
  considers the overall protection of its patent, trademark and license rights
  to be of material value and acts to protect these rights from infringement.
  In the years 2001 and 2002 exclusivity periods are scheduled to expire or have
  expired for MONOPRIL* and certain TAXOL* claims. The Company believes that no
  single patent or license is of material importance in relation to the business
  as a whole. </font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">COMPETITION, DISTRIBUTION AND CUSTOMERS</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">The markets in which Bristol-Myers Squibb
  competes are generally broad-based and highly competitive. The principal means
  of competition utilized to market the products of Bristol-Myers Squibb include
  quality, service, price and product performance. Pharmaceutical products and
  the products of ConvaTec are promoted on a national and international basis
  in medical journals and directly to the medical profession. The Company is also
  utilizing direct-to-consumer advertising for a number of its pharmaceutical
  products. Most of the other products of Bristol-Myers Squibb are generally advertised
  and promoted on a national and international basis through the use of television,
  radio, print media, consumer offers, and window and in-store displays. Bristol-Myers
  Squibb's products are principally sold to the wholesale and retail trade both
  nationally and internationally. Certain products are also sold to other drug
  manufacturers, hospitals and the medical profession. Two wholesalers accounted
  for approximately 13% and 12% of net sales from continuing operations in 2000.</font></P>
<font color="#000000">_____________________________________________________________________________________________
</font>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="center"><font color="#000000">4</font></P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">RESEARCH AND DEVELOPMENT</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Research and development is essential
  to Bristol-Myers Squibb's business. Pharmaceutical research and development
  is carried out by the Bristol-Myers Squibb Pharmaceutical Research Institute,
  which has major facilities in Princeton, Hopewell and New Brunswick, New Jersey
  and Wallingford, Connecticut. Pharmaceutical research and development is also
  carried out at various other facilities in the United States and in Belgium,
  Canada, France, Italy and the United Kingdom. Management continues to emphasize
  leadership, innovation and productivity as strategies for success in the Research
  Institute.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Bristol-Myers Squibb spent $1,939 million
  in 2000, $1,759 million in 1999 and $1,506 million in 1998 on Company sponsored
  research and development activities. Pharmaceutical research and development
  spending, as a percentage of pharmaceutical sales, was 13.0% in 2000 compared
  with 12.6% in 1999 and 12.4% in 1998.</font></P>
<P ALIGN="JUSTIFY"></P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">REGULATION</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Most aspects of the Company's business
  are subject to some degree of government regulation in the countries in which
  its operations are conducted. The Company's policy is to comply fully with all
  regulatory requirements applying to its products and operations. For some products,
  and in some countries, government regulation is significant and, in general,
  there is a trend to more stringent regulation. The Company devotes significant
  time, effort and expense addressing the extensive governmental regulatory requirements
  applicable to its business. Governmental regulatory actions can result in the
  recall or seizure of products, suspension or revocation of the authority necessary
  for the production or sale of a product, and other civil and criminal sanctions.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">In the United States, the drug, medical
  device, diagnostic and food industries in which the Company operates have long
  been subject to regulation by various federal, state and local agencies, primarily
  as to product manufacture, safety, efficacy, advertising and labeling. </font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">In addition, governmental bodies in the
  United States as well as other countries have expressed concern about costs
  relating to health care and, in some cases, have focused attention on the pricing
  of drugs and on appropriate drug utilization. Government regulation in these
  areas already exists in some countries and may be expanded significantly in
  the United States and other countries in the future.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">While the Company is unable to predict
  the extent to which its business may be affected by future regulatory developments,
  it believes that its substantial experience dealing with governmental regulatory
  requirements and restrictions on its operations throughout the world and its
  development of new and improved products should enable it to compete effectively
  within this environment.</font></P>
</FONT>
<p align="center"><font face="CG Times" color="#000000">_____________________________________________________________________________________________
  5</font></p>
<p>&nbsp;</p>
<FONT FACE="CG Times">
<P ALIGN="JUSTIFY"></P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">EMPLOYEES</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Bristol-Myers Squibb employees from continuing
  operations were approximately 44,000 people at December 31, 2000.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U>
<P ALIGN="JUSTIFY"><font color="#000000">DOMESTIC AND FOREIGN OPERATIONS</font></P>
</U>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Reference is made to Note 12 Financial
  Instruments, and Note 14 Segment Information in the Notes to Consolidated Financial
  Statements included in Part II, Item 8 of this Form 10-K Annual Report.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">International operations are subject
  to certain risks which are inherent in conducting business abroad, including
  possible nationalization or expropriation, price and exchange controls, limitations
  on foreign participation in local enterprises and other restrictive governmental
  actions. In addition, changes in the relative value of currencies take place
  from time to time and their effects may be favorable or unfavorable on Bristol-Myers
  Squibb's operations. There are currency restrictions relating to repatriation
  of earnings in certain countries.</font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P>&nbsp;</P>
<P><font color="#000000">Item 2. PROPERTIES. </font></P>
<P ALIGN="JUSTIFY"><font color="#000000">Bristol-Myers Squibb's world headquarters
  is located at 345 Park Avenue, New York, New York, where it leases approximately
  460,000 square feet of floor space, approximately 206,300 square feet of which
  is sublet to others. </font></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><font color="#000000">Bristol-Myers Squibb manufactures products
  at forty major worldwide locations with an aggregate floor space of approximately
  12,800,000 square feet. All facilities are owned by Bristol-Myers Squibb. The
  following table illustrates the geographic location of the Company's significant
  manufacturing facilities. </font></P>
<P>&nbsp;</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=333>
  <TR bgcolor="" align="none">
    <TD WIDTH="62%" VALIGN="TOP" align="none">&nbsp;</TD>
    <TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="62%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">United States
      </FONT></TD>
    <TD WIDTH="38%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">15
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="62%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Europe, Mid East and Africa
      </FONT></TD>
    <TD WIDTH="38%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">11
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="62%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Other Western Hemisphere
      </FONT></TD>
    <TD WIDTH="38%" VALIGN="TOP"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY"> 9
      </FONT></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="62%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Pacific
      </FONT></TD>
    <TD WIDTH="38%" VALIGN="TOP"> <U><FONT FACE="CG Times">
      <P ALIGN="JUSTIFY"> 5
      </font></U></TD>
  </TR>
  <TR bgcolor="">
    <TD WIDTH="62%" VALIGN="TOP" align="none"> <FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">Total
      </FONT></TD>
    <TD WIDTH="38%" VALIGN="TOP"> <U><FONT FACE="CG Times">
      <P ALIGN="JUSTIFY">40
      </font></U></TD>
  </TR>
</TABLE>
<FONT FACE="CG Times">
<P ALIGN="JUSTIFY"><font color="#000000">&#9;</font></P>
<P ALIGN="JUSTIFY"><font color="#000000">Portions of these facilities and other
  facilities owned or leased by Bristol-Myers Squibb in the United States and
  elsewhere are used for research, administration, storage and distribution. Bristol-Myers
  Squibb's facilities are well-maintained, adequately insured and in satisfactory
  condition.</font></P>
<P>&nbsp;</P>
</FONT>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________<br>
  </font></p>
<p align="center"><font face="CG Times" color="#000000">6</font> </p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 3. LEGAL PROCEEDINGS.
  </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Various lawsuits, claims
  and proceedings of a nature considered normal to its businesses are pending
  against the Company and certain of its subsidiaries. The most significant of
  these are described below.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Reference is made to
  Note 17 Litigation in the Notes to the Consolidated Financial Statements included
  in Part II, Item 8 of this Report. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">Breast Implant
  Litigation</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company, together
  with its subsidiary, Medical Engineering Corporation (MEC), and certain other
  companies, has been named as a defendant in a number of claims and lawsuits
  alleging damages for personal injuries of various types resulting from polyurethane-covered
  breast implants and smooth-walled breast implants formerly manufactured by MEC
  or a related Company. Of the more than 90,000 claims or potential claims against
  the Company in direct lawsuits or through registration in the nationwide class
  action settlement approved by the Federal District Court in Birmingham, Alabama
  (the "Revised Settlement"), most have been dealt with through the Revised Settlement,
  other settlements, or trial. As of December 31, 2000, the Company's contingent
  liability in respect of breast implant claims was limited to residual unpaid
  Revised Settlement obligations and to roughly 850 remaining opt-outs who have
  pursued or may pursue their claims in court.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">As of December 31, 2000,
  approximately 4,790 United States and 310 foreign breast implant recipients
  were plaintiffs in lawsuits pending in federal and state courts in the United
  States and certain courts in Canada and Australia. These figures include the
  claims of plaintiffs that are in the process of being settled and/or dismissed.
  In these lawsuits, about 2,140 US and 68 foreign plaintiffs opted out of the
  Revised Settlement. The lawsuits of the 2,650 US plaintiffs who did not opt
  out are expected to be dismissed since these plaintiffs are among the estimated
  74,000 women with MEC implants who chose to participate in the nationwide settlement.
  Of the 2,140 opt-out plaintiffs, an estimated 1,290 have claims based upon products
  that were not manufactured or sold by MEC or that have been or are in the process
  of being settled and/or dismissed. Accordingly, the number of remaining plaintiffs
  who have pursued or may pursue their claims in court against the Company is
  roughly 850, as stated in the preceding paragraph.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Under the terms of the
  Revised Settlement, additional opt-outs are expected to be minimal since the
  deadline for US class members to opt out has passed. In addition, the Company's
  remaining obligations under the Revised Settlement Program are limited because
  most payments to "Current Claimants" have already been made, no additional "Current
  Claims" may be filed without court approval, and because payments of claims
  to so-called "Other Registrants" and "Late Registrants" are limited by the terms
  of the Revised Settlement. Separate class action settlements have been approved
  in the provincial courts of Ontario and Quebec, and an agreement has been reached
  under which other foreign breast implant recipients may settle their claims.
  The Company believes it will be able to address remaining opt-out claims as
  well as expected remaining obligations under the Revised Settlement Program
  within its reserves described below.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Breast implants were
  manufactured by several companies, including MEC, which the Company acquired
  in 1982. Until 1991, MEC manufactured two types of breast implants, polyurethane-covered
  silicone breast implants and smooth-walled silicone breast implants. In these
  lawsuits, plaintiffs typically contend that silicone in breast implants causes
  systemic disease and/or local complications. Some plaintiffs with polyurethane-covered
  silicone implants contend that the polyurethane component causes injury, including
  cancer. Most of the disease claims involve non-specific complaints such as chronic
  fatigue, aches and pains and other symptoms that commonly affect the population
  at large. Many women claim local complications such as rupture, hardening or
  contracture, and disfigurement or scarring. The plaintiffs typically seek compensatory
  damages for alleged medical conditions and emotional distress as well as punitive
  damages. The defendants have based their defense in part on the lack of credible
  scientific evidence that breast implants cause disease. Many large-scale epidemiological
  studies have found no connection between breast implants and the alleged diseases.
  Defendants also contend that warnings set forth in the product literature adequately
  advised physicians and surgeons of the risks of local complications.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">7</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company is a participant
  in the national class action Revised Settlement Program approved on December
  22, 1995, by the federal court in Alabama (Lindsey, et al., v. Dow Corning,
  et al., CV-94-P-11558-S), before which all federal breast implant cases were
  consolidated for pretrial purposes. On January 16, 1996, the Company, Baxter
  Healthcare Corporation and Baxter International (collectively, Baxter), and
  Minnesota, Mining and Manufacturing Company (3M) (hereinafter, the Settling
  Defendants) each paid $125 million into a court-established fund as an initial
  reserve to pay claims under the Revised Settlement. The Company has made and
  will make additional contributions to the court-established fund.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The fifteen-year Revised
  Settlement, which ends on December 15, 2010, provides benefits to those US breast
  implant recipients who have had at least one breast implant manufactured by
  one of the Settling Defendants (or their related companies). For Current Claimants
  - those who submitted the proper documentation to the Claims Office in Houston
  by the 1994 deadline - benefits are payable regardless of the number of claimants
  seeking compensation, and regardless of the total dollar value of approved claims.
  For Other and Late Registrants - those who registered with the Claims Office
  after the Current Claimant deadline - benefits are subject to an aggregate $725
  million limit for the three Settling Defendants over the fifteen-year life of
  the program. The Company's individual aggregate limit for such benefits is $400
  million, $27.6 million annually for the first ten years, and $24.8 million annually
  for the last five years. Amounts unused in one year may be rolled over to pay
  claims in ensuing years. In the event the dollar value of the claims subject
  to these limits were to exceed the amounts available to pay claims, claimants
  may be afforded additional opt-out rights but without the right to assert punitive
  or other statutory multiple damage claims. The Company's obligations to make
  payments under the Revised Settlement are not affected by the number of class
  members electing to opt out of the settlement or the number of class members
  making claims under it except to the extent of the above-mentioned dollar limits.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In addition to individual
  suits and the Lindsey class action, the Company is a defendant, together with
  other defendants, in a class action certified on April 11, 1996, in the Canadian
  province of British Columbia, on the single issue of whether silicone gel breast
  implants are reasonably fit for their intended purpose (Harrington v. Dow Corning
  Corporation et al., Supreme Court, British Columbia, C954330). On March 31,
  2000, the federal government filed a civil suit in federal court in Birmingham,
  Alabama, against several parties in the breast implant litigation, including
  the Company. The government claims it is entitled to reimbursement for certain
  costs allegedly incurred in connection with the medical treatment provided to
  women with breast implants. The Company believes it will be able to address
  the government lawsuit within its reserves as described below.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company entered into
  several other settlements of breast implant-related claims. In July of 1995,
  the Company entered into a $20.5 million (US funds) class action settlement
  with plaintiff representatives in the provinces of Ontario and Quebec. The class
  includes persons who have or had MEC breast implants and who reside in Ontario</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">8</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000"> and Quebec or who received
  their MEC implants there. The settlement, which had minimal opt-outs, was approved
  by the provincial courts of Ontario and Quebec. In May of 1996, the Company,
  together with other Settling Defendants in the Revised Settlement Program, entered
  into a $50 million settlement of claims asserted by certain health insurers
  based upon payments made or benefits provided by insurers and represented health
  plans to participating registrants that allegedly involve or relate to silicone
  gel breast implants. The Company has contributed $22.5 million to the settlement
  which extinguished the potential claims of the majority of the US commercial
  and non-governmental health care insurer market against both the defendants
  and settlement class members. In November 1996, the benefits of the Revised
  Settlement were extended, with certain modifications, to foreign breast implant
  recipients. The Company paid roughly $5.3 million into a court-approved fund
  in settlement of these claims. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company's insurers
  were notified of the breast implant claims and the Revised Settlement, and a
  number reserved their rights or declined coverage. The Company reached settlement
  with many of these insurers in connection with coverage litigation filed by
  it in state court in Texas. In 1993, the Company offset its breast implant product
  liability special charges by $1.0 billion of expected insurance proceeds (recorded
  as Insurance Recoverable). Because of its belief that additional amounts of
  insurance proceeds above that amount will be recovered, the Company recorded
  an additional Insurance Recoverable in the fourth quarter of 1998 of approximately
  $100 million. As a result of certain settlements, the Company has recovered
  or reached agreements to recover the $1.1 billion offset amount.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">While there have been
  a few large judgments, defendants have won more trials than they have lost,
  and the Company's trial experience has been mostly favorable. The Company has
  maintained throughout this litigation that breast implants do not cause disease,
  and medical and scientific data support the Company's position. The Company's
  view has found support in the trial courts. Courts in several states have ruled
  to exclude the testimony of plaintiffs' experts concerning a causal link between
  silicone gel breast implants and systemic illness on the ground that it fails
  to satisfy standards for reliability under current US Supreme Court guidelines.
  In 1998, a national science panel of four independent experts appointed by the
  federal court issued its unanimous report, based on a comprehensive review of
  the medical and scientific literature, that there is no evidence linking silicone
  breast implants and systemic disease. Similarly, in 1999, the Institute of Medicine
  of the National Academy of Sciences - while commenting that the frequency of
  local injuries is greater than expected - concluded there is insufficient evidence
  to link silicone breast implants with disease. The Company intends to dispose
  of the claims of remaining opt-outs by continuing to implement its plan to settle
  cases at values it deems acceptable, and to wage a vigorous defense, including
  taking cases to trial, of those cases that do not settle at such values.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In the fourth quarter
  of 1993, the Company recorded a charge of $500 million before taxes ($310 million
  after taxes) in respect of breast implant cases. The charge consisted of $1.5
  billion for potential liabilities and expenses, offset by $1.0 billion of expected
  insurance proceeds. In the fourth quarters of 1994 and 1995, the Company recorded
  additional special charges of $750 million before taxes ($488 million after
  taxes) and $950 million before taxes ($590 million after taxes), respectively,
  related to breast implant product liability claims. In the fourth quarter of
  1998, the Company recorded an additional special charge to earnings in the amount
  of $800 million before taxes and increased its insurance receivable in the amount
  of $100 million, resulting in a net charge to earnings of $433 million after
  taxes in respect of breast implant product liability claims.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">TAXOL*<i> </i>Litigation</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In 1997 and 1998, the
  company filed several lawsuits alleging that a number of generic drug companies
  infringed its patents covering methods of administering paclitaxel when they
  filed abbreviated new drug applications seeking regulatory approval to sell
  paclitaxel. These actions were consolidated for discovery in the United States
  District Court for the District of New Jersey. The company does not assert a
  monetary claim against any of the defendants, but seeks to prevent the defendants
  from marketing paclitaxel in a manner that violates the company's patents. </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">9</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The defendants have asserted
  that they do not infringe the company's patents and that these patents are invalid
  and unenforceable. Some defendants also asserted counterclaims seeking damages
  for alleged antitrust and unfair competition violations. The company believes
  its patents are valid and the counterclaims asserted are without merit. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">On January 4, 2000, the
  District Court granted the company's motion to dismiss certain of the antitrust
  and unfair competition counterclaims. The company's motion for summary judgment
  on the remaining antitrust and unfair competition counterclaims was denied on
  March 17, 2000. On February 29, 2000, the District Court granted in part the
  generic companies' summary judgment motions for invalidity by finding all claims
  of the Company's patents invalid, except for claims limited to the treatment
  of ovarian cancer. The District Court's opinion left for determination at trial
  the validity of the claims of the Company's patents directed to the low dose,
  three-hour administration of paclitaxel for ovarian cancer and denied the generic
  companies' summary judgment motion arguing non-infringement of the Company's
  patents. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In order to pursue an
  immediate appellate review of the District Court's invalidity findings, the
  Company voluntarily relinquished all rights in the remaining ovarian tumor specific
  claims of its patents. On April 7, 2000, the District Court granted the company's
  request for an entry of judgment. The Company's appeal of the District Court's
  judgment is pending before the Federal Circuit Court of Appeals. If the company
  is successful on appeal and the trial that would follow a successful appeal,
  the company believes its remaining patent rights would apply to all tumor types.
  </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In September 2000, one
  of the defendants received final approval from the United States Food and Drug
  Administration for its Abbreviated New Drug Application (ANDA) for paclitaxel
  and is marketing the product. FDA approvals of additional ANDAs for paclitaxel
  can occur at any time beginning in April 2001.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">It is not possible at
  this time to make a reasonable assessment of the outcome of the appeal and the
  remaining claims in these actions nor to reasonably estimate the impact on TAXOL*
  sales or the amount of damages were the company not to prevail.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u>VANLEV* Litigation</u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company, its Chairman
  of the Board and Chief Executive Officer, Charles A. Heimbold, Jr. and its Chief
  Scientific Officer and President - Pharmaceutical Research Institute, Peter
  S. Ringrose, Ph.D., are defendants in a number of purported class actions filed
  in the US District Court for the District of New Jersey in April, May and June
  2000 alleging violations of federal securities laws and regulations. Plaintiffs
  claim that the defendants disseminated materially false and misleading statements
  and failed to disclose information concerning the safety and expected availability
  of its product VANLEV* during the period November 8, 1999 through April 19,
  2000. Plaintiffs seek compensatory damages and costs and expenses. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">It is not possible at
  this time to make a reasonable assessment of the outcome of this matter or the
  amount of damages were the Company not to prevail.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">Environmental
  Matters</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company, together
  with others, is a party to, or otherwise involved in, a number of proceedings
  brought by the Environmental Protection Agency or comparable state agencies
  under the Comprehensive Environmental Response, Compensation and Liability Act
  (CERCLA or Superfund) or comparable state laws directed at the cleanup of hazardous
  waste sites. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">10</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">While it is not possible
  to predict with certainty the outcome of these cases, it is the opinion of management
  that they will not have a material adverse effect on the Company's operating
  results, liquidity or consolidated financial position. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 4. &#9;SUBMISSION
  OF MATTERS TO A VOTE OF SECURITY HOLDERS.</font></p>
<p></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">None.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">11</font></p>
<p align="center"><font color="#000000"><b><font face="CG Times"><u>PART IA</u></font></b></font></p>
<p align="left"><font color="#000000"><u>EXECUTIVE OFFICERS OF THE REGISTRANT</u></font></p>
<p align="left"><font color="#000000">The following are the executive corporate
  officers and the other executive officers of the Company:</font></p>
<table width="95%" border="0" cellpadding="7">
  <tr>
    <td width="25%">
      <div align="center"><u><b>Name</b></u></div>
    </td>
    <td width="6%">
      <div align="center"><u><b>Age</b></u></div>
    </td>
    <td width="69%">
      <div align="center"><u><b>Positions and Offices Presently Held with the
        Company</b></u></div>
    </td>
  </tr>
  <tr>
    <td width="25%">Charles A. Heimbold, Jr.</td>
    <td width="6%">
      <div align="center">67</div>
    </td>
    <td width="69%">Chairman of the Board, Chief Executive Officer and Director</td>
  </tr>
  <tr>
    <td width="25%">Harrison M. Bains, Jr.</td>
    <td width="6%">
      <div align="center">57</div>
    </td>
    <td width="69%">Treasurer and Vice President, Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">Peter R. Dolan</td>
    <td width="6%">
      <div align="center">57</div>
    </td>
    <td width="69%">President, Chief Executive Officer-Designate and Director</td>
  </tr>
  <tr>
    <td width="25%">Donald J. Hayden, Jr.</td>
    <td width="6%">
      <div align="center">45</div>
    </td>
    <td width="69%">Executive Vice President, E-Business and Strategy, Corporate
      Staff </td>
  </tr>
  <tr>
    <td width="25%">George P. Kooluris</td>
    <td width="6%">
      <div align="center">56</div>
    </td>
    <td width="69%">Senior Vice President, Corporate Development, Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">Richard J. Lane</td>
    <td width="6%">
      <div align="center">50</div>
    </td>
    <td width="69%">President, Worldwide Medicines Group</td>
  </tr>
  <tr>
    <td width="25%">Sandra Leung</td>
    <td width="6%">
      <div align="center">40</div>
    </td>
    <td width="69%">Secretary and Head of Office of Corporate Conduct, Corporate
      Staff </td>
  </tr>
  <tr>
    <td width="25%">John L. McGoldrick</td>
    <td width="6%">
      <div align="center">60</div>
    </td>
    <td width="69%">President, Medical Devices Group and Executive Vice President
      and <br>
      General Counsel, Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">Michael F. Mee</td>
    <td width="6%">
      <div align="center">58</div>
    </td>
    <td width="69%">Executive Vice President and Chief Financial Officer, Corporate
      Staff </td>
  </tr>
  <tr>
    <td width="25%">Peter S. Ringrose, Ph. D.</td>
    <td width="6%">
      <div align="center">54</div>
    </td>
    <td width="69%">Chief Scientific Officer and President, Bristol-Myers Squibb
      Company Pharmaceutical Research Institute</td>
  </tr>
  <tr>
    <td width="25%">Stephen I. Sadove</td>
    <td width="6%">
      <div align="center">49</div>
    </td>
    <td width="69%">President, Worldwide Beauty Care and Senior Vice President,
      Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">Frederick S. Schiff</td>
    <td width="6%">
      <div align="center">53</div>
    </td>
    <td width="69%">Controller and Senior Vice President Financial Operations,
      Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">John L. Skule</td>
    <td width="6%">
      <div align="center">57</div>
    </td>
    <td width="69%">Senior Vice President, Corporate and Environmental Affairs,
      Corporate Staff</td>
  </tr>
  <tr>
    <td width="25%">Charles G. Tharp, Ph.D.</td>
    <td width="6%">
      <div align="center">49</div>
    </td>
    <td width="69%">Senior Vice President, Human Resources, Corporate Staff</td>
  </tr>
</TABLE>
<p align="left"><font face="CG Times" color="#000000">Persons who hold titles
  as elected corporate officers of the Company were last elected or reelected
  to the office held at the general election of officers by the Company's Board
  of Directors on May 2, 2000 unless otherwise indicated. Officers of the Company
  serve in such capacity at the pleasure of the Board of Directors of the Company.</font></p>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">12</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">CHARLES A. HEIMBOLD,
  JR. - From 1992 to 1996, President of the Company. Mr. Heimbold has been a director
  of the Company since 1989, the Chief Executive Officer of the Company since
  1994 and Chairman of the Board of Directors of the Company since 1995.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">HARRISON M. BAINS, JR.
  - Mr. Bains has been Treasurer and Vice President, Corporate Staff of the Company
  since 1988.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">PETER R. DOLAN - From
  1995 to 1996, President, Mead Johnson Nutritional Group, a division of the Company,
  from 1996 to 1997, President, Nutritionals and Medical Devices Group, a division
  of the Company and from 1997 to 1998, President, Pharmaceutical Group - Europe,
  a division of the Company, and from 1998 to 2000, Senior Vice President, Strategy
  and Organizational Effectiveness, Corporate Staff. From 2000 to the present,
  Mr. Dolan has been President of the Company, a Director of the Company, a member
  of the Office of the Chairman and Chairman of the Corporate Operating Committee.
  In addition, Mr. Dolan was named Chief Executive Officer-Designate earlier this
  year. He will be the Chief Executive Officer of the Company on May 1, 2001.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">DONALD J. HAYDEN, JR.
  - From 1995 to 1997, Senior Vice President, Worldwide Franchise Management and
  Business Development, a division of the Company, in 1997, President, Intercontinental
  Pharmaceutical Group and Senior Vice President, Worldwide Business Development,
  Worldwide Medicines Group, a division of the Company, from 1997 to 1998, President,
  Intercontinental, Worldwide Medicines Group, a division of the Company, from
  1998-2000, President, Worldwide Medicines Group, a division of the Company.
  Mr. Hayden has been Executive Vice President of the Company and a member of
  the Office of the Chairman and Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">GEORGE P. KOOLURIS -
  Mr. Kooluris has been Senior Vice President, Corporate Development, Corporate
  Staff of the Company since 1994.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">RICHARD J. LANE - From
  1995 to 1997, Senior Vice President Marketing, US Pharmaceuticals, a division
  of the Company, in 1997, President, US Primary Care, a division of the Company,
  from 1997 to 1998, President, US Pharmaceuticals, a division of the Company,
  and from 1998 to 2000, President, US Medicines and Global Pharmaceutical Group,
  a division of the Company. Mr. Lane has been President, Worldwide Medicines
  Group, a division of the Company, and a member of the Office of the Chairman
  and Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">SANDRA LEUNG - From 1994
  to 1996, Senior Staff Attorney, Corporate Staff of the Company, from 1996 to
  1997, Assistant Counsel, Corporate Staff of the Company, from 1997 to 1999,
  Associate Counsel, 1999, Counsel, Corporate Staff of the Company. Ms. Leung
  has been Secretary, Corporate Staff of the Company, and Head of the Office of
  Corporate Conduct since 1999.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">JOHN L. McGOLDRICK -
  From 1995 to 1997, General Counsel and Senior Vice President, Corporate Staff
  of the Company and from 1997 to 1998, General Counsel and Senior Vice President,
  Law and Strategic Planning, Corporate Staff of the Company, and General Counsel
  and Senior Vice President, Corporate Staff of the Company and President, Medical
  Devices Group, a division of the Company, since 1998. Mr. McGoldrick has been
  Executive Vice President and General Counsel of the Company, President, Medical
  Devices Group, a division of the Company, and a member of the Office of the
  Chairman and Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">13</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">MICHAEL F. MEE - From
  1994 to 2000, Chief Financial Officer and Senior Vice President, Corporate Staff
  of the Company. Mr. Mee has been Executive Vice President and Chief Financial
  Officer, Corporate Staff of the Company and a member of the Office of the Chairman
  and Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">PETER S. RINGROSE, Ph.D.
  - From 1994 to 1996, Senior Vice President, Worldwide Discovery and Medicinal
  Research Development, Europe of Pfizer Inc., a health care company. From 1997-2000,
  President, Bristol-Myers Squibb Pharmaceutical Research Institute, a division
  of the Company. Dr. Ringrose has been Chief Scientific Officer of the Company
  and a member of the Office of the Chairman and Corporate Operating Committee
  since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">STEPHEN I. SADOVE - From
  1994 to 1996, President, Worldwide Clairol, a division of the Company. Mr. Sadove
  has been President, Worldwide Beauty Care, a division of the Company, since
  1996 and Senior Vice President, Corporate Staff of the Company since 1998. Mr.
  Sadove has been a member of the Office of the Chairman and Corporate Operating
  Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">FREDERICK S. SCHIFF -
  From 1990 to 1997, Controller and Vice President, Corporate Staff of the Company,
  from 1997 to 2000 Controller and Vice President, Financial Operations, Corporate
  Staff of the Company. Mr. Schiff has been Controller and Senior Vice President,
  Financial Operations, Corporate Staff of the Company since March 2000. Mr. Schiff
  has been a member of the Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">JOHN L. SKULE - From
  1993 to 1997, Vice President, Public Affairs, Corporate Staff of the Company.
  Mr. Skule has been Senior Vice President, Corporate and Environmental Affairs,
  Corporate Staff of the Company since 1998. Mr. Skule has been a member of the
  Corporate Operating Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">CHARLES G. THARP, Ph.D.
  Dr. Tharp has been Senior Vice President, Human Resources, Corporate Staff of
  the Company since 1993. Mr. Tharp has been a member of the Corporate Operating
  Committee since 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In addition to the positions
  and offices heretofore listed, all of the foregoing executive corporate officers
  and other executive officers of the Company are directors and/or officers of
  one or more affiliates of the Company, with the exception of Mr. Skule and Dr.
  Tharp.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">14</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">PART II</font></u></b></font></p>
<p align="JUSTIFY"><font color="#000000">Item 5. MARKET FOR THE REGISTRANT'S COMMON
  STOCK AND </font></p>
<p align="JUSTIFY"><font color="#000000">RELATED STOCKHOLDER MATTERS.</font></p>
<dir>
  <dir>
    <dir>
      <dir>
        <p align="JUSTIFY"></p>
      </dir>
    </dir>
  </dir>
</dir>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">MARKET PRICES</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Bristol-Myers Squibb
  common and preferred stocks are traded on the New York Stock Exchange and the
  Pacific Exchange, Inc. (symbol: BMY). A quarterly summary of the high and low
  market prices is presented below:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=648>
  <tr bgcolor="" align="none">
    <td width="41%" valign="TOP" align="none">&nbsp;</td>
    <td width="30%" valign="TOP" colspan=2><b>
      <p align="CENTER"><u><font face="CG Times">2000</font></u>
      </b></td>
    <td width="30%" valign="TOP" colspan=2><b>
      <p align="CENTER"><u><font face="CG Times">1999</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">&nbsp;</td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">High</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Low</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">High</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Low</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">
      <p><font face="CG Times">Common:</font>
    </td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">First Quarter&#9;</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">$68.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">$43.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">$66.19</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">$58.50</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Second Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 66.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 49.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 70.44</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 57.44</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Third Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 58.94</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 47.75</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 75.94</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 64.63</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Fourth Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 73.94</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 55.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 77.00</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 60.13</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="41%" valign="TOP" align="none">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
    <td width="15%" valign="TOP">&nbsp;</td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Preferred:</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company's preferred
  stock traded at a high of $962 and a low of $857 during the second quarter of
  2000 and at a price of $1,000 in the first quarter of 1999. During the first,
  third and fourth quarters of 2000, and the second, third and fourth quarters
  of 1999, there were no trades of the Company's preferred stock.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">HOLDERS OF COMMON
  STOCK</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The approximate number
  of record holders of common stock at December 31, 2000 was 114,096.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The number of record
  holders is based upon the actual number of holders registered on the books of
  Bristol-Myers Squibb at such date and does not include holders of shares in
  "street names" or persons, partnerships, associations, corporations or other
  entities identified in security position listings maintained by depository trust
  companies.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u>VOTING SECURITIES AND PRINCIPAL HOLDERS</u></font></p>
<p align="JUSTIFY"><font color="#000000"> At the close of business on March 5,
  2001, there were 1,949,674,068 shares of $0.10 par value Common Stock and 9,702
  shares of $2.00 Convertible Preferred Stock outstanding and entitled to vote.</font></p>
<p align="JUSTIFY"><font color="#000000"> The following table sets forth, as of
  February 1, 2001, beneficial ownership of shares of Common Stock of the company
  by each director, each of the named executive officers and all directors and
  officers as a group. None of these persons beneficially owns greater than 1%
  of the outstanding Common Shares nor any Preferred Shares. In addition, the
  table sets forth, as of the indicated dates, the beneficial ownership of shares
  of Common Stock of the company by each person known to be a beneficial holder
  of more than 5% of the outstanding class of Common Stock.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">15</font></p>
<p align="JUSTIFY"><font color="#000000"> Unless otherwise noted, such shares
  are owned directly or indirectly with sole voting and investment power. </font></p>
<table width="85%" border="0" cellpadding="7">
  <tr>
    <td width="34%">
      <p><b><u>Name</u></b></p>
    </td>
    <td width="22%">
      <div align="center"><b>Total Shares <u>Owned (a)</u></b></div>
    </td>
    <td width="22%">
      <div align="center"><b>Common Shares Acquirable In 60 <u>Days(b)</u></b>
      </div>
    </td>
    <td width="22%">
      <div align="center"><b>Deferred Common Share <u><br>
        Units(c)</u></b></div>
    </td>
  </tr>
  <tr>
    <td width="34%">R. E. Allen</td>
    <td width="22%">
      <div align="right">89,908</div>
    </td>
    <td width="22%">
      <div align="right">29,625</div>
    </td>
    <td width="22%">
      <div align="right">54,415</div>
    </td>
  </tr>
  <tr>
    <td width="34%">L. B. Campbell</td>
    <td width="22%">
      <div align="right">6,400</div>
    </td>
    <td width="22%">
      <div align="right">625</div>
    </td>
    <td width="22%">
      <div align="right">3,665</div>
    </td>
  </tr>
  <tr>
    <td width="34%">V. D. Coffman</td>
    <td width="22%">
      <div align="right">9,522(d)</div>
    </td>
    <td width="22%">
      <div align="right">2,625</div>
    </td>
    <td width="22%">
      <div align="right">6,825</div>
    </td>
  </tr>
  <tr>
    <td width="34%">P. R. Dolan</td>
    <td width="22%">
      <div align="right">490,547</div>
    </td>
    <td width="22%">
      <div align="right">299,625</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">E. V. Futter</td>
    <td width="22%">
      <div align="right">35,788</div>
    </td>
    <td width="22%">
      <div align="right">25,625</div>
    </td>
    <td width="22%">
      <div align="right">6,387</div>
    </td>
  </tr>
  <tr>
    <td width="34%">L. V. Gerstner, Jr.</td>
    <td width="22%">
      <div align="right">67,586</div>
    </td>
    <td width="22%">
      <div align="right">22,625</div>
    </td>
    <td width="22%">
      <div align="right">14,761(e)</div>
    </td>
  </tr>
  <tr>
    <td width="34%">L. H. Glimcher, M.D.</td>
    <td width="22%">
      <div align="right">8,150</div>
    </td>
    <td width="22%">
      <div align="right">2,625</div>
    </td>
    <td width="22%">
      <div align="right">5,525</div>
    </td>
  </tr>
  <tr>
    <td width="34%">C. A. Heimbold, Jr.</td>
    <td width="22%">
      <div align="right">4,723,451(f)</div>
    </td>
    <td width="22%">
      <div align="right">3,173,550</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">L. Johansson</td>
    <td width="22%">
      <div align="right">5,665</div>
    </td>
    <td width="22%">
      <div align="right">625</div>
    </td>
    <td width="22%">
      <div align="right">3,040</div>
    </td>
  </tr>
  <tr>
    <td width="34%">R. J. Lane</td>
    <td width="22%">
      <div align="right">374,967</div>
    </td>
    <td width="22%">
      <div align="right">294,625</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">J. L. McGoldrick</td>
    <td width="22%">
      <div align="right">749,390</div>
    </td>
    <td width="22%">
      <div align="right">726,000</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">M. F. Mee</td>
    <td width="22%">
      <div align="right">434,137(g)</div>
    </td>
    <td width="22%">
      <div align="right">113,500</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">J. D. Robinson III</td>
    <td width="22%">
      <div align="right">52,691</div>
    </td>
    <td width="22%">
      <div align="right">25,625</div>
    </td>
    <td width="22%">
      <div align="right">6,866</div>
    </td>
  </tr>
  <tr>
    <td width="34%">L. W. Sullivan, MD </td>
    <td width="22%">
      <div align="right">29,751(h)</div>
    </td>
    <td width="22%">
      <div align="right">21,625</div>
    </td>
    <td width="22%">
      <div align="right">7,674</div>
    </td>
  </tr>
  <tr>
    <td width="34%">K. E. Weg</td>
    <td width="22%">
      <div align="right">1,791,113</div>
    </td>
    <td width="22%">
      <div align="right">1,672,934</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
  <tr>
    <td width="34%">All Directors and Officers as a Group</td>
    <td width="22%">
      <div align="right">11,787,810(i)</div>
    </td>
    <td width="22%">
      <div align="right">8,408,548</div>
    </td>
    <td width="22%">
      <div align="right">109,158</div>
    </td>
  </tr>
  <tr>
    <td width="34%">FMR Corp.</td>
    <td width="22%">
      <div align="right">120,731,785(j)</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
    <td width="22%">
      <div align="right">0</div>
    </td>
  </tr>
</TABLE>
<ol type="a">
  <li><font color="#000000"> includes direct and indirect ownership of shares,
    stock options that are currently exercisable, stock options that will become
    exercisable in 60 days and deferred common share units. </font></li>
  <li><font color="#000000"> includes stock options that are currently exercisable
    and stock options that will be exercisable within 60 days. </font></li>
  <li><font color="#000000"> amounts credited to directors' accounts in the 1987
    Deferred Compensation Plan for Non-Employee Directors as deferred common share
    units which are valued according to the market value and stockholder return
    on equivalent shares of Common Stock. </font></li>
  <li><font color="#000000"> includes 72 shares held by a family living trust
    over which neither Dr. Coffman nor his wife exercise voting or investment
    power. </font></li>
  <li><font color="#000000"> includes 5,742 deferred common share units credited
    to Mr. Gerstner's account in the Squibb Corporation Deferred Plan for Fees
    of Outside Directors which are valued according to the market value and stockholder
    return on equivalent shares of Common Stock. </font></li>
  <li>
    <div align="left"><font color="#000000"> includes 5,000 shares held by Mr.
      Heimbold's wife over which he exercises shared voting and investment power
      and also includes 78,438 shares owned by a family charitable foundation
      over which Mr. Heimbold exercises shared voting and investment power. Mr.
      Heimbold disclaims beneficial ownership of the shares owned by the family
      charitable foundation. <font face="CG Times">__________________________________________________________________________________________<br>
      16<br>
      <br>
      </font></font></div>
  </li>
  <li><font color="#000000"> includes 550 shares held by one of Mr. Mee's children
    over which he exercises shared voting and investment power. </font></li>
  <li><font color="#000000"> includes 452 shares owned jointly by Dr. Sullivan
    and his wife over which he exercises shared voting and investment power. </font></li>
  <li><font color="#000000"> Includes 24,428 shares and 300 stock options held
    by other executive officers' immediate family members over which the executive
    officers share voting and investment power. </font></li>
  <li><font color="#000000"> The source of this information is the Schedule 13G
    dated February 12, 2001 filed by FMR Corp. and certain other persons with
    the Securities and Exchange Commission reporting beneficial ownership as of
    December 31, 2000. Assuming that such persons continued to beneficially own
    the same number of shares at February 1, 2001, such beneficial ownership would
    represent approximately 6.2% of the outstanding class of Common Stock. The
    Schedule 13G reported that Edward C. Johnson, 3rd, Abigail P. Johnson, and
    certain other family members may be deemed to form a controlling group with
    respect to FMR Corp. and, therefore, Mr. Johnson and Ms. Johnson each also
    had beneficial ownership of 120,731,785 shares (which shares are the same
    shares as those beneficially owned by FMR Corp.) The Schedule 13G stated that
    Fidelity Management & Research Company, a wholly-owned subsidiary of FMR Corp.
    and a registered investment advisor, beneficially owned 110,721,446 shares
    at December 31, 2000 (representing approximately 5.7% of the outstanding class
    as of February 1, 2001; these shares are included in the shares reported as
    beneficially owned by FMR Corp.) The address of FMR Corp. and the named affiliates
    is 82 Devonshire Street, Boston, MA 02109 </font></li>
</ol>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">DIVIDENDS</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Dividend payments per
  share in 2000 and 1999 were:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr bgcolor="" align="none">
    <td width="38%" valign="TOP" align="none">&nbsp;</td>
    <td width="31%" valign="TOP" colspan=2><b>
      <p align="CENTER"> <font face="CG Times" size="3"><u>Common</u></font>
      </b></td>
    <td width="31%" valign="TOP" colspan=2><b>
      <p align="CENTER"> <font face="CG Times" size="3"><u>Preferred</u></font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none" height="32">&nbsp;</td>
    <td width="15%" valign="TOP" height="32">
      <p align="right"><u><font face="CG Times" size="3">2000</font></u>
    </td>
    <td width="15%" valign="TOP" height="32">
      <p align="right"><u><font face="CG Times" size="3">1999</font></u>
    </td>
    <td width="15%" valign="TOP" height="32">
      <p align="right"><u><font face="CG Times" size="3">2000</font></u>
    </td>
    <td width="15%" valign="TOP" height="32">
      <p align="right"><u><font face="CG Times" size="3">1999</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">First Quarter&#9;</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">$ .245</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">$ .215</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">$ .50</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">$ .50</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Second Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.245</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.215</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3"> .50</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.50</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Third Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.245</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.215</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.50</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><font face="CG Times" size="3">.50</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Fourth Quarter</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">.245</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">.215</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">.50</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">.50</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="38%" valign="TOP" align="none">&nbsp;</td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">$ .98 </font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3"> $ .86 </font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">$2.00</font></u>
    </td>
    <td width="15%" valign="TOP">
      <p align="right"><u><font face="CG Times" size="3">$2.00</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In December 2000, the
  Board of Directors of the Company declared a quarterly dividend of $.275 per
  share on the common stock of the Company, payable on February 1, 2001 to shareholders
  of record as of January 5, 2001. The 2001 indicated annual payment of $1.10
  per share represents the twenty-ninth consecutive year that the Company has
  raised the dividend on its common stock. &#9;</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">17</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">Item 6.&#9;SELECTED
  FINANCIAL DATA.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">FIVE-YEAR FINANCIAL
  SUMMARY</font></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times" size="3">OPERATING
  RESULTS</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">(in millions,
  except per share amounts)</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=95%>
  <tr bgcolor="" align="none">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times">2000</font></u> </b>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times">1999</font></u> </b>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times">1998</font></u> </b>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times">1997</font></u> </b>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times">1996</font></u> </b>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=24 align="none"><i>
      <p></p>
      </i></td>
    <td width="11%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=18 align="none">
      <p><font face="CG Times" size="3">Net Sales</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$18,216</font></u>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$16,878</font></u>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$15,061</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$13,698</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$12,268</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=10 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Expenses:</font>
    </td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="14%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Cost of products sold</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">4,759</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">4,542</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,896</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,548</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,134</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Marketing, selling and administrative</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,860</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,789</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,685</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,425</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">3,220</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Advertising and product promotion</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,672</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,549</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,518</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,582</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,355</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Research and development</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,939</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,759</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,506</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,322</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,203</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Other (*)</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3"> 508</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3"> 81</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3"> 818</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3"> 83</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3"> (67)</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=10 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">12,738</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">11,720</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">11,423</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">9,960</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">8,845</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="14%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Earnings from Continuing Operations Before
        Income Taxes (*)</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><br>
        <font face="CG Times" size="3">5,478</font> </p>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3"><br>
        5,158</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3"><br>
        3,638</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3"><br>
        3,738</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3"><br>
        3,423</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=13 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=13>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Provision for income taxes</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">1,382</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">1,369</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">888</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">994</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">939</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=10 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Earnings from Continuing Operations (*)</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$4,096</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$3,789</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$2,750</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$2,744</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$2,484</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=16 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=10 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Earnings per common share </font>
    </td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="14%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=16 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Basic</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.08</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.91</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.38</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.38</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.24</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=16 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Diluted</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.05</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.87</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.36</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.34</font></u>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.22</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" height=10 align="none">
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="13%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Dividends per common share</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">.98</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">.86</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">.78</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">.76</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">.75</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">(*)&#9;Includes
      a gain on sale of businesses of $160 million before taxes, $116 million
      after taxes, or $.06 per common share, basic and diluted, in 2000; and $201
      million before taxes, $125 million after taxes, or $.06 per common share,
      basic and diluted, in 1998. Includes a special charge for prescription drug
      pricing litigation of $100 million before taxes, $62 million after taxes,
      or $.03 per common share, basic and diluted, in 1998. Includes a special
      charge for pending and future product liability claims of $700 million before
      taxes, $433 million after taxes, or $.22 per common share, basic, and $.21
      per common share, diluted, in 1998. Includes a provision for restructuring
      of $508 million before taxes, $329 million after taxes, or $.17 per common
      share, basic and diluted, in 2000; $157 million before taxes, $98 million
      after taxes, or $.05 per common share, basic and diluted, in 1998; and $120
      million before taxes, $74 million after taxes, or $.04 per common share,
      basic and diluted, in 1997.</font></p>
    <p align="left"><font face="CG Times" color="#000000">______________________________________________________________________________________</font></p>
    <p align="left"><font face="CG Times" color="#000000">18</font></p>
  </dir>
</dir>
<p><font color="#000000">SELECTED FINANCIAL DATA. (Con't.)</font></p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">FIVE-YEAR FINANCIAL
  SUMMARY</font></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times" size="3">FINANCIAL
  POSITION AT DECEMBER 31**</font></u></font></p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">(in millions,
  except per share amounts)</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=95%>
  <tr bgcolor="" align="none">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP"><b>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
      </b></td>
    <td width="12%" valign="TOP"><b>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
      </b></td>
    <td width="12%" valign="TOP"><b>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
      </b></td>
    <td width="12%" valign="TOP"><b>
      <p align="RIGHT"><u><font face="CG Times">1997</font></u>
      </b></td>
    <td width="12%" valign="TOP"><b>
      <p align="RIGHT"><u><font face="CG Times">1996</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Total assets</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$17,578</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$17,114</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">$16,272</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">$14,977</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">$14,685</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Long-term debt</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,336</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,342</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,364</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">1,279</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times" size="3">966</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Average common shares outstanding - Basic</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">1,965</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">1,984</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">1,987</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">1,992</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">2,007</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="40%" valign="TOP" align="none">
      <p><font face="CG Times" size="3">Average common shares outstanding - Diluted</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">1,997</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">2,027</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">2,031</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">2,042</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">2,035</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">Reference is
  made to Note 2 Discontinued Operations, Note 3 Acquisitions and Divestitures,
  Note 4 Restructuring and Note 17 Litigation, appearing in the Notes to Consolidated
  Financial Statements included in Part II, Item 8 of this Form 10-K Annual Report.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">** Financial position
  data relates to the Company's assets and liabilities, including discontinued
  operations.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">19</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">Item 7.&#9;MANAGEMENT'S DISCUSSION AND
  ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</font></p>
<p align="JUSTIFY"></p>
<p><font face="CG Times" color="#000000">Summary</font></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In September 2000, the Company
  announced the planned divestitures of the Zimmer and Clairol businesses. Accordingly,
  their results have been reported as discontinued operations and excluded from
  consolidated sales and expenses for all years. In February 2001, the Company
  announced </font><font face="CG Times" color="#000000">its intention to separate
  the Zimmer business in a tax-free spin-off to shareholders. This transaction
  is expected to be completed by the end of the third quarter of 2001.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In 2000, Bristol-Myers Squibb
  reported $18.2 billion in annual global sales, an increase of 8% (11% excluding
  foreign exchange) over 1999. Domestic sales, representing 67% of worldwide sales,
  increased 14% to $12.1 billion, while international sales decreased 2% (a 5%
  increase excluding foreign exchange) to $6.1 billion. Sales growth resulted
  from an 8% increase due to volume, a 3% increase from changes in selling prices
  and a 3% decrease due to exchange rate fluctuations. Total Company sales including
  discontinued operations increased 5% (8% excluding foreign exchange) to $21.3
  billion.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company's most important
  product lines made significant contributions to the Company's sales growth,
  many of which experienced double-digit growth on a worldwide basis. Three products,
  PRAVACHOL*, TAXOL* (paclitaxel) and GLUCOPHAGE, each exceeded $1.5 billion in
  annual sales, while five additional products exceeded $500 million in annual
  sales. Bristol-Myers Squibb had 54 product lines with more than $50 million
  in annual sales, including 31 with more than $100 million in annual sales.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Total Company earnings (continuing
  and discontinued operations) before income taxes increased 12% to $6.5 billion
  from $5.8 billion in 1999. Net earnings increased 13% to $4.7 billion; basic
  and diluted earnings per share increased 14% to $2.40 and 15% to $2.36, respectively.
  Earnings from continuing operations before income taxes, excluding restructuring
  charges and gain on sales of businesses, increased 13% to $5.8 billion in 2000.
  Net earnings, on this basis, increased 14% to $4.3 billion; basic and diluted
  earnings per share increased 15% to $2.19 and 16% to $2.16, respectively. Over
  the past five years, net earnings and diluted earnings per share from continuing
  operations, excluding gains from sales of businesses and restructuring and special
  charges, have increased at a compound annual growth rate of 14%. This growth
  rate enabled the Company to achieve its goal of doubling 1993 earnings and earnings
  per share by the end of 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In 2000, consistent with
  the Company's mission to extend and enhance human life and to develop the highest
  quality products, the Company invested more than $1.9 billion in research and
  development, a 10% increase over the prior year. Research and development expenditure
  dedicated to pharmaceutical products increased 14% over 1999 with a compound
  annualized rate of 14% over the past five years. This significant investment
  has led to the discovery of innovative new products and the development of new
  indications for existing products leading, in 2000, to eight regulatory approvals
  and the filing of three dossiers in the US Notable approvals included GLUCOVANCE,
  a new oral combination drug, and GLUCOPHAGE XR Extended Release Tablets, a once-daily
  version of GLUCOPHAGE, both for diabetes; VANIQA*, a topical treatment for unwanted
  facial hair in women; and VIDEX* EC, a once-a-day, easier-to-digest, enteric-coated
  form of VIDEX* for HIV/AIDS. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Also in 2000, the Company
  announced a number of research alliances, collaborations and commercialization
  agreements with other companies, including a global agreement (excluding Japan)
  with Novartis AG to codevelop and copromote tegaserod, Novartis's new investigational
  drug treatment for irritable bowel syndrome; and a drug discovery alliance in
  the field of genomics with 3-Dimensional Pharmaceuticals, Inc., under which
  the Company will receive worldwide rights to compounds discovered or developed
  through the collaboration. This agreement is one of more than a dozen major
  genomics agreements the Company has entered into over the past three years.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">20</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Bristol-Myers Squibb's financial
  position remains strong. At December 31, 2000, the Company held almost $3.4
  billion in cash, time deposits and marketable securities. Cash provided by operating
  activities reached $4.7 billion, the highest in the past 10 years. Returns to
  shareholders included dividend distributions of $1.9 billion and stock repurchases
  of $2.3 billion. Dividends per common share were $.98 in 2000, increasing from
  $.86 per share paid in 1999. In December 2000, the Company announced a dividend
  increase, the 29th consecutive year that dividends have increased. The 2001
  indicated annual payment is $1.10 per common share, a 12% increase over 2000.
  As further evidence of its strong financial position, Bristol-Myers Squibb is
  one of only seven US industrial companies to receive a triple-A credit rating
  from both Moody's and Standard &amp; Poor's. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Net Sales </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales increased 8% in 2000
  to $18.2 billion, compared with increases of 12% and 10% in 1999 and 1998, respectively.
  The consolidated sales growth in 2000 resulted from an 8% increase due to volume,
  a 3% increase due to changes in selling prices and a 3% decrease due to foreign
  exchange rate fluctuations. In 1999, the 12% increase in sales reflected an
  11% increase due to volume, a 2% increase due to changes in selling prices and
  a 1% decrease due to foreign exchange rate fluctuations. In 1998, the 10% increase
  in sales reflected an 11% increase due to volume, a 2% increase due to changes
  in selling prices and a 3% decrease due to foreign exchange rate fluctuations.
  Domestic sales increased 14% in 2000 and 19% in 1999, while international sales
  decreased 2% in 2000 (a 5% increase excluding foreign exchange) and increased
  2% in 1999 (5% excluding foreign exchange). In general, the business of the
  Company is not seasonal.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In 2000, worldwide pharmaceutical
  sales increased 11% with US pharmaceutical sales up 18% over the prior year.
  Key pharmaceutical product sales include:</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of PRAVACHOL*, a cholesterol-lowering
  agent and the Company's largest selling product, increased 7% to $1,817 million
  primarily as a result of an increase in retail prescriptions. Domestic sales
  increased 9% to $1,127 million, while international sales increased 3% (14%
  excluding foreign exchange) to $690 million. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">GLUCOPHAGE sales increased
  32% to $1,732 million. GLUCOPHAGE, the leading branded oral medication for treatment
  of non-insulin dependent (type 2) diabetes, had a market share of 33.4% in 2000,
  up from 31.3% in the prior year. The marketing exclusivity for GLUCOPHAGE expired
  in September 2000; however, no generic competition existed at the end of the
  year. During the year, the Company received FDA approval for </font></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">GLUCOVANCE, an important
  advance in diabetes treatment, and for GLUCOPHAGE XR Extended Release tablets,
  a once-daily version of GLUCOPHAGE. Sales of GLUCOVANCE and GLUCOPHAGE XR since
  their launches were $110 million and $50 million, respectively. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of TAXOL*, the Company's
  leading anticancer agent, increased 7% to $1,592 million as the product continued
  to benefit from increased use in ovarian, breast and non-small cell lung cancer
  following standard chemotherapy. Generic paclitaxel became available in the
  US during the third quarter of 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of PLAVIX, an anti-platelet
  medication, increased 65% to $903 million. Results of the landmark CURE trial
  (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events), jointly
  sponsored by the company and Sanofi-Synthelabo, were announced in March 2001.
  In this international trial of more than 12,500 patients with acute coronary
  syndromes (unstable angina or non-Q wave myocardial infarction), PLAVIX was
  significantly superior to standard therapies, including aspirin, in reducing
  a cluster of clinical events: heart attack, stroke and cardiovascular death.
  Sales of AVAPRO, an angiotensin II receptor blocker for the treatment of hypertension,
  increased 49% to $381 million. AVAPRO and PLAVIX are cardiovascular products
  that were launched from the Bristol-Myers Squibb and Sanofi-Synthelabo joint
  venture.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">21</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"> Sales of BUSPAR*, the Company's novel
  antianxiety agent, increased 17% to $709 million. The US anxiolytic use patent
  expired in June 2000. The Food and Drug Administration (FDA) granted the company
  an additional six months exclusivity based on its performance of pediatric studies.
  In November 2000, the Company received a patent covering the anxiolytic use
  of a BUSPAR* metabolite, a compound produced in the body by the oral administration
  of BUSPAR* and buspirone itself. The patent was subsequently de-listed during
  the course of litigation brought by generic manufacturers. On March 28, 2001,
  three generic manufacturers received final approval from the FDA for their respective
  Abbreviated New Drug Applications (ANDAs) for buspirone. Each of these three
  ANDAs covers a separate dosage strength of buspirone. FDA approvals of additional
  ANDAs for buspirone (of any dosage strength) can occur at any time beginning
  in September 2001. The litigation is on-going. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of SERZONE*, a novel
  antidepressant, increased 8% to $360 million. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of PARAPLATIN*, which
  is used in combination therapy for the treatment of ovarian cancer, increased
  15% to $690 million.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of MEGACE* O/S, indicated
  for the treatment of anorexia and cachexia in patients with AIDS, increased
  58% to $180 million. Sales of MAXIPIME*, a fourth-generation injectable cephalosporin
  antibiotic, increased 10% to $146 million. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of TEQUIN*, a quinolone
  antibiotic launched in December 1999, were $131 million. In November 2000, TEQUIN*
  became the first quinolone antibiotic to be prescribed for more than one million
  patients in the US after just 10 months on the market.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of DOVONEX*, an adult
  dermatological treatment, increased 20% from the prior year to $121 million.
  Sales of IFEX*, used in combination chemotherapy treatment, increased 23% to
  $108 million.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales of captopril, an ACE
  inhibitor sold primarily under the trademark CAPOTEN*, declined 26% to $356
  million due to generic competition.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales from the Oncology
  Therapeutics Network, a specialty distributor of anticancer medicines and related
  products, were $1,080 million for the year, an increase of 21% over 1999. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Nonpharmaceutical sales
  included sales of BUFFERIN*, which increased 10% (5% excluding foreign exchange)
  to $161 million due to increased sales in Japan, while sales of EFFERALGAN*,
  an effervescent analgesic sold primarily in France, increased 4% (20% excluding
  foreign exchange) to $172 million.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Total infant formula sales
  decreased 2% to $1,212 million. Sales of ENFAMIL*, the Company's largest selling
  infant formula, remained at prior year levels of $732 million worldwide. Sales
  of ostomy products decreased 5% (a 1% increase excluding foreign exchange) to
  $428 million while sales of wound care products decreased 3% (a 3% increase
  excluding foreign exchange) to $232 million.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">22</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Earnings</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In 2000, earnings from continuing
  operations before income taxes, excluding the nonrecurring items described below,
  increased 13% to $5,826 million from $5,158 million in 1999. Net earnings, on
  this basis, increased 14% to $4,309 million compared with $3,789 million in
  1999. Basic earnings per share increased 15% to $2.19 from $1.91 in the prior
  year and diluted earnings per share increased 16% to $2.16 from $1.87. Net earnings
  margins increased to 23.7% in 2000 from 22.4% in 1999. In 1999, net earnings
  were $3,789 million, an 18% increase over 1998, excluding the nonrecurring items
  described below. On this basis, basic earnings per share and diluted earnings
  per share both increased 18% over 1998 and net earnings margins increased to
  22.4% in 1999 from 21.4% in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company recorded certain
  nonrecurring items (&quot;nonrecurring items&quot;) in 2000 to earnings of continuing
  operations, including the gain on sales of businesses (three pharmaceutical
  products - Estrace Cream, Ovcon 35 and Ovcon 50 as well as its Sea Breeze brand
  in Japan) of $160 million before taxes, $116 million after taxes or $.06 per
  diluted share; as well as restructuring charges of $508 million before taxes,
  $329 million after taxes or $.17 per diluted share, in connection with workforce
  reductions and asset write-downs related to the consolidation and closure of
  plants and facilities and other expenses. In 1998, the Company recorded certain
  nonrecurring items to earnings of continuing operations, including the gain
  on sales of businesses (Ban, A/S GEA and Hexachimie) of $201 million before
  taxes, $125 million after taxes or $.06 per diluted share; as well as restructuring
  charges of $157 million before taxes, $98 million after taxes or $.05 per diluted
  share in connection with asset write-downs and employee-related costs related
  to the consolidation and closure of plants and facilities. Also, in 1998, the
  Company recorded a special charge of $800 million before taxes, $495 million
  after taxes, or $.24 per diluted share, to augment the reserve for breast implant
  liability and for prescription drug pricing litigation, offset by expected insurance
  recoveries. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The effective income tax
  rate on earnings from continuing operations before income taxes was 25.2% in
  2000, compared with 26.5% in 1999, and 24.4% in 1998. The effective income tax
  rate on earnings from continuing operations before income taxes, excluding the
  nonrecurring items, was 26.0% in 2000, compared with 26.5% in 1999, and 26.8%
  in 1998. The effective income tax rate has decreased since 1998 due to increased
  income in lower tax jurisdictions.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Total Company earnings (continuing
  and discontinued operations) before taxes increased 12% to $6,486 million from
  $5,767 million in 1999. Net earnings increased 13% to $4,711 million compared
  with $4,167 million in 1999. Basic earnings per share increased 14% to $2.40
  from $2.10 in the prior year and diluted earnings per share increased 15% to
  $2.36 from $2.06. In 1999, net earnings were $4,167 million, an increase of
  15% from $3,636 million in 1998, excluding the special charge. On this basis,
  basic earnings per share were $2.10 and diluted earnings per share were $2.06,
  both increasing 15% over 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Expenses</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Total costs and expenses,
  excluding the nonrecurring items, as a percentage of sales, improved over the
  past three years to 68.0% in 2000 compared with 69.4% in 1999, and 70.8% in
  1998. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Cost of products sold, as
  a percentage of sales, improved to 26.1% in 2000 from 26.9% in 1999, principally
  due to manufacturing efficiencies. In 1999, cost of products sold as a percentage
  of sales increased to 26.9%, compared with 25.9% in 1998, principally due to
  sales growth of lower margin products from the Oncology Therapeutics Network.
  </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">23</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Advertising and promotion
  expenses increased 8% over the prior year to $1,672 million in 2000, primarily
  as a result of a direct-to-consumer campaign for PRAVACHOL* and launch spending
  for GLUCOVANCE and TEQUIN*. In 1999, advertising and promotion expenses increased
  2% from 1998 to $1,549 million. As a percentage of sales, advertising and promotion
  expenses remained at prior year levels of 9.2% and decreased from 10.1% in 1998,
  reflecting an improvement in the effectiveness of the advertising and promotion
  spending. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Marketing, selling and administrative
  expenses, as a percentage of sales, decreased to 21.2% in 2000 from 22.4% in
  1999 and 24.5% in 1998. This decreasing trend is a result of slower rates of
  increase in marketing, sales force and general administrative expenses compared
  with revenue increases in the same period. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company's investment
  in research and development totaled $1,939 million in 2000, an increase of 10%
  over 1999, and to 10.6% in 2000, as a percentage of sales, compared with 10.4%
  in 1999 and 10.0% in 1998. This spending level reflects the Company's commitment
  to research over a broad range of therapeutic areas and to clinical development
  of new products. Over the past five years, research and development expenses
  have increased at a compound annual growth rate of 11%. In 2000, research and
  development spending dedicated to pharmaceutical products increased 14%, and
  was 13.0% of pharmaceutical sales compared with 12.6% and 12.4% in 1999 and
  1998, respectively. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">As described in the notes
  to the financial statements, in the first quarter of 2000, the Company completed
  the sale of three pharmaceutical products - Estrace Cream, Ovcon 35 and Ovcon
  50 as well as its Sea Breeze brand in Japan. In 1999, the Company acquired CAL-C-TOSE*,
  a leading nutritional milk modifier product in Mexico. Also, in 1999, the Company
  completed the sale of Laboratori Guieu, SpA, an Italian-based gynecological,
  pediatric and dermatological products business. In 1998, the Company acquired
  Dong-A Biotech Co., Ltd., a marketer and distributor of pharmaceutical products
  in South Korea. Also, in 1998, the Company divested its Ban brand of anti-perspirants
  and deodorants; A/S GEA, a Denmark-based generic drug business; and Hexachimie,
  a specialty chemical manufacturer based in France. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Discontinued Operations</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Clairol sales decreased
  6% to $1,894 million. Domestic sales decreased 4% while international sales
  decreased 9% (8% excluding foreign exchange). In 1999, Clairol sales increased
  4% to $2,020 million from $1,940 million in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Zimmer sales increased 9%
  to $1,053 million, led by an increase in sales of knee joint replacements of
  10% to $416 million, of hip replacements of 14% to $329 million and of fracture
  management products of 15% to $145 million. In 1999, Zimmer sales increased
  5% to $963 million from $919 million in 1998.&#9;</font></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">&#9;</font></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">As described in the notes
  to the financial statements, in the third quarter of 2000, the Company completed
  the sale of Matrix Essentials, Inc. (Matrix), an affiliate of Clairol. Matrix
  sales for the first six months of 2000 were $168 million and were $361 million
  for the full year in 1999.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">As described in Note 2 to
  the financial statements, in 2000 and 1998 the Company recorded restructuring
  charges to discontinued operations of $34 million and $44 million before taxes,
  respectively, primarily in connection with workforce reductions. In 2000, the
  Company recorded a pretax gain of $402 million ($240 million after taxes) on
  the sale of Matrix. The gain is included in the gain on disposal of discontinued
  operations.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">As a result of the restructuring
  charges, net earnings from discontinued operations were $375 million in 2000
  and $391 million in 1998. Net earnings from discontinued operations, excluding
  the restructuring charges, increased 5% to $397 million in 2000 and decreased
  10% to $378 million in 1999. </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">24</font></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Geographic Areas</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Bristol-Myers Squibb products
  are available in virtually every country in the world; the Company's largest
  markets are the US, France, Japan, Germany and Canada. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales in the United States
  increased 14% in 2000. Products with strong growth in the region included GLUCOPHAGE,
  PLAVIX, BUSPAR*, PARAPLATIN* and AVAPRO. In 1999, sales in the United States
  increased 19%, primarily due to growth of GLUCOPHAGE, TAXOL*, ENFAMIL*, BUSPAR*,
  PLAVIX, PARAPLATIN* and AVAPRO. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales in Europe, Mid-East
  and Africa decreased 9% in 2000. Sales increased 3%, excluding foreign exchange,
  as a result of growth in France due to increased sales of PRAVACHOL* and EFFERALGAN*,
  partially offset by decreased sales of CAPOTEN* due to generic competition;
  in Italy due to increased sales of TAXOL* and AVAPRO; and in Spain due to increased
  sales of PRAVACHOL*, AVAPRO and PLAVIX. Excluding foreign exchange, sales in
  Germany were 2% below prior year levels due to increased emphasis on generics
  and governmental spending controls. In 1999, sales in Europe, Mideast and Africa
  increased 2% (4% excluding foreign exchange), due to sales growth of products
  including PRAVACHOL*, TAXOL*, PLAVIX and AVAPRO. These increases were partially
  offset by decreases in sales of ostomy supplies and of CAPOTEN* due to generic
  competition. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales in Other Western Hemisphere
  countries increased 3% (6% excluding foreign exchange) in 2000 primarily as
  a result of growth in Canada due to increased sales of PLAVIX, AVAPRO and ENFAMIL*,
  and in Mexico due to growth of ENFAMIL* and CAL-C-TOSE*. In 1999, sales in Other
  Western Hemisphere countries decreased 9% (a 3% increase excluding foreign exchange)
  primarily resulting from decreases in sales of CAPOTEN* and PRAVACHOL*, partially
  offset by growth in ENFAMIL*, AVAPRO and PLAVIX. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Sales in the Pacific region
  increased 12% in 2000 (11% excluding foreign exchange). Products with strong
  growth included BUFFERIN*, TAXOL* and PARAPLATIN* in Japan and nutritional products
  in the Philippines and Thailand. In 1999, Pacific region sales increased 18%
  (10% excluding foreign exchange) as a result of increases in BUFFERIN*, TAXOL*
  and PARAPLATIN*. The favorable effect from foreign exchange was experienced
  primarily in Japan.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Financial Instruments</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Cash and cash equivalents,
  time deposits and marketable securities totaled almost $3.4 billion at December
  31, 2000 compared with $3.0 billion and $2.5 billion at December 31, 1999 and
  1998, respectively. Working capital continued to improve with $4.2 billion at
  December 31, 2000, compared with $3.7 billion and $3.0 billion at December 31,
  1999 and 1998, respectively. Cash and cash equivalents, time deposits and marketable
  securities, in addition to the conversion of other working capital items are
  expected to fund near-term operations of the Company.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company is exposed to
  market risk due to changes in currency exchange rates. To reduce this risk,
  the Company enters into certain derivative financial instruments when available
  on a cost-effective basis to hedge its underlying economic exposure. These instruments
  also are managed on a consolidated basis to efficiently net exposures and thus
  take advantage of any natural offsets. Derivative financial instruments are
  not used for trading purposes. Gains and losses on hedging transactions are
  offset by gains and losses on the underlying exposures being hedged. </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">25</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Foreign exchange option
  contracts and, to a lesser extent, forward contracts are used to hedge anticipated
  transactions. The Company's primary foreign currency exposures in relation to
  the US dollar are the euro, Mexican peso, Canadian dollar, Brazilian real and
  Japanese yen.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The table below summarizes
  the Company's outstanding foreign exchange option contracts as of December 31,
  2000. The fair value of option contracts, which changes over time, is estimated
  by using the Black-Scholes model and is based on year-end currency rates. The
  fair value of option contracts should be viewed in relation to the fair value
  of the underlying hedged transactions and the overall reduction in exposure
  to adverse fluctuations in foreign currency exchange rates.</font></p>
<table border=0 cellspacing=1 cellpadding=7 width=672>
  <tr bgcolor="" align="none">
    <td width="34%" valign="TOP" height="60" align="none">
      <div align="left">Dollars in Millions</div>
    </td>
    <td width="16%" valign="TOP" height="60">
      <p align="CENTER">Weighted Average Strike Price
    </td>
    <td width="13%" valign="TOP" height="60">
      <p align="CENTER"></p>
      <p align="CENTER">Notional Amount
    </td>
    <td width="13%" valign="TOP" height="60">
      <p align="CENTER"></p>
      <p align="CENTER">Carrying Value
    </td>
    <td width="13%" valign="TOP" height="60">
      <p align="CENTER"></p>
      <p align="CENTER"></p>
      <p align="CENTER">Fair Value
    </td>
    <td width="11%" valign="TOP" height="60">
      <p align="CENTER"></p>
      <p align="CENTER"></p>
      <p align="CENTER">Maturity
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">Option Contracts Purchased Right
      to Sell:</td>
    <td width="16%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Euro
    </td>
    <td width="16%" valign="TOP">
      <p align="right">0.95
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">$842
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">$16
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">$31
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Mexican Peso
    </td>
    <td width="16%" valign="TOP">
      <p align="right">9.42
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">143
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">7
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">11
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Brazilian Real
    </td>
    <td width="16%" valign="TOP">
      <p align="right">1.78
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">119
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">5
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">17
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Australian Dollar
    </td>
    <td width="16%" valign="TOP">
      <p align="right">0.58
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">47
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">1
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">3
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Philippine Peso
    </td>
    <td width="16%" valign="TOP">
      <p align="right">44.56
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">37
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">2
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">5
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Canadian Dollar
    </td>
    <td width="16%" valign="TOP">
      <p align="right">1.49
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">23
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">-
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">-
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Chinese renminbi
    </td>
    <td width="16%" valign="TOP">
      <p align="right">8.28
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">21
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">1
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">-
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> British Pound
    </td>
    <td width="16%" valign="TOP">
      <p align="right">1.56
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">20
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">-
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">1
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p> Other Currencies
    </td>
    <td width="16%" valign="TOP">
      <p align="right">Various
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">67
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">1
      </dir>
    </td>
    <td width="13%" valign="TOP">
      <dir>
        <p align="RIGHT">5
      </dir>
    </td>
    <td width="11%" valign="TOP">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none">
      <p>Right to buy:&#9;
    </td>
    <td width="16%" valign="TOP">&nbsp; </td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none" height="41">
      <p> Japanese Yen
    </td>
    <td width="16%" valign="TOP" height="41">
      <p align="right">108.78
    </td>
    <td width="13%" valign="TOP" height="41">
      <p align="RIGHT"><u>76 </u>
    </td>
    <td width="13%" valign="TOP" height="41">
      <dir>
        <p align="RIGHT"><u>- </u>
      </dir>
    </td>
    <td width="13%" valign="TOP" height="41">
      <p align="RIGHT"><u>1 </u>
    </td>
    <td width="11%" valign="TOP" height="41">
      <p>2001
    </td>
  </tr>
  <tr bgcolor="">
    <td width="34%" valign="TOP" align="none" height="45">
      <div align="right">TOTAL</div>
    </td>
    <td width="16%" valign="TOP" height="45">&nbsp; </td>
    <td width="13%" valign="TOP" height="45">
      <p align="right"><u>$1,395</u>
    </td>
    <td width="13%" valign="TOP" height="45">
      <p align="right"><u>$33</u>
    </td>
    <td width="13%" valign="TOP" height="45">
      <div align="right">
        <blockquote><u>$74</u></blockquote>
      </div>
    </td>
    <td width="11%" valign="TOP" height="45">&nbsp; </td>
  </tr>
</TABLE>
<p align="JUSTIFY"><font face="TIMES" color="#000000">At December 31, 1999, the
  Company held right-to-sell option contracts with an aggregate notional amount,
  carrying value and fair value of $1,621 million, $28 million and $69 million,
  respectively. These contracts related primarily to option contracts with the
  right to sell euros, Mexican pesos and Canadian dollars. Other contracts at
  December 31, 1999 included right-to-buy option contracts, primarily to buy Japanese
  yen for US dollars. These contracts had an aggregate notional amount and fair
  value of $141 million and $20 million, respectively, and no carrying value.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company maintains cash
  and cash equivalents, time deposits and marketable securities with various financial
  institutions. These financial institutions are located primarily in the US and
  Europe. Company policy is designed to limit exposure to any one financial institution.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Recently Issued Accounting
  Standards</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">In June 1998, the Financial
  Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards
  (SFAS) No. 133, <i>Accounting for Derivative Instruments and Hedging Activities</i>.
  This statement requires that companies recognize all derivatives as either assets
  or liabilities on the balance sheet and measure these instruments at fair value.
  In June 1999, the FASB issued SFAS No. 137, <i>Accounting for Derivative Instruments
  and Hedging Activities - Deferral of the effective date of FASB Statement No.
  133</i>. This statement deferred the effective date of SFAS No. 133 to fiscal
  years beginning after June 15, 2000. In June 2000, the FASB issued SFAS No.
  138, <i>Accounting for Certain Derivative Instruments and Certain Hedging Activities</i>,
  which made minor amendments to SFAS No. 133. The Company adopted SFAS No. 133,
  as amended, on January 1, 2001. The adoption of this accounting requirement
  will not have a material effect on either the Company's consolidated financial
  statements or hedging programs.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">26</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Euro Conversion</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">On January 1, 1999, certain
  members of the European Union established fixed conversion rates between their
  existing currencies and the European Union's common currency, known as the euro.
  It is planned that by July 1, 2002 the participating countries will withdraw
  all currencies and use the euro exclusively.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company has committed
  resources to conduct assessments and to take corrective actions to ensure it
  is prepared for the introduction of the euro. The Company is actively addressing
  the many areas involved with the introduction of the euro, including information
  management, finance, legal and tax. This review includes the conversion of information
  technology, business and financial systems; evaluation of currency risk; and
  the effect on the Company's financial instruments, as well as the impact on
  the pricing and distribution of Company products. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">The Company believes the
  effect of introduction of the euro, as well as any related cost of conversion,
  will not have a material impact on the results of operations, financial condition
  and cash flows. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Financial Position</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Cash and cash equivalents,
  time deposits and marketable securities at December 31, 2000 were denominated
  primarily in US dollar instruments with near-term maturities. The average interest
  yield on cash and cash equivalents was 5.9% at December 31, 2000, while interest
  yields on time deposits and marketable securities averaged 5.7% at December
  31, 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Short-term borrowings and
  long-term debt at December 31, 2000 are denominated primarily in US dollars
  but also include Japanese yen long-term debt of $272 million. During the year
  the Company reduced short-term borrowings by $247 million primarily as a result
  of the paydown of the international commercial paper program.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Internally generated cash
  provided by operations was $4.7 billion in 2000, $4.2 billion in 1999 and $3.8
  billion in 1998. Cash provided by operations continued to be the Company's primary
  source of funds to finance operating needs and expenditures for new plants and
  equipment. As part of the Company's ongoing commitment to improve plant efficiency
  and maintain superior research facilities, the Company has invested $2.1 billion
  in capital expansion over the past three years. Cash flow from operations also
  included product liability payments, net of insurance recoverable receipts of
  $73 million in 2000, $667 million in 1999 and $519 million in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Cash provided by operations
  also was used over the past three years to pay dividends of $5.2 billion, to
  finance $5.3 billion of the Company's share repurchase program and to fund business
  acquisitions, including the purchase of patents and trademarks, at a cost of
  $555 million. The Company's share repurchase program authorizes the Company
  to purchase common stock from time to time in the open market or through private
  transactions as market conditions permit.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">27</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">During 2000, the Company
  purchased 40 million shares of common stock at a cost of $2.3 billion, bringing
  the total shares acquired since the program's inception to 340 million. In September
  2000, the Company announced a $2 billion increase in the stock repurchase program
  authorization. During the past three years, the Company has repurchased 93 million
  shares at a cost of $5.3 billion. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Employment levels for continuing
  operations of 44,004 at December 2000 decreased from prior year levels of 45,955.
  Sales per employee improved to $414 thousand in 2000 from $367 thousand in 1999
  and $324 thousand in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Return on Stockholders'
  Equity, excluding nonrecurring items, improved over the last three years and
  was 48.3% in 2000, 46.7% in 1999 and 43.5% in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">Forward Looking Information</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="TIMES" color="#000000">This Form 10-K Annual Report,
  and other written and oral statements that the Company makes from time to time,
  contain certain forward-looking statements within the meaning of the Private
  Securities Litigation Reform Act of 1995 regarding, among other things, statements
  relating to goals, plans and projections with respect to the Company's financial
  position, results of operations, market position, product development and business
  strategy. These statements may be identified by the fact that they use words
  such as &quot;anticipate,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;project,&quot;
  &quot;intend,&quot; &quot;plan,&quot; &quot;believe,&quot; and other words and
  terms of similar meaning in connection with any discussion of future operating
  or financial performance. Such forward-looking statements are based on current
  expectations and involve inherent risks and uncertainties, including factors
  that could delay, divert or change any of them, and could cause actual outcomes
  and results to differ materially from current expectations. These factors include,
  among other things, market factors, competitive product development, governmental
  regulations and legislation, patent positions and litigation. Further details
  and a discussion of these and other risks and uncertainties, are included in
  Exhibit 99 to this Form 10-K Annual Report. We undertake no obligation to publicly
  update any forward-looking statement, whether as a result of new information,
  future events or otherwise. </font></p>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">28</font></p>
<p>&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" size="3" color="#000000">Item 8. FINANCIAL
  STATEMENTS AND SUPPLEMENTARY DATA.</font></p>
<p align="JUSTIFY"></p>
<p align="CENTER"><font face="CG Times" color="#000000"><b>&#9;</b></font><font face="CG Times" size="4" color="#000000">BRISTOL-MYERS
  SQUIBB COMPANY</font></p>
<p align="CENTER"><font color="#000000"><b><font face="CG Times" size="3">CONSOLIDATED
  STATEMENT OF EARNINGS</font></b></font></p>
<p align="CENTER"><font face="CG Times" size="3" color="#000000">(in millions
  except per share amounts)</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=672>
  <tr bgcolor="" align="none">
    <td width="57%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="43%" valign="TOP" colspan=3 height=21><b>
      <dir>
        <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u></p>
        <p align="CENTER">
      </dir>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><u><font face="CG Times" size="3">EARNINGS</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">2000 </font></u> </b>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1999 </font></u> </b>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1998 </font></u> </b>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=37 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><font face="CG Times" size="3">Net Sales</font>
    </td>
    <td width="14%" valign="TOP" height=37>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3">$18,216</font></u>
    </td>
    <td width="14%" valign="TOP" height=37>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3">$16,878</font></u>
    </td>
    <td width="14%" valign="TOP" height=37>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3">$15,061</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Expenses:</font>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Cost of products sold</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">4,759</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">4,542</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">3,896</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Marketing, selling and
          administrative</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">3,860</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">3,789</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">3,685</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Advertising and product
          promotion</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,672</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,549</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,518</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Research and development</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,939</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,759</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,506</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Special charge</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">-</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">-</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">800</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Provision for restructuring</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">508</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">-</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">157</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Gain on sale of business</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">(160)</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">-</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">(201)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Other</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 160</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 81</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 62</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">12,738</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">11,720</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">11,423</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=29 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Earnings from Continuing
        Operations Before Income Taxes</font> </p>
    </td>
    <td width="14%" valign="TOP" height=29>
      <p align="RIGHT"><br>
        <font face="CG Times" size="3">5,478</font> </p>
    </td>
    <td width="14%" valign="TOP" height=29>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3"><br>
        5,158</font>
    </td>
    <td width="14%" height=29>
      <p align="RIGHT"> <font face="CG Times" size="3">3,638</font> </p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=8 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none">
      <p><font face="CG Times" size="3">Provision for income taxes</font>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3">1,382</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3">1,369</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 888</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Earnings from Continuing
        Operations</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">4,096</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">3,789</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">2,750</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=10 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Discontinued Operations</font>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3"> Net earnings</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">375</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">378</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">391</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3"> Net gain on disposal</font>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3">240</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=26 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 615</font></u>
    </td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 378</font></u>
    </td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 391</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=24 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Net Earnings</font>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$4,711</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$4,167</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$3,141</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Earnings Per Common Share</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=8 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Basic</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Earnings from Continuing
          Operations</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$2.08</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$1.91</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$1.38</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Discontinued Operations</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <blockquote>
        <p><font face="CG Times" size="3"> Net earnings</font> </p>
      </blockquote>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.19</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.19</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.20</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <blockquote>
        <p><font face="CG Times" size="3"> Net gain on disposal</font> </p>
      </blockquote>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .13</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .32</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 19</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .20</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Net Earnings</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.40</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.10</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.58</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=8 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Diluted</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Earnings from Continuing
          Operations</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$2.05</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$1.87</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$1.36</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Discontinued Operations</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <blockquote>
        <p><font face="CG Times" size="3"> Net earnings</font> </p>
      </blockquote>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.19</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.19</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">.19</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <blockquote>
        <p><font face="CG Times" size="3"> Net gain on disposal</font> </p>
      </blockquote>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .12</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> -</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .31</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .19</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times" size="3"> .19</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=24 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Net Earnings</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.36</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$2.06</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$1.55</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Average Common Shares
        Outstanding </font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"></p>
      <p align="RIGHT">&nbsp;
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT">&nbsp;</p>
      <p align="RIGHT">&nbsp;
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT">&nbsp;</p>
      <p align="RIGHT">&nbsp;
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3"> Basic</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,965</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,984</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,987</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3"> Diluted</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">1,997</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">2,027</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">2,031</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=8 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=8>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Dividends Per Common Share</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$.98</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$.86</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">$.78</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p><font face="CG Times" size="3" color="#000000">The accompanying notes are an
  integral part of these financial statements.</font></p>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">29</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" size="4" color="#000000">BRISTOL-MYERS
  SQUIBB COMPANY</font></p>
<p align="CENTER"><font color="#000000"><b><font face="CG Times" size="3">CONSOLIDATED
  STATEMENT OF</font></b></font></p>
<p align="CENTER"><font color="#000000"><b><font face="CG Times" size="3">COMPREHENSIVE
  INCOME AND RETAINED EARNINGS</font></b></font></p>
<p align="CENTER"><font size="3" color="#000000">(in millions except per share
  amounts)</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=672>
  <tr bgcolor="" align="none">
    <td width="57%" valign="TOP" height=26 align="none"><b>
      <p></p>
      </b></td>
    <td width="43%" valign="TOP" colspan=3 height=26><b>
      <dir>
        <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u>
      </dir>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">2000 </font></u> </b>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1999 </font></u> </b>
    </td>
    <td width="14%" valign="TOP" height=21>
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1998</font></u> </b>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><u><font face="CG Times" size="3">COMPREHENSIVE INCOME</font></u>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><font face="CG Times" size="3">Net Earnings</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">$4,711</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">$4,167</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">$3,141</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><font face="CG Times" size="3">Other Comprehensive Income:</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Foreign currency translation</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">(282)</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">(212)</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size="3">(86)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <dir>
        <p align="JUSTIFY"><font face="CG Times" size="3">Tax effect</font>
      </dir>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><u><font face="CG Times" size="3"> (5)</font></u>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 18</font></u>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><font face="CG Times" size=3><u> (3</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=10 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=16 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Total Other Comprehensive
        Income</font>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><u><font face="CG Times" size="3"> (287)</font></u>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><u><font face="CG Times" size="3"> (194)</font></u>
    </td>
    <td width="14%" valign="TOP" height=16>
      <p align="RIGHT"><u><font face="CG Times" size="3"> (89)</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=10 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=10>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=24 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Comprehensive Income</font>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$4,424</font></u></p>
      <p align="RIGHT">
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$3,973</font></u></p>
      <p align="RIGHT">
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$3,052</font></u></p>
      <p align="RIGHT">
    </td>
  </tr>
</TABLE>
<table cellspacing=0 border=0 cellpadding=7 width=672>
  <tr bgcolor="" align="none">
    <td width="57%" valign="TOP" height=18 align="none">&nbsp;</td>
    <td width="14%" valign="TOP" height=18>&nbsp;</td>
    <td width="14%" valign="TOP" height=18>&nbsp;</td>
    <td width="14%" valign="TOP" height=18>&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><u><font face="CG Times" size="3">RETAINED EARNINGS</font></u>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><font face="CG Times" size="3"> Retained Earnings, January
        1</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">$15,000</font> </p>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">$12,540</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times" size="3">$10,950</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=34 align="none">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><font face="CG Times"> Net earnings</font>
    </td>
    <td width="14%" valign="TOP" height=34>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 4,711</font></u>
    </td>
    <td width="14%" valign="TOP" height=34>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 4,167</font></u>
    </td>
    <td width="14%" valign="TOP" height=34>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 3,141</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">19,711</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">16,707</font>
    </td>
    <td width="14%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times" size="3">14,091</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=26 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3"> Less dividends</font>
    </td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 1,930</font></u>
    </td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 1,707</font></u>
    </td>
    <td width="14%" valign="TOP" height=26>
      <p align="RIGHT"><u><font face="CG Times" size="3"> 1,551</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="57%" valign="TOP" height=24 align="none">
      <p align="JUSTIFY"><font face="CG Times" size="3">Retained Earnings, December
        31</font>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$17,781</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$15,000</font></u>
    </td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times" size="3">$12,540</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY">&nbsp;</p>
<p>&nbsp;</p>
<p><font face="CG Times" size="3" color="#000000">The accompanying notes are an
  integral part of these financial statements.</font></p>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">30</font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;BRISTOL-MYERS
  SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;<b>CONSOLIDATED
  BALANCE SHEET</b></font></p>
<p align="center"><font color="#000000"><b><font face="CG Times" size="3">&#9;ASSETS</font></b></font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;(dollars
  in millions)</font></p>
<p align="left"></p>
<div align="left">
  <table 0 cellspacing=1 cellpadding=7 width=691>
    <tr bgcolor="" align="none">
      <td width="63%" valign="TOP" align="none">&nbsp;</td>
      <td width="38%" valign="TOP" colspan=3><b>
        <p align="CENTER"> <font face="CG Times" size="3"><u> December 31, </u></font>
        </b></td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=34 align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><u><font face="CG Times">ASSETS</font></u>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><b><u><font face="CG Times">2000</font></u> </b>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><b><u><font face="CG Times">1999</font></u> </b>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><b><u><font face="CG Times">1998</font></u> </b>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><font face="CG Times">Current Assets:</font>
      </td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Cash and cash equivalents</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$3,182</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$2,720</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$2,244</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Time deposits and marketable
            securities</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">203</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">237</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">285</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Receivables, net of allowances</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">3,662</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">3,272</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">3,190</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Inventories</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,831</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">2,126</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,873</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=12 align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Prepaid expenses</font>
        </dir>
      </td>
      <td width="13%" valign="TOP" height=12>
        <p align="RIGHT"><u><font face="CG Times"> 946</font></u>
      </td>
      <td width="13%" valign="TOP" height=12>
        <p align="RIGHT"><u><font face="CG Times"> 912</font></u>
      </td>
      <td width="13%" valign="TOP" height=12>
        <p align="RIGHT"><u><font face="CG Times">1,190</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=34 align="none">
        <p align="JUSTIFY"></p>
        <dir>
          <p align="JUSTIFY"><font face="CG Times"> Total Current Assets</font>
        </dir>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">9,824</font></u>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">9,267</font></u>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">8,782</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><font face="CG Times">Property, Plant and Equipment,
          net</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">4,548</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">4,621</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">4,429</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><font face="CG Times">Insurance Recoverable</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">262</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">468</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">523</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Excess of cost over net tangible
            assets arising from business acquisitions</font> </p>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><br>
          <font face="CG Times">1,436</font> </p>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><br>
          <font face="CG Times">1,502</font> </p>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times"><br>
          1,587</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=34 align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><font face="CG Times">Other Assets</font>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times"> 1,508</font></u>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times"> 1,256</font></u>
      </td>
      <td width="13%" valign="TOP" height=34>
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times"> 951</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none" height="47">
        <p align="JUSTIFY"></p>
        <dir>
          <dir>
            <p align="JUSTIFY"><font face="CG Times">Total Assets</font>
          </dir>
        </dir>
      </td>
      <td width="13%" valign="TOP" height="47">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">$17,578</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP" height="47">
        <p align="RIGHT"><u><font face="CG Times">$17,114</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP" height="47">
        <p align="RIGHT"><u><font face="CG Times">$16,272</font></u></p>
        <p align="RIGHT">
      </td>
    </tr>
  </TABLE>
</div>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY">&nbsp;</p>
<p><font face="CG Times" size="3" color="#000000">The accompanying notes are an
  integral part of these financial statements.</font></p>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">31</font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;BRISTOL-MYERS
  SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;<b>CONSOLIDATED
  BALANCE SHEET</b></font></p>
<p align="center"><font color="#000000"><b><font face="CG Times" size="3">&#9;LIABILITIES
  AND STOCKHOLDERS' EQUITY</font></b></font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;(dollars
  in millions)</font></p>
<div align="left">
  <table cellspacing=0 border=0 cellpadding=7 width=691>
    <tr bgcolor="" align="none">
      <td width="63%" valign="TOP" height=21 align="none"><b>
        <p></p>
        </b></td>
      <td width="38%" valign="TOP" colspan=3 height=21><b>
        <p align="CENTER"> <font face="CG Times" size="3"><u> December 31, </u></font>
        </b></td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=45 align="none">
        <p align="JUSTIFY"><font face="CG Times"><u>LIABILITIES</u></font> </p>
      </td>
      <td width="13%" valign="TOP" height=45>
        <p align="RIGHT"></p>
        <p align="RIGHT"><b><u><font face="CG Times">2000</font></u></b></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP" height=45>
        <p align="RIGHT"><b><u><font face="CG Times">1999</font></u></b></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP" height=45>
        <p align="RIGHT"><b><u><font face="CG Times">1998</font></u></b></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times">Current Liabilities:</font>
      </td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Short-term borrowings</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$162</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$432</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$482</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Accounts payable</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,702</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,657</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,380</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Accrued expenses</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">2,881</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">2,367</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">2,302</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Product liability</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">186</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">287</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">877</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=21 align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">US and foreign income taxes
            payable</font>
        </dir>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times"> 701</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times"> 794</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times"> 750</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times"> Total Current Liabilities</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">5,632</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">5,537</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">5,791</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=16 align="none"><i>
        <p></p>
        </i></td>
      <td width="13%" valign="TOP" height=16>
        <p></p>
      </td>
      <td width="13%" valign="TOP" height=16>
        <p></p>
      </td>
      <td width="13%" valign="TOP" height=16>
        <p></p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=16 align="none">
        <p align="JUSTIFY"><font face="CG Times">Other Liabilities</font>
      </td>
      <td width="13%" valign="TOP" height=16>
        <p align="RIGHT"><font face="CG Times">1,430</font>
      </td>
      <td width="13%" valign="TOP" height=16>
        <p align="RIGHT"><font face="CG Times">1,590</font>
      </td>
      <td width="13%" valign="TOP" height=16>
        <p align="RIGHT"><font face="CG Times">1,541</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=21 align="none">
        <p align="JUSTIFY"><font face="CG Times">Long-Term Debt</font>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">1,336</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">1,342</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">1,364</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <dir>
          <p align="JUSTIFY"><font face="CG Times"> Total Liabilities</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">8,398</font></u>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">8,469</font></u>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">8,696</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <p align="JUSTIFY"><u><font face="CG Times">STOCKHOLDERS' EQUITY</font></u>
      </td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
      <td width="13%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none" height="112">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Preferred stock, $2 convertible
            series:</font></p>
          <dir>
            <p align="JUSTIFY"><font face="CG Times">Authorized 10 million shares;
              issued and outstanding 9,864 in 2000, 10,977 in 1999 and 11,684
              in 1998, liquidation value of $50 per share</font>
          </dir>
        </dir>
      </td>
      <td width="13%" valign="TOP" height="112">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="13%" valign="TOP" height="112">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="13%" valign="TOP" height="112">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Common stock, par value of
            $.10 per share:</font></p>
          <dir>
            <p align="JUSTIFY"><font face="CG Times">Authorized 4.5 billion shares;
              issued 2,197,900,835 in 2000, 2,192,970,504 in 1999 and 2,188,316,808
              in 1998</font>
          </dir>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times"><br>
          <br>
          220</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times"><br>
          <br>
          219</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT">&nbsp;</p>
        <p align="RIGHT"><font face="CG Times"><br>
          <br>
          219</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Capital in excess of par value
            of stock</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">2,002</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,533</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">1,075</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Other Comprehensive Income</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(1,103)</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(816)</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(622)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" height=21 align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Retained earnings</font>
        </dir>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">17,781</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">15,000</font></u>
      </td>
      <td width="13%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">12,540</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">&nbsp;</td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">18,900</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">15,936</font>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">13,212</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Less cost of treasury stock
            - 244,365,726 common shares in 2000, 212,164,851 in 1999 and 199,550,532
            in 1998</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><br>
          <u><font face="CG Times">9,720</font></u> </p>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><br>
          <u><font face="CG Times">7,291</font></u> </p>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><br>
          <u><font face="CG Times">5,636</font></u> </p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <dir>
          <dir>
            <p align="JUSTIFY"><font face="CG Times">Total Stockholders' Equity</font>
          </dir>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">9,180</font></u>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">8,645</font></u>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">7,576</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="63%" valign="TOP" align="none">
        <p align="JUSTIFY"></p>
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Total Liabilities and Stockholders'
            Equity</font>
        </dir>
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><u><font face="CG Times">$17,578</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><u><font face="CG Times">$17,114</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="13%" valign="TOP">
        <p align="RIGHT"><u><font face="CG Times">$16,272</font></u></p>
        <p align="RIGHT">
      </td>
    </tr>
  </TABLE>
</div>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font color="#000000">T<font face="CG Times" size="3">he accompanying
  notes are an integral part of these financial statements.</font></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER"><font face="CG Times" size="3" color="#000000">32</font></p>
<p align="CENTER"><font face="CG Times" size="3" color="#000000">BRISTOL-MYERS
  SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;<b>CONSOLIDATED
  STATEMENT OF CASH FLOWS</b></font></p>
<p align="center"><font face="CG Times" size="3" color="#000000">&#9;(dollars
  in millions)</font></p>
<p align="JUSTIFY"> </p>
<div align="left">
  <table cellspacing=0 border=0 cellpadding=7 width=690>
    <tr bgcolor="" align="none">
      <td width="66%" valign="TOP" height=21 align="none"><b>
        <p></p>
        </b></td>
      <td valign="TOP" colspan=3 height=21>
        <dir>
          <p align="CENTER"><b><u><font face="CG Times" size="3"> Year Ended December
            31, </font></u> </b>
        </dir>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none"><i>
        <p align="JUSTIFY"><font face="CG Times" size="3">&#9;</font>
        </i></td>
      <td width="10%" valign="TOP">
        <dir>
          <p align="CENTER"><u><font face="CG Times">2000</font></u>
        </dir>
      </td>
      <td width="12%" valign="TOP">
        <dir>
          <p align="CENTER"><u><font face="CG Times">1999</font></u>
        </dir>
      </td>
      <td width="12%" valign="TOP">
        <dir>
          <p align="CENTER"><u><font face="CG Times">1998</font></u>
        </dir>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=8 align="none"><i>
        <p></p>
        </i></td>
      <td width="10%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times">Cash Flows From Operating Activities:</font>
      </td>
      <td width="10%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Net earnings</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$4,711</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$4,167</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">$3,141</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Depreciation and amortization</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">746</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">678</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">625</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Special Charge</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">800</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Provision for restructuring/other</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">542</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">201</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p><font face="CG Times">Gain on sale of businesses/product divestitures</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(562)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(201)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Other operating items</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">10</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(79)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(1)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Receivables</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(494)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(176)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(253)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Inventories</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">75</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(317)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(139)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Accounts payable and accrued
            expenses</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">256</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">258</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">284</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Income taxes</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(54)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">477</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">34</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Product liability</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(173)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(726)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(715)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Insurance recoverable</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">100</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">59</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">196</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Pension Contribution</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(230)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">-</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=32 align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Other assets and liabilities</font>
        </dir>
      </td>
      <td width="10%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(275</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(117</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(190</u>)</font></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=21 align="none">
        <p align="JUSTIFY"><font face="CG Times"> Net Cash Provided by Operating
          Activities</font>
      </td>
      <td width="10%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">4,652 </font></u>
      </td>
      <td width="12%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">4,224 </font></u>
      </td>
      <td width="12%" valign="TOP" height=21>
        <p align="RIGHT"><u><font face="CG Times">3,782</font></u>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times">Cash Flows From Investing Activities:</font>
      </td>
      <td width="10%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p><font face="CG Times">Proceeds from sales of time deposits and marketable
            securities</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">45</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">51</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times">309</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Purchases of time deposits
            and marketable securities</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(10)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(4)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(256)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Additions to fixed assets</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(589)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(709)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(788)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Proceeds from sale of businesses/product
            divestitures</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">848</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">134</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">417</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p><font face="CG Times">Businesses acquisitions(including purchase
            of trademarks/patents)</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"></p>
        <p align="RIGHT"><font face="CG Times"><br>
          (196)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><br>
          <font face="CG Times">(266)</font> </p>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><br>
          <font face="CG Times">(93)</font> </p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Other, net</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><u><font face="CG Times"> (82) </font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><u><font face="CG Times"> 35 </font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><u><font face="CG Times"> 65 </font></u></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=32 align="none">
        <p align="JUSTIFY"><font face="CG Times"> Net Cash Provided by (Used in)
          Investing Activities</font>
      </td>
      <td width="10%" valign="TOP" height=32>
        <p align="RIGHT"><u><font face="CG Times"> 16 </font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(759</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(346</u>) </font></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times">Cash Flows From Financing Activities:</font>
      </td>
      <td width="10%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
      <td width="12%" valign="TOP">&nbsp;</td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Short-term borrowings</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(247)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(26)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(81)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Long-term debt</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">6</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(54)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">73</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Issuances of common stock under
            stock plans</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">352</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">254</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">478</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p><font face="CG Times">Purchases of treasury stock</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(2,338)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(1,419)</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">(1,561)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <dir>
          <p align="JUSTIFY"><font face="CG Times">Dividends paid</font>
        </dir>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times"><u>(1,930</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times"><u>(1,707</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times"><u>(1,551</u>) </font></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=32 align="none">
        <p align="JUSTIFY"><font face="CG Times"> Net Cash Used in Financing Activities</font>
      </td>
      <td width="10%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(4,157</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(2,952</u>) </font></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><font face="CG Times"><u>(2,642</u>) </font></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=8 align="none"><i>
        <p></p>
        </i></td>
      <td width="10%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=26 align="none">
        <p align="JUSTIFY"><font face="CG Times">Effect of Exchange Rates on Cash</font>
      </td>
      <td width="10%" valign="TOP" height=26>
        <p align="RIGHT"><font face="CG Times"><u> (49</u>)</font>
      </td>
      <td width="12%" valign="TOP" height=26>
        <p align="RIGHT"><font face="CG Times"><u> (37</u>)</font>
      </td>
      <td width="12%" valign="TOP" height=26>
        <p align="RIGHT"><font face="CG Times"><u> (6</u>)</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" align="none">
        <p align="JUSTIFY"><font face="CG Times">Increase in Cash and Cash Equivalents</font>
      </td>
      <td width="10%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">462</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">476</font>
      </td>
      <td width="12%" valign="TOP">
        <p align="RIGHT"><font face="CG Times">788</font>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=32 align="none">
        <p align="JUSTIFY"><font face="CG Times">Cash and Cash Equivalents at
          Beginning of Period</font>
      </td>
      <td width="10%" valign="TOP" height=32>
        <p align="RIGHT"><u><font face="CG Times">2,720 </font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><u><font face="CG Times">2,244 </font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=32>
        <p align="RIGHT"><u><font face="CG Times">1,456 </font></u></p>
        <p align="RIGHT">
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=8 align="none"><i>
        <p></p>
        </i></td>
      <td width="10%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
      <td width="12%" valign="TOP" height=8>
        <p></p>
      </td>
    </tr>
    <tr bgcolor="">
      <td width="66%" valign="TOP" height=29 align="none">
        <p align="JUSTIFY"><font face="CG Times">Cash and Cash Equivalents at
          End of Period</font>
      </td>
      <td width="10%" valign="TOP" height=29>
        <p align="RIGHT"><u><font face="CG Times">$3,182</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=29>
        <p align="RIGHT"><u><font face="CG Times">$2,720</font></u></p>
        <p align="RIGHT">
      </td>
      <td width="12%" valign="TOP" height=29>
        <p align="RIGHT"><u><font face="CG Times">$2,244</font></u></p>
        <p align="RIGHT">
      </td>
    </tr>
  </TABLE>
</div>
<p>&nbsp;</p>
<p><font face="CG Times" size="3" color="#000000">The accompanying notes are an
  integral part of these financial statements.</font></p>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">33</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 1 ACCOUNTING
  POLICIES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Basis of Consolidation
  - The consolidated financial statements include the accounts of Bristol-Myers
  Squibb Company and all of its subsidiaries.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Cash and Cash Equivalents
  - Cash and cash equivalents primarily include securities with a maturity of
  three months or less at the time of purchase, recorded at cost, which approximates
  market value.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Time Deposits and Marketable
  Securities - Time deposits and marketable securities are available for sale
  and are recorded at fair value, which approximates cost.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Inventory Valuation -
  Inventories are generally stated at average cost, not in excess of market.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Capital Assets and Depreciation
  - Expenditures for additions, renewals and betterments are capitalized at cost.
  Depreciation is generally computed by the straight-line method based on the
  estimated useful lives of the related assets. The estimated useful lives of
  the major classes of depreciable assets are 50 years for buildings and 3 to
  40 years for machinery, equipment and fixtures.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Excess of Cost over Net
  Tangible Assets - The excess of cost over net tangible assets received in business
  acquisitions is being amortized on a straight-line basis over periods not exceeding
  40 years. The excess of cost over net tangible assets is periodically reviewed
  for impairment based on an assessment of future operations (including cash flows)
  to ensure that the excess of cost over net tangible assets is appropriately
  valued.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Product Liability - Accruals
  for product liability are recorded, on an undiscounted basis, when it is probable
  that a liability has been incurred and the amount of the liability can be reasonably
  estimated, based on existing information. These accruals are adjusted periodically
  as assessment efforts progress or as additional information becomes available.
  Receivables for related insurance or other third-party recoveries for product
  liabilities are recorded, on an undiscounted basis, when it is probable that
  a recovery will be realized. Insurance recoverable recorded on the balance sheet
  has, in general, payment terms of two years or less.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Revenue Recognition -
  Revenue from product sales is recognized upon shipment to customers.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Earnings Per Share -
  Basic earnings per common share are computed using the weighted average number
  of shares outstanding during the year. Diluted earnings per common share are
  computed using the weighted average number of shares outstanding during the
  year, plus the incremental shares outstanding assuming the exercise of dilutive
  stock options.</font></p>
<p align="CENTER"></p>
<p><font face="CG Times" color="#000000">Reclassifications - Certain reclassifications
  have been made to prior year amounts to conform with current year presentation.</font></p>
<p align="CENTER"></p>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">34</font></p>
<p align="center"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 2 DISCONTINUED
  OPERATIONS</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">On September 28, 2000,
  the Company announced the planned divestitures of its Clairol and Zimmer businesses.
  The Company expects these businesses to be divested in 2001. Accordingly, the
  operations of Clairol (which includes its Matrix Essentials, Inc. "Matrix" affiliate)
  and Zimmer have been reflected as discontinued operations in the accompanying
  consolidated statement of earnings.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In 2000, the Company
  completed the sale of Matrix to Cosmair, Inc., a wholly owned US subsidiary
  of L'Oreal S.A., resulting in a pretax gain of $402 million ($240 million after
  taxes). This gain is included in gain on disposal of discontinued operations.</font></p>
<p align="CENTER"></p>
<p><font face="CG Times" color="#000000">The net sales and earnings of discontinued
  operations are as follows:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times" size="3">Year Ended December
        31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times" size="3">2000</font></u> </b>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1999</font></u> </b>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><b><u><font face="CG Times" size="3">1998</font></u> </b>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=13 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p><font face="CG Times">Net sales</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$3,115</font></u></p>
      <p align="RIGHT">
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$3,344</font></u></p>
      <p align="RIGHT">
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$3,223</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=13 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=13>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p><font face="CG Times">Earnings before income taxes</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">606</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">609</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">630</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p><font face="CG Times">Income taxes</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 231</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 231</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 239</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p><font face="CG Times">Net earnings from discontinued operations</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> $375</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> $378</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> $391</font></u>
    </td>
  </tr>
</TABLE>
<p><font face="CG Times" color="#000000">Earnings before income taxes for the
  years ended December 31, 2000 and 1998 include restructuring charges of $34
  million and $44 million, respectively. </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The consolidated balance
  sheet and consolidated statement of cash flows include the Clairol and Zimmer
  businesses. The net assets of discontinued operations expected to be disposed
  at December 31, 2000, 1999 and 1998 were as follows:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=26 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=26><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><b><u>2000</u> </b>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><b><u><font face="CG Times">1999</font></u> </b>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><b><u><font face="CG Times">1998</font></u> </b>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Current assets</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT">$866
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$1,141</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$1,055</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Property, Plant and Equipment,
        net</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT">340
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">396</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">375</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Noncurrent Assets</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT">276
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">280</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">236</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Less:</font>
    </td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
    <td width="12%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Liabilities (principally current)</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u> 558</u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 622</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 466</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net assets of discontinued operations</font>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> $924</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,195</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,200</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company uses a centralized
  approach to cash management and financing of its operations and, accordingly,
  the Company did not allocate debt to these businesses.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Cash flows from operating
  and investing activities of discontinued operations for the years ended December
  31, 2000, 1999 and 1998 were $988 million (including $438 million of net proceeds
  from the sale of Matrix), $261 million and $289 million, respectively.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">35</font></p>
<p align="center"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 3 ACQUISITIONS
  AND DIVESTITURES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In 2000, the company
  completed the sale of three pharmaceutical products - Estrace Cream, Ovcon 35
  and Ovcon 50 as well as its Sea Breeze brand in Japan, resulting in a pretax
  gain of $160 million, recorded in continuing operations.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In June 1999, the company
  acquired CAL-C-TOSE*, a nutritional milk modifier. In September 1999, the company
  entered into a development and commercialization agreement for aripiprazole,
  a novel drug under study in phase III trials as a treatment for schizophrenia,
  with Otsuka Pharmaceutical Co., Ltd. In December 1999, the company completed
  the sale of Laboratori Guieu, a gynecological, pediatric and dermatological
  products business headquartered in Milan, Italy. The gain on the sale was not
  material.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In 1998, the company
  acquired Dong-A Biotech Co., Ltd., a marketer and distributor of pharmaceutical
  products in South Korea. In 1998, the company divested its Ban brand of antiperspirants
  and deodorants, A/S GEA, a Denmark-based generic drug business, and Hexachimie,
  a specialty chemical manufacturer based in France, resulting in a combined pretax
  gain of $201 million.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 4 RESTRUCTURING</font></u></b></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">During 2000, the Company
  recorded pretax charges of $508 million for continuing operations. These charges
  were primarily for restructuring activities related to workforce reductions,
  downsizing and streamlining of operations in certain international markets and
  the ConvaTec business, and the reorganization of the Company's Global Business
  Services. The $508 million of restructuring charges consisted of $298 million
  of employee termination benefits for approximately 5,200 employees, $136 million
  of asset write-downs related to the closure of manufacturing and research facilities
  and $74 million of other expenses. The $398 million liability originally recorded
  in accrued expenses was reduced to $247 million at December 31, 2000. The Company
  expects to substantially complete these restructuring activities by mid-2001.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In 1998, the Company
  recorded pretax charges of $157 million for continuing operations. These restructuring
  charges consisted primarily of asset write-downs and employee-related costs
  related to the consolidation and closure of plants and facilities.<br>
  _____________________________________________________________________________________________
  </font></p>
<p align="JUSTIFY"></p>
<p align="CENTER">&nbsp;</p>
<p align="center"><font face="CG Times" color="#000000">36</font></p>
<p align="center"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 5 EARNINGS
  PER SHARE</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The computations for
  basic earnings per common share and diluted earnings per common share are as
  follows:</font></p>
<p><font face="CG Times" color="#000000">&#9;&#9;&#9;&#9;&#9;</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=679>
  <tr>
    <td width="55%" valign="TOP">
      <p><font face="CG Times">&#9;&#9;&#9;&#9;&#9;&#9;&#9;</font>
    </td>
    <td valign="TOP" colspan=3>
      <p align="CENTER"><u><font face="CG Times" size="3">Year Ended December
        31,</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=16>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP">
      <p><font face="CG Times">Net Earnings from Continuing Operations</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$4,096</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$3,789</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$2,750</font>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP">
      <p><font face="CG Times">Discontinued Operations</font>
    </td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
    <td width="11%" valign="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=38>
      <dir>
        <p><font face="CG Times">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=38>
      <p align="RIGHT"><font face="CG Times">375</font>
    </td>
    <td width="11%" valign="TOP" height=38>
      <p align="RIGHT"><font face="CG Times"> 378</font>
    </td>
    <td width="11%" valign="TOP" height=38>
      <p align="RIGHT"><font face="CG Times"> 391</font>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=37>
      <dir>
        <p><font face="CG Times">Net Gain on Disposal</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=37>
      <p align="RIGHT"><u><font face="CG Times"> 240</font></u>
    </td>
    <td width="11%" valign="TOP" height=37>
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
    <td width="11%" valign="TOP" height=37>
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">615</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">378</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">391</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <dir>
        <p><font face="CG Times">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$4,711</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$4,167</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,141</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=13>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <p><font face="CG Times">Basic:</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <p><font face="CG Times">Average Common Shares Outstanding</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1,965</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1,984</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1,987</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP">
      <p><font face="CG Times">Earnings from Continuing Operations</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$2.08</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$1.91</font>
    </td>
    <td width="11%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$1.38</font>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <p><font face="CG Times">Discontinued Operations</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <dir>
        <p><font face="CG Times">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"> .19</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"> .19</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"> .20</font>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <dir>
        <p><font face="CG Times">Net Gain on Disposal</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">.13</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">.32</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">.19</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">.20</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Net Earnings</font> </p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$2.40</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$2.10</font></u>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1.58</font></u>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Diluted:</font> </p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>&nbsp;</td>
    <td width="11%" valign="TOP" height=21>&nbsp;</td>
    <td width="11%" valign="TOP" height=21>&nbsp;</td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Average Common Shares Outstanding</font></p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><font face="CG Times">1,965</font></div>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="right"><font face="CG Times">1,984</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><font face="CG Times">1,987</font> </div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Incremental Shares Outstanding Assuming the Exercise
          of Dilutive Stock Options</font></p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u><font face="CG Times"><br>
        32</font></u> </div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="right"><br>
        <u><font face="CG Times">43</font></u> </p>
    </td>
    <td width="11%" valign="TOP" height=21>
      <p align="right"><br>
        <u><font face="CG Times">44</font></u> </p>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>&nbsp;</td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>1,997</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>2,027</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>2,031</u></div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>&nbsp;</td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Earnings from Continuing Operations</font></p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right">$2.05</div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right">$1.87</div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right">$1.36</div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>
      <blockquote>
        <p><font face="CG Times">Discontinued Operations</font></p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
    <td width="11%" valign="TOP" height=21>&nbsp; </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=26>
      <blockquote>
        <p><font face="CG Times">Net Earnings</font> </p>
      </blockquote>
    </td>
    <td width="11%" valign="TOP" height=26>
      <div align="right">.19</div>
    </td>
    <td width="11%" valign="TOP" height=26>
      <div align="right">.19</div>
    </td>
    <td width="11%" valign="TOP" height=26>
      <div align="right">.19</div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21><font face="CG Times">Net Gain on Disposal</font>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>.12</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>-</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>-</u></div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21>&nbsp;</td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>.31</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>.19</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>.19</u></div>
    </td>
  </tr>
  <tr>
    <td width="55%" valign="TOP" height=21><font face="CG Times">Net Earnings</font></td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>$2.36</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>$2.06</u></div>
    </td>
    <td width="11%" valign="TOP" height=21>
      <div align="right"><u>$1.55</u></div>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">37</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 6 OTHER
  INCOME AND EXPENSES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=26 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=26><b>
      <p align="CENTER"> <font face="CG Times"><u> Year Ended December 31, </u></font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">&nbsp;</td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Interest income</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$157</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$107</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$87</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Interest expense</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(108)</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(130)</font>
    </td>
    <td width="12%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(154)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" align="none" height="32">
      <p align="JUSTIFY"><font face="CG Times">Other - net</font>
    </td>
    <td width="12%" valign="TOP" height="32">
      <p align="RIGHT"><font face="CG Times"><u>(209</u>)</font>
    </td>
    <td width="12%" valign="TOP" height="32">
      <p align="RIGHT"><font face="CG Times"><u>(58</u>)</font>
    </td>
    <td width="12%" valign="TOP" height="32">
      <p align="RIGHT"><u><font face="CG Times"> 5</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$(160)</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$(81)</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$(62)</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Cash payments for interest
  were $112 million, $119 million and $157 million in 2000, 1999 and 1998, respectively.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 7 PROVISION
  FOR INCOME TAXES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The components of earnings
  from continuing operations before income taxes were:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">US</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$2,570</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$3,203</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$2,191</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY">Non-U.S.
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u>2,908</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u>1,955</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u>1,447</u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u>$5,478</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u>$5,158</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">$3,638</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The above amounts are
  categorized based on the location of the taxing authorities. In 2000, the Company
  continued to convert domestic Puerto Rico operations to non-U.S. operations.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The provision for income
  taxes attributable to continuing operations consisted of:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"> <font face="CG Times"><u> Year Ended December 31,</u></font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Current:</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">US</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$900</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$602</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$658</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY">Non-U.S.
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> 447</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> 346</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times"> 271</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 1,347</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 948</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 929</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Deferred:</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">US</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">44</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">369</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(71)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY">Non-U.S.
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> (9</u>)
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> 52</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times"> 30</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> 35</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u> 421</u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times"><u> (41</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,382</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,369</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$888</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">38</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company's provision
  for income taxes in 2000, 1999 and 1998 was different from the amount computed
  by applying the statutory United States Federal income tax rate to earnings
  before income taxes, as a result of the following:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"><font face="CG Times">% of Earnings</font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="35%" valign="TOP" colspan=3 height=18>
      <p align="CENTER"><u><font face="CG Times">Before Income Taxes</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">US statutory rate</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times"> 35.0%</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">35.0%</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">35.0%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Effect of operations in Ireland
        and Puerto Rico</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(12.2)</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(8.1)</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(7.8)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Special charge</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(.7)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">State and local taxes</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1.2</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.5</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.4</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Foreign/ Other</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1.2</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">(.9)</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">(2.5)</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">25.2%</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">26.5%</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">24.4%</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Prepaid taxes at December
  31, 2000, 1999 and 1998 were $537 million, $567 million and $809 million, respectively.
  The deferred income tax liability, included in Other Liabilities, at December
  31, 2000, 1999 and 1998 was $425 million, $445 million and $277 million, respectively.
  </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The components of prepaid
  and deferred income taxes consisted of:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="65%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="35%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY">Depreciation
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT">$(285)
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT">$(278)
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT">$(278)
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Postretirement and pension benefits</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">49</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">120</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">195</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Product liability</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(54)</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">(13)</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">248</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Restructuring</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">142</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">25</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">55</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Other</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">260</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">268</font></u>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">312</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="65%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$112</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$122</font></u>
    </td>
    <td width="12%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$532</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Income taxes paid during
  the year were $1,620 million, $805 million and $654 million in 2000, 1999 and
  1998, respectively.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company has settled
  its United States Federal income tax returns with the Internal Revenue Service
  through 1991.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">United States Federal
  income taxes have not been provided on substantially all of the unremitted earnings
  of non-U.S. subsidiaries, since it is management's practice and intent to reinvest
  such earnings in the operations of these subsidiaries. The total amount of the
  net unremitted earnings of non-U.S. Subsidiaries was approximately $6.0 billion
  at December 31, 2000.<br>
  _____________________________________________________________________________________________
  </font></p>
<p align="JUSTIFY"></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">39</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 8 INVENTORIES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="38%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Finished goods</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT">$890
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT">$1,472
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$1,209</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Work in process</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">473</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">302</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">236</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Raw and packaging materials</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">468</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">352</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">428</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,831</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$2,126</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,873</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Inventories of discontinued
  operations constituted approximately 18% of total Company inventory for the
  year ended December 31, 2000 and 23% of total Company inventory for the years
  ended December 31, 1999 and 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 9 PROPERTY,
  PLANT AND EQUIPMENT</font></u></b></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="38%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Land</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$167</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$170</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$176</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Buildings</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,142</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,096</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2,875</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Machinery, equipment and fixtures</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">4,059</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">4,093</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,885</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Construction in progress</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">558</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">482</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">572</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">7,926</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">7,841</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">7,508</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Less accumulated depreciation</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">3,378</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">3,220</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">3,079</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$4,548</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$4,621</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$4,429</font></u>
    </td>
  </tr>
</TABLE>
<p align="CENTER"></p>
<p><font face="CG Times" color="#000000">Depreciation expense for the years ended
  December 31, 2000, 1999 and 1998 was $408 million, $384 million and $359 million,
  respectively.</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Property, plant and equipment
  of discontinued operations constituted approximately 8% of total Company property,
  plant and equipment for the years ended December 31, 2000, 1999 and 1998.</font></p>
<p align="JUSTIFY"> </p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 10 SHORT-TERM
  BORROWINGS AND LONG-TERM DEBT</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Included in short-term
  borrowings were amounts due to banks, primarily foreign banks, of $152 million,
  $245 million and $272 million at December 31, 2000, 1999 and 1998, respectively,
  and current installments of long-term debt of $10 million at December 31, 2000
  and 1999 and $43 million at December 31, 1998. Also included in short-term borrowings
  at December 31, 1999 and 1998, was $177 million and $167 million, respectively,
  of commercial paper outstanding. The average interest rate on short-term borrowings
  was 7.97% and on current installments of long-term debt was 6.38% at December
  31, 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">During 2000, the Company
  renewed two credit facilities, aggregating $500 million, with a syndicate of
  lenders as support for its commercial paper program. The credit facilities consist
  of a $250 million, 364-day credit facility, which may be renewed annually with
  the consent of the lenders for an additional 364-day period and a $250 million,
  five-year credit facility, extendible at each anniversary date with the consent
  of the lenders. There were no borrowings outstanding under the credit facilities
  at December 31, 2000. In addition, the Company has unused short-term lines of
  credit with foreign banks of $337 million.<br>
  </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER"><font color="#000000">40</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The components of long-term
  debt were:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=18 align="none"><b>
      <p></p>
      </b></td>
    <td width="38%" valign="TOP" colspan=3 height=18><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">6.80% Debentures, due in 2026</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$345</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$345</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$345</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">7.15% Debentures, due in 2023</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">344</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">344</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">344</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">6.875% Debentures, due in 2097</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">296</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">296</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">296</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Various Rate Yen Term Loans, due
        in 2003</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">69</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">71</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">71</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">2.14% Yen Notes, due in 2005</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">60</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">62</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">55</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">1.73% Yen Notes, due in 2003 </font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">60</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">62</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">54</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=32 align="none">
      <p align="JUSTIFY"><font face="CG Times">3.51% Deutsche Mark Interest on
        Yen Principal Term Loan, due in 2005</font> </p>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times"><br>
        55</font>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"><br>
        <font face="CG Times">57</font> </p>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"><br>
        <font face="CG Times">50</font> </p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">5.75% Industrial Revenue Bonds,
        due in 2024</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">34</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">34</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">34</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">5.00% Yen Term Loan, paid in 1999</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">29</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">2.83% Yen Term Loan, due in 2002</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">28</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">28</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">25</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Variable Rate Industrial Revenue
        Bonds, due in 2030</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">15</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Capitalized Leases</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">19</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">22</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">29</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=32 align="none">
      <p align="JUSTIFY"><font face="CG Times">Other, 4.50% to 7.9%,due in varying
        amounts through 2014</font> </p>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times"> 11</font></u>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times"> 21</font></u>
    </td>
    <td width="13%" valign="TOP" height=32>
      <p align="RIGHT"></p>
      <p align="RIGHT"><u><font face="CG Times"> 32</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,336</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,342</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$1,364</font></u>
    </td>
  </tr>
</TABLE>
<p align="CENTER"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 11 STOCKHOLDERS'
  EQUITY</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Changes in capital shares
  and capital in excess of par value of stock were:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=685>
  <tr bgcolor="" align="none">
    <td width="45%" valign="TOP" align="none" height="50">&nbsp;</td>
    <td valign="TOP" colspan=2 height="50"><b>
      <p align="CENTER"></p>
      <p align="CENTER"><u><font face="CG Times">Shares of Common Stock</font></u>
      </b></td>
    <td width="17%" valign="TOP" height="50"><b>
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">Capital in <u>Excess of Par </u></font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">&nbsp;</td>
    <td width="18%" valign="TOP">
      <div align="center"><b><u>Issued</u></b></div>
    </td>
    <td width="20%" valign="TOP">
      <div align="center"><b><u>Treasury</u></b></div>
    </td>
    <td width="17%" valign="TOP">
      <div align="center"><b><u>Value of Stock</u></b></div>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1997</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,083,253,703</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">90,069,383</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$544</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Effect of two-for-one stock split</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,083,253,703</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">90,069,383</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(108)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Issued pursuant to stock plans
        and options</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">16,931,302</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(11,189,998)</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">700</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Conversions of preferred stock</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">21,230</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Purchases</font>
    </td>
    <td width="18%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="20%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">30,601,764</font>
    </td>
    <td width="17%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Other</font>
    </td>
    <td width="18%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 4,856,870</font></u>
    </td>
    <td width="20%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
    <td width="17%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> (61)</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1998</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2,188,316,808</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">199,550,532</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,075</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Issued pursuant to stock plans
        and options</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4,641,700</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(9,694,871)</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">458</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Conversions of preferred stock</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">11,996</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Purchases</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 22,309,190</font></u>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1999</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2,192,970,504</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">212,164,851</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,533</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Issued pursuant to stock plans
        and options</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4,911,457</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(8,197,329)</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">469</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Conversions of preferred stock</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,874</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Purchases</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 40,398,204</font></u>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> -</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="45%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 2000</font>
    </td>
    <td width="18%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2,197,900,835</font></u>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">244,365,726</font></u>
    </td>
    <td width="17%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$2,002</font></u>
    </td>
  </tr>
</TABLE>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">41</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Each share of the Company's
  preferred stock is convertible into 16.96 shares of common stock and is callable
  at the Company's option. The reductions in the number of issued shares of preferred
  stock in 2000, 1999 and 1998 were due to conversions into shares of common stock.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Dividends per common
  share were $.98 in 2000, $.86 in 1999 and $.78 in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">Stock Compensation
  Plans</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Under the Company's 1997
  Stock Incentive Plan, officers, directors and key employees may be granted options
  to purchase the Company's common stock at no less than 100% of the market price
  on the date the option is granted. Options generally become exercisable in installments
  of 25% per year on each of the first through the fourth anniversaries of the
  grant date and have a maximum term of 10 years. Additionally, the plan provides
  for the granting of stock appreciation rights whereby the grantee may surrender
  exercisable options and receive common stock and/or cash measured by the excess
  of the market price of the common stock over the option exercise price. The
  plan also provides for the granting of performance-based stock options to certain
  key executives.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Under the terms of the
  1997 Stock Incentive Plan, as amended, additional shares are authorized in the
  amount of 0.9% of the outstanding shares per year through 2002. The plan incorporates
  the Company's long-term performance awards.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In addition, the 1997
  Stock Incentive Plan provides for the granting of up to 20,000,000 shares of
  common stock to key employees, subject to restrictions as to continuous employment
  except in the case of death or normal retirement. Restrictions generally expire
  over a five-year period from date of grant. Compensation expense is recognized
  over the restricted period. At December 31, 2000, a total of 1,821,194 restricted
  shares were outstanding under the plan.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Under the TeamShare Stock
  Option Plan, all full-time employees, excluding key executives, meeting certain
  years of service requirements are granted options to purchase the Company's
  common stock at the market price on the date the options are granted. The Company
  has authorized 62,000,000 shares for issuance under the plan. As of December
  31, 2000, a total of 28,455,134 shares have been exercised under the plan. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company applies Accounting
  Principles Board Opinion No. 25, <i>Accounting for Stock Issued to Employees</i>,
  and related interpretations in accounting for its plans. Accordingly, no compensation
  expense has been recognized for its stock-based compensation plans other than
  for restricted stock and performance-based awards. Had compensation cost for
  the Company's other stock option plans been determined based upon the fair value
  at the grant date for awards under these plans consistent with the methodology
  prescribed under Statement of Financial Accounting Standards No. 123, <i>Accounting
  for Stock-Based Compensation</i>, the Company's net income and earnings per
  share would have been reduced by approximately $218 million, or $.11 per common
  share, basic and diluted, in 2000, $198 million, or $.10 per common share, basic
  and diluted, in 1999 and $136 million, or $.07 per common share, basic and diluted,
  in 1998. The fair value of the options granted during 2000, 1999 and 1998 was
  estimated as $17.17 per common share, $17.37 per common share and $11.80 per
  common share, respectively, on the date of grant using the Black-Scholes option-pricing
  model with the following assumptions:<br>
  </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">42</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY">&nbsp;</p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="13%" valign="TOP" height=21><b>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
      </b></td>
    <td width="13%" valign="TOP" height=21><b>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
      </b></td>
    <td width="13%" valign="TOP" height=21><b>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Dividend yield</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1.5%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2.4%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3.1%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Volatility</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">24.5%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">21.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18.2%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Risk-free interest rate</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">6.3%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">5.5%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">6.3%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Assumed forfeiture rate</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3.0%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Expected life (years)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="right"><font face="CG Times">7</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="right"><font face="CG Times">7</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="right"><font face="CG Times">7</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"> </p>
<p align="JUSTIFY"><font face="CG Times" color="#000000"><b>Stock option transactions
  were:</b></font></p>
<table cellspacing=0 border=0 cellpadding=7 width=688>
  <tr bgcolor="" align="none">
    <td width="36%" valign="TOP" align="none">&nbsp;</td>
    <td valign="TOP" colspan=2><b>
      <p align="CENTER"></p>
      <p align="CENTER">&nbsp;</p>
      <p align="CENTER"><u><font face="CG Times">Shares of Common Stock</font></u></p>
      <p align="CENTER">
      </b></td>
    <td width="22%" valign="TOP"><b>
      <p align="CENTER"><font face="CG Times">Weighted Average Exercise Price
        of <u>Shares Under Plan</u> </font>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">&nbsp;</td>
    <td width="23%" valign="TOP">
      <p align="CENTER"><font face="CG Times"><u>Available for Option</u></font>
    </td>
    <td width="19%" valign="TOP">
      <p align="CENTER"><font face="CG Times"><u>Under Plan </u></font>
    </td>
    <td width="22%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1997</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,272,550</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">66,300,902</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">40.08</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Effect of two-for-one stock split</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,272,550</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">66,300,902</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Authorized</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">17,877,318</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Granted</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(35,498,350)</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">35,498,350</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">51.40</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Exercised</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(36,697,942)</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">16.30</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Lapsed</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2,382,746</font></u>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">(2,382,746)</font></u>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">34.27</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1998</font>
    </td>
    <td width="23%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">21,306,814</font>
    </td>
    <td width="19%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">129,019,466</font>
    </td>
    <td width="22%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">29.47</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Authorized</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">19,898,896</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Granted</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(24,221,950)</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">24,221,950</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">65.39</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Exercised</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(20,425,070)</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">20.41</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Lapsed</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">3,552,037</font></u>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">(3,552,037)</font></u>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">42.51</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 1999</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">20,535,797</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">129,264,309</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">37.27</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Authorized</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">17,827,251</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Granted</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(20,851,475)</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">20,851,475</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">49.72</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Exercised</font>
    </td>
    <td width="23%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(17,605,519)</font>
    </td>
    <td width="22%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">25.26</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Lapsed</font>
    </td>
    <td width="23%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">3,665,969</font></u>
    </td>
    <td width="19%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">(3,665,969)</font></u>
    </td>
    <td width="22%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">58.12</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="36%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Balance, December 31, 2000</font>
    </td>
    <td width="23%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">21,177,542</font></u>
    </td>
    <td width="19%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">128,844,296</font></u>
    </td>
    <td width="22%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times">$40.32</font>
    </td>
  </tr>
</TABLE>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">43</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="left"></p>
<p align="left"><font face="CG Times" color="#000000">The following table summarizes
  information concerning currently outstanding and exercisable options:</font></p>
<p align="JUSTIFY"></p>
<table 0 cellspacing=1 cellpadding=7 width=698>
  <tr bgcolor="" align="none">
    <td width="11%" valign="TOP" align="none">&nbsp;</td>
    <td valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">Options Outstanding</font></u>
      </b></td>
    <td valign="TOP" colspan=2><b>
      <p align="CENTER"><u><font face="CG Times">Options Exercisable</font></u></p>
      <p align="CENTER">
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" height=73 align="none">
      <p align="CENTER"><font face="CG Times" size="3">Range of Exercise Prices</font>
      </p>
    </td>
    <td width="14%" valign="TOP" height=73>
      <p align="CENTER"></p>
      <p align="CENTER"><b><font face="CG Times" size="3">Number Outstanding</font>
        </b>
    </td>
    <td width="19%" valign="TOP" height=73>
      <p align="CENTER"><b><font face="CG Times" size="3">Weighted Average Remaining
        Contractual Life</font> </b>
    </td>
    <td width="15%" valign="TOP" height=73>
      <p align="CENTER"><b><font face="CG Times" size="3">Weighted Average Exercise
        Price</font> </b></p>
    </td>
    <td width="20%" valign="TOP" height=73>
      <p align="CENTER"></p>
      <p align="CENTER"><b><font face="CG Times" size="3">Number Exercisable</font>
        </b> </p>
    </td>
    <td width="21%" valign="TOP" height=73>
      <p align="CENTER"><b><font face="CG Times" size="3">Weighted Average Exercise
        Price</font> </b></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$10 - $20</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">28,016,861</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3.27</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$15.54</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">28,016,861</font>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">$15.54</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$20 - $30</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,124,623</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">5.44</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">24.05</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,124,623</font>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">24.05</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$30 - $40</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10,657,762</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">6.18</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">33.68</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">8,169,537</font>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">33.68</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$40 - $50</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">18,976,088</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">8.77</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">45.14</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,146,224</font>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">41.46</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$50 - $60</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">28,272,049</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.32</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">51.95</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">8,398,277</font>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">51.01</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">$60 - up</font>
    </td>
    <td width="14%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">24,796,913</font></u>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">8.32</font>
    </td>
    <td width="15%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">66.10</font>
    </td>
    <td width="20%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 6,984,005</font></u>
    </td>
    <td width="21%" valign="TOP">
      <p align="CENTER"><font face="CG Times">65.41</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="11%" valign="TOP" height=24 align="none"><i>
      <p></p>
      </i></td>
    <td width="14%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times">128,844,296</font></u>
    </td>
    <td width="19%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="15%" valign="TOP" height=24>
      <p></p>
    </td>
    <td width="20%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times">70,839,527</font></u>
    </td>
    <td width="21%" valign="TOP" height=24>
      <p></p>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">At December 31, 2000,
  209,405,290 shares of common stock were reserved for issuance pursuant to stock
  plans, options and conversions of preferred stock. Options related to discontinued
  operations and included in the above amounts are not material.</font></p>
<p align="CENTER"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 12 FINANCIAL
  INSTRUMENTS</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Foreign exchange option
  contracts and, to a lesser extent, forward contracts, are used to hedge anticipated
  foreign currency transactions, primarily intercompany inventory purchases expected
  to occur within the next year. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company has exposures
  to net foreign currency denominated assets and liabilities, which approximated
  $1,781 million, $2,179 million and $2,310 million at December 31, 2000, 1999
  and 1998, respectively, primarily in Europe, Japan and Mexico. The Company mitigates
  the effect of these exposures through third-party borrowings. The exposures
  to net foreign currency denominated assets and liabilities related to discontinued
  operations and included in the above amounts are not material.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The risk of loss associated
  with the types of foreign exchange option contracts entered into by the Company
  is limited to premium amounts paid for the option contracts. Premiums are deferred
  in Prepaid Expenses and amortized in the consolidated statement of earnings
  (in the Other caption) over the time frame of the underlying hedged transaction.
  Gains related to the option contracts, which qualify as hedges of foreign currency
  anticipated transactions, are recognized in earnings when the hedged transactions
  are recognized. Gains and losses on foreign exchange forward contracts are recognized
  in the basis of the underlying transaction being hedged.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The notional amounts
  of the Company's foreign exchange option contracts at December 31, 2000, 1999
  and 1998 were $1,395 million, $1,762 million and $1,307 million, respectively.
  The notional amounts of foreign exchange contracts related to discontinued operations
  and included in the above amounts are not material.</font></p>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">44</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font color="#000000">(dollars in millions)</font></p>
<p align="left"></p>
<p align="left"><font face="CG Times" color="#000000">The Company does not anticipate
  any material adverse effect on its financial position resulting from its involvement
  in these instruments, nor does it anticipate nonperformance by any of its counterparties.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">At December 31, 2000,
  1999 and 1998, the carrying value of all financial instruments, both short-
  and long-term, approximated their fair values.</font></p>
<p align="CENTER"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 13 LEASES</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Minimum rental commitments
  under all noncancelable operating leases, primarily real estate, in effect at
  December 31, 2000 were:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr bgcolor="" align="none">
    <td width="69%" valign="TOP" height=21 align="none"><b>
      <p align="JUSTIFY"><u><font face="CG Times">Years Ending December 31,</font></u>
      </b></td>
    <td width="31%" valign="TOP" height=21><b>
      <p></p>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">2001</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$102</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">2002</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">81</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">2003</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">61</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">2004</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">48</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">2005</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">42</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Later years</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">141</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Total minimum payments</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">475</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Less total minimum sublease rentals</font>
    </td>
    <td width="31%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">90</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="69%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net minimum rental commitments</font>
    </td>
    <td width="31%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$385</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Minimum rental commitments
  and operating lease rental expense related to discontinued operations and included
  in the above amounts are not material. Operating lease rental expense (net of
  sublease rental income of $21 million in 2000, $24 million in 1999 and $27 million
  in 1998) was $85 million in 2000, $87 million in 1999 and $102 million in 1998.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="center"><font color="#000000">45</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 14 SEGMENT
  INFORMATION</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company operates
  in one significant business segment - medicines. Operations of the Nutritional
  and ConvaTec businesses are not material and share many of the same economic
  and operating characteristics as the medicines business. Most of the pharmaceutical
  products are distributed through wholesalers. Two wholesalers accounted for
  approximately 13% and 12% of net sales from continuing operations in 2000.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Sales of selected products
  and product categories are as follows:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="61%" valign="TOP" align="none">&nbsp;</td>
    <td width="39%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="CENTER"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="CENTER"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="CENTER"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
    <td width="13%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;PRAVACHOL*</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">$1,817
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT">$1,704
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$1,643</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;GLUCOPHAGE</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,732</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,317</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">862</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;TAXOL*</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,592</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,481</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,206</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;Oncology Therapeutics Network</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,080</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">894</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">657</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;PLAVIX</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">903</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">547</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">144</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;BUSPAR*</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">709</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">605</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">531</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;PARAPLATIN*</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">690</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">600</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">525</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;ZERIT*</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">618</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">605</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">551</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;Infant formulas</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,212</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,233</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,203</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">&#9;Ostomy</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">428</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">449</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">464</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">GEOGRAPHIC AREAS</font></u></font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="61%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="39%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times">Net Sales</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">United States</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$12,114</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$10,631</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$8,955</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Europe, Mideast and Africa</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3,414</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3,738</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3,665</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Other Western Hemisphere</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,314</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,279</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,398</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Pacific</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1,374</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1,230</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1,043</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net sales</font>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">$18,216</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">$16,878</font></u>
    </td>
    <td width="13%" valign="TOP" height=18>
      <p align="RIGHT"><u><font face="CG Times">$15,061</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<table cellspacing=0 border=0 cellpadding=7 width=662>
  <tr bgcolor="" align="none">
    <td width="61%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="39%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times">Year-End Assets</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">United States</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$10,640</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$9,708</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$9,348</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Europe, Mideast and Africa</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4,453</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4,942</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4,620</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Other Western Hemisphere</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,376</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,432</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">1,322</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Pacific</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1,109</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1,032</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">982</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="61%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Total Assets</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$17,578</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$17,114</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$16,272</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________&#9;</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">46</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 15 RETIREMENT
  PLANS</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company and certain
  of its subsidiaries have defined benefit pension plans and defined contribution
  plans for regular full-time employees. The principal pension plan is the Bristol-Myers
  Squibb Retirement Income Plan. The Company's funding policy is to contribute
  amounts to provide for current service and to fund past service liability. Plan
  benefits are primarily based on years of credited service and on the participants'
  compensation. Plan assets principally consist of equity and fixed income securities.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company's share of
  the components of total net pension expense and pension assets and obligation,
  related to continuing operations as well as any curtailment gain or loss, has
  not yet been determined, and therefore the following information relates to
  the Company's pension plan including discontinued operations. The amounts related
  to discontinued operations are estimated to represent approximately 10% of total
  pension obligations and assets of the Company's retirement plans.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Cost for the Company's
  defined benefit plans included the following components:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Service cost - benefits earned
        during the year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$159</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$161</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$132</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Interest cost on projected benefit
        obligation</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">235</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">217</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">207</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Expected earnings on plan assets</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(332)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(285)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(258)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net amortization and deferral</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 3</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 4</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (1</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net pension expense</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$65</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$97</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$80</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<p align="left"><font face="CG Times" color="#000000">The weighted average actuarial
  assumptions for the Company's pension plans were as follows:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="38%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Discount rate</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.0%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Compensation increase</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">4.3%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Long-term rate of return</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
  </tr>
</TABLE>
<p align="CENTER"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Changes in benefit obligation
  and plan assets were:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Benefit obligation at beginning
        of year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$3,137</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$3,216</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$2,928</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Service cost - benefits earned
        during the year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">159</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">161</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">132</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Interest cost on projected benefit
        obligation</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">235</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">217</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">207</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY">Actuarial (gains) and losses
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">22</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(203)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">160</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Benefits paid
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u>(259</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u>(254</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u>(211</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Benefit obligation at end of year
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,294</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,137</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,216</font></u>
    </td>
  </tr>
</TABLE>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">47</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Fair value of plan assets at beginning
        of year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$3,490</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$3,137</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$2,949</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Actual earnings on plan assets</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">25</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">561</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">359</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Employer contribution</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">267</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">46</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">40</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Benefits paid</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (259</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (254</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (211</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Fair value of plan assets at end
        of year</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,523</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,490</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3,137</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Plan assets in excess of (less
        than) projected benefit obligation</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$229</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$353</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$(79)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Unamortized net obligation (assets)
        at adoption</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(2)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(33)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Unrecognized prior service cost</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">55</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">37</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">48</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Unrecognized net (gains) and losses</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u>(83</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u>(385</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> 87</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net amount recognized</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> $208</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times"> $3</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$23</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Amounts recognized in
  the consolidated balance sheet consist of:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Prepaid benefit cost</font>
      </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">405</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">181</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">187</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY">Accrued benefit liability
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(214)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(190)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(190)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Other asset
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">17</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">12</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">26</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Net amount recognized
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$208</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$3</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$23</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The projected benefit
  obligation, accumulated benefit obligation, and fair value of plan assets for
  the pension plans with accumulated benefit obligations in excess of plan assets
  were $332 million, $254 million and $47 million, respectively, as of December
  31, 2000, $319 million, $245 million and $56 million, respectively, as of December
  31, 1999 and $288 million, $230 million and $40 million, respectively, as of
  December 31, 1998. This is primarily attributable to an unfunded benefit equalization
  plan.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The principal defined
  contribution plan is the Bristol-Myers Squibb Savings and Investment Program.
  The Company's contribution is based on employee contributions and the level
  of company match. Company contributions to the plan were $53 million in 2000,
  $49 million in 1999 and $45 million in 1998. <br>
  _____________________________________________________________________________________________
  </font></p>
<p align="CENTER"><font color="#000000">48</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="center"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 16 POSTRETIREMENT
  BENEFIT PLANS OTHER THAN PENSIONS</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company provides
  comprehensive medical and group life benefits to substantially all US retirees
  who elect to participate in the Company's comprehensive medical and group life
  plans. The medical plan is contributory. Contributions are adjusted periodically
  and vary by date of retirement and the original retiring company. The life insurance
  plan is noncontributory. Plan assets principally consist of equity securities
  and fixed income securities.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Company's share of
  the components of total postretirement benefit expense and postretirement benefit
  assets and obligation, related to continuing operations as well as any curtailment
  gain or loss, has not yet been determined, and therefore the following information
  relates to the Company's postretirement benefit plans including discontinued
  operations.</font></p>
<p align="left"></p>
<p align="left"><font face="CG Times" color="#000000">Cost for the Company's postretirement
  benefit plans included the following components:</font></p>
<p align="CENTER"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" height=21 align="none"><b>
      <p></p>
      </b></td>
    <td width="38%" valign="TOP" colspan=3 height=21><b>
      <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=24 align="none"><i>
      <p></p>
      </i></td>
    <td width="13%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP" height=24>
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Service cost - benefits earned
        during the year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$9</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$10</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$8</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Interest cost on accumulated postretirement
        benefit obligation</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">39</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">36</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">35</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Expected earnings on plan assets</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(17)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(13)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(11)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Net amortization and deferral</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> (2)</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times"> 1</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times"><u> (3</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Net postretirement benefit expense</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$29</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$34</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$29</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The weighted average
  actuarial assumptions for the Company's postretirement benefit plans were as
  follows:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Discount rate</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.8%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">7.0%</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Long-term rate of return</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10.0%</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p>&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Changes in benefit obligation
  and plan assets were:</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">Year Ended December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Benefit obligation at beginning
        of year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$521</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$507</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$495</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Service cost - benefits earned
        during the year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">9</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">10</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">8</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p><font face="CG Times">Interest cost on accumulated post-retirement benefit
        obligation</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">39</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">36</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">35</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Plan participants' contributions</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Plan amendments</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">-</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(9)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(1)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Actuarial losses</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">21</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">16</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">6</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY"><font face="CG Times">Benefits paid</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (44</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (41</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (38</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Benefit obligation at end of year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$548</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$521</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$507</font></u>
    </td>
  </tr>
</TABLE>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER"><font face="CG Times" color="#000000"><br>
  49</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="CENTER"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="38%" valign="TOP" colspan=3><b>
      <p align="CENTER"><u><font face="CG Times">December 31,</font></u>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">2000</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1999</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">1998</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Fair value of plan assets at beginning
        of year</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$152</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$128</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$113</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Actual earnings on plan assets</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">6</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">24</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">15</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Employer contribution</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">63</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">39</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">36</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY">Plan participants' contributions
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">2</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Benefits paid
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (44</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (41</u>)</font>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><font face="CG Times"><u> (38</u>)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" height=21 align="none">
      <p align="JUSTIFY">Fair value of plan assets at end of year
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$179</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$152</font></u>
    </td>
    <td width="13%" valign="TOP" height=21>
      <p align="RIGHT"><u><font face="CG Times">$128</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Accumulated postretirement benefit
        obligation </font> in excess of plan assets </p>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"></p>
      <p align="RIGHT"><br>
        $(369)
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><br>
        $(369) </p>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><br>
        <font face="CG Times">$(379)</font> </p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY"><font face="CG Times">Unrecognized prior service cost</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(5)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">(6)</font>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">3</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY">Unrecognized net earnings
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">(22)</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">(55)</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">(60)</font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="JUSTIFY">Accrued postretirement benefit expense
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$(396)</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$(430)</font></u>
    </td>
    <td width="13%" valign="TOP">
      <p align="RIGHT"><u><font face="CG Times">$(436)</font></u>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">For measurement purposes,
  an annual rate of increase in the per capita cost of covered health care benefits
  of 9% for participants was assumed for 2001; the rate was assumed to decrease
  gradually to 5% in 2007 and to remain at that level thereafter.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">A one-percentage-point
  change in assumed health care cost trend rates would have the following effects:</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=691>
  <tr bgcolor="" align="none">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="19%" valign="TOP"> <b>
      <p align="center"><font face="CG Times">1-Percentage-<br>
        </font><u><font face="CG Times">Point Increase</font></u> </p>
      </b></td>
    <td width="19%" valign="TOP"> <b>
      <p align="center"><font face="CG Times">1-Percentage-<br>
        </font><u><font face="CG Times">Point Decrease</font></u> </p>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">&nbsp;</td>
    <td width="19%" valign="TOP">&nbsp;</td>
    <td width="19%" valign="TOP">&nbsp;</td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none" height="55">
      <p align="left"><font face="CG Times">Effect on the aggregate of the service
        and interest cost components of net postretirement benefit expense</font>
      </p>
    </td>
    <td width="19%" valign="TOP" height="55">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">$1</font>
    </td>
    <td width="19%" valign="TOP" height="55">
      <p align="RIGHT"></p>
      <p align="RIGHT"><font face="CG Times">$(1)</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="63%" valign="TOP" align="none">
      <p align="left"><font face="CG Times">Effect on the accumulated postretirement
        benefit obligation</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$22</font>
    </td>
    <td width="19%" valign="TOP">
      <p align="RIGHT"><font face="CG Times">$(20)</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 17 LITIGATION</font></u></b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">Various lawsuits, claims and proceedings
  of a nature considered normal to its businesses are pending against the Company
  and certain of its subsidiaries. The most significant of these are described
  below.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000"><b>Breast Implant</b></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">The Company, together with its subsidiary,
  Medical Engineering Corporation (MEC), and certain other companies, has been
  named as a defendant in a number of claims and lawsuits alleging damages for
  personal injuries of various types resulting from polyurethane-covered breast
  implants and smooth-walled breast implants formerly manufactured by MEC or a
  related company. Of the more than 90,000 claims or potential claims against
  the Company in direct lawsuits or through registration in the nationwide class
  action settlement approved by the Federal District Court in Birmingham, Alabama
  (the "Revised Settlement"), most have been dealt with through the Revised Settlement,
  other settlements, or trial. As of December 31, 2000, the Company's contingent
  liability in respect of breast implant claims was limited to residual unpaid
  Revised Settlement obligations and to roughly 850 remaining opt-outs who have
  pursued or may pursue their claims in court.<br>
  <font face="CG Times">_____________________________________________________________________________________________</font></font>
</p>
<p align="center"><font color="#000000">50</font></p>
<p align="JUSTIFY"> </p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">As of December 31, 2000, approximately
  4,790 US and 310 foreign breast implant recipients were plaintiffs in lawsuits
  pending in federal and state courts in the United States and certain courts
  in Canada and Australia. These figures include the claims of plaintiffs that
  are in the process of being settled and/or dismissed. In these lawsuits, about
  2,140 US and 68 foreign plaintiffs opted out of the Revised Settlement. The
  lawsuits of the 2,650 US plaintiffs who did not opt out are expected to be dismissed
  since these plaintiffs are among the estimated 74,000 women with MEC implants
  who chose to participate in the nationwide settlement. Of the 2,140 opt-out
  plaintiffs, an estimated 1,290 have claims based upon products that were not
  manufactured or sold by MEC or that have been or are in the process of being
  settled and/or dismissed. Accordingly, the number of remaining plaintiffs who
  have pursued or may pursue their claims in court against the Company is roughly
  850, as stated in the preceding paragraph.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">Under the terms of the Revised Settlement,
  additional opt-outs are expected to be minimal since the deadline for US class
  members to opt out has passed. In addition, the Company's remaining obligations
  under the Revised Settlement Program are limited because most payments to &quot;Current
  Claimants&quot; have already been made, no additional &quot;Current Claims&quot;
  may be filed without court approval, and because payments of claims to so-called
  &quot;Other Registrants&quot; and &quot;Late Registrants&quot; are limited by
  the terms of the Revised Settlement. Separate class action settlements have
  been approved in the provincial courts of Ontario and Quebec, and an agreement
  has been reached under which other foreign breast implant recipients may settle
  their claims. The Company believes it will be able to address remaining opt-out
  claims as well as expected remaining obligations under the Revised Settlement
  program within its reserves described below.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">In the fourth quarter of 1993, the Company
  recorded a charge of $500 million before taxes ($310 million after taxes) in
  respect of breast implant cases. The charge consisted of $1.5 billion for potential
  liabilities and expenses, offset by $1.0 billion of expected insurance proceeds.
  In the fourth quarters of 1994 and 1995, the Company recorded additional special
  charges of $750 million before taxes ($488 million after taxes) and $950 million
  before taxes ($590 million after taxes), respectively, related to breast implant
  product liability claims. In the fourth quarter of 1998, the Company recorded
  an additional special charge to earnings in the amount of $800 million before
  taxes and increased its insurance receivable in the amount of $100 million,
  resulting in a net charge to earnings of $433 million after taxes in respect
  of breast implant product liability claims. During 2000, 1999 and 1998, cash
  payments, net of insurance receipts, of $68 million, $631 million and $551 million,
  respectively, were made related to the breast implant product liability claims.
  At December 31, 2000, $186 million was included in current liabilities for breast
  implant product liability claims.</font></p>
<p align="JUSTIFY"></p>
<p><font color="#000000"><b>TAXOL*</b></font></p>
<p align="JUSTIFY"><font color="#000000">In 1997 and 1998, the Company filed several
  lawsuits alleging that a number of generic drug companies infringed its patents
  covering methods of administering paclitaxel when they filed Abbreviated New
  Drug Applications seeking regulatory approval to sell paclitaxel. These actions
  were consolidated for discovery in the US District Court for the District of
  New Jersey. The Company does not assert a monetary claim against any of the
  defendants, but seeks to prevent the defendants from marketing paclitaxel in
  a manner that violates the Company's patents.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">The defendants have asserted that they
  do not infringe the Company's patents and that these patents are invalid and
  unenforceable. Some defendants also asserted counterclaims seeking damages for
  alleged antitrust and unfair competition violations. The Company believes its
  patents are valid and the counterclaims asserted are without merit. <br>
  <font face="CG Times">_____________________________________________________________________________________________</font></font>
</p>
<p align="CENTER"><font color="#000000">51</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="center"><font face="CG Times" color="#000000">&#9;NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"><font color="#000000">On January 4, 2000, the District Court
  granted the Company's motion to dismiss certain of the antitrust and unfair
  competition counterclaims. The Company's motion for summary judgment on the
  remaining antitrust and unfair competition counterclaims was denied on March
  17, 2000. On February 29, 2000, the District Court granted in part the generic
  companies' summary judgment motions for invalidity by finding all claims of
  the Company's patents invalid, except for claims limited to the treatment of
  ovarian cancer. The District Court's opinion left for determination at trial
  the validity of the claims of the Company's patents directed to the low dose,
  three-hour administration of paclitaxel for ovarian cancer and denied the generic
  companies' summary judgment motion arguing non-infringement of the Company's
  patents. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">In order to pursue an immediate appellate
  review of the District Court's invalidity findings, the Company voluntarily
  relinquished all rights in the remaining ovarian tumor-specific claims of its
  patents. </font></p>
<p align="JUSTIFY"><font color="#000000">On April 7, 2000, the District Court
  granted the Company's request for an entry of judgment. The Company's appeal
  of the District Court's judgment is pending before the Federal Circuit Court
  of Appeals. If the Company is successful on appeal and the trial that would
  follow a successful appeal, the Company believes its remaining patent rights
  would apply to all tumor types. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">In September 2000, one of the defendants
  received final approval from the US Food and Drug Administration for its Abbreviated
  New Drug Application for paclitaxel and is marketing the product. Two additional
  tentative approvals have been announced by the United States Food and Drug Administration.
  One has been issued to a company in the same corporate family as the defendant
  that received final approval. The other tentative approval was issued to an
  unrelated defendant. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">It is not possible at this time to make
  a reasonable assessment of the outcome of the appeal and the remaining claims
  in these actions or to reasonably estimate the impact on TAXOL* sales or the
  amount of damages were the Company not to prevail.</font></p>
<p><font color="#000000"><b>VANLEV* </b></font></p>
<p align="JUSTIFY"><font color="#000000">The Company, its Chairman of the Board
  and Chief Executive Officer, Charles A. Heimbold, Jr., and its Chief Scientific
  Officer and President - Pharmaceutical Research Institute, Peter S. Ringrose,
  Ph.D., are defendants in a number of purported class actions filed in the US
  District Court for the District of New Jersey in April, May and June alleging
  violations of federal securities laws and regulations. Plaintiffs claim that
  the defendants disseminated materially false and misleading statements and failed
  to disclose information concerning the safety and expected availability of its
  product Vanlev during the period November 8, 1999 through April 19, 2000. Plaintiffs
  seek compensatory damages and costs and expenses. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font color="#000000">It is not possible at this time to make
  a reasonable assessment of the outcome of this matter or the amount of damages
  were the Company not to prevail.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p><font color="#000000">While it is not possible to predict with certainty the
  outcome of these cases, it is the opinion of management that they will not have
  a material adverse effect on the Company's operating results or consolidated
  financial position.</font></p>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font face="CG Times" color="#000000">52</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">NOTES TO CONSOLIDATED
  FINANCIAL STATEMENTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="JUSTIFY"><font color="#000000"><b><u><font face="CG Times">Note 18 SELECTED
  QUARTERLY FINANCIAL DATA (UNAUDITED)</font></u></b></font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=690>
  <tr bgcolor="" align="none">
    <td width="44%" valign="TOP" align="none">&nbsp;</td>
    <td width="11%" valign="TOP">
      <p align="CENTER"><font face="CG Times">First </font><u><font face="CG Times">Quarter</font></u>
      </p>
    </td>
    <td width="11%" valign="TOP">
      <p align="CENTER"><font face="CG Times">Second </font><u><font face="CG Times">Quarter</font></u>
      </p>
    </td>
    <td width="10%" valign="TOP">
      <p align="CENTER"><font face="CG Times">Third </font><u><font face="CG Times">Quarter</font></u>
      </p>
    </td>
    <td width="12%" valign="TOP">
      <p align="CENTER"><font face="CG Times">Fourth </font><u><font face="CG Times">Quarter</font></u>
      </p>
    </td>
    <td width="12%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times"><br>
        Year </font></u>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">2000:</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Sales</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,451</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,418</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,563</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,784</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$18,216</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Gross Profit</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,310</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,288</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,363</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,496</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">13,457</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings
        from Continuing Operations *</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,129</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,005</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">893</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,069</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">4,096</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings
        from Discontinued Operations **</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">92</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">86</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">343</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">94</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">615</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,221</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,091</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,236</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,163</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">4,711</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings Per
        Common Share</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Basic</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings
          from Continuing Operations *</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.57</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.51</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.45</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.55</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.08</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Discontinued
          Operations **</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.04</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.18</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.32</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.62</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.55</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.63</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.60</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.40</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Diluted</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings
          from Continuing Operations *</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.56</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.50</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.45</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.54</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.05</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Discontinued
          Operations **</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.04</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.17</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.31</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.61</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.54</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.62</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.59</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.36</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">1999:</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Sales</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,044</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,054</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,190</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$4,590</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">$16,878</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Gross Profit</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2,983</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2,948</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,035</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,370</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">12,336</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings
        from Continuing Operations</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">975</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">865</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">988</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">961</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">3,789</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings
        from Discontinued Operations</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">91</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">87</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">109</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">91</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">378</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net earnings</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,066</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">952</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,097</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1,052</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">4,167</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings Per
        Common Share</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Basic</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings
          from Continuing Operations</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.49</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.44</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.50</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.48</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1.91</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Discontinued
          Operations</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.04</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.19</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.54</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.48</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.55</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.53</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.10</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Diluted</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Earnings
          from Continuing Operations</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.48</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.43</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.49</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.47</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">1.87</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Discontinued
          Operations</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.04</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.05</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.19</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="44%" valign="TOP" height=18 align="none">
      <dir>
        <p align="JUSTIFY"><font face="Times New Roman, Times, serif">Net Earnings</font>
      </dir>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.53</font>
    </td>
    <td width="11%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.47</font>
    </td>
    <td width="10%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.54</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">.52</font>
    </td>
    <td width="12%" valign="TOP" height=18>
      <p align="RIGHT"><font face="CG Times">2.06</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">* In 2000, the first
  quarter results included a gain on the sale of a business of $120 million ($87
  million after taxes) and a provision for restructuring of $102 million ($74
  million after taxes). The second quarter results included a gain on the sale
  of businesses of $40 million ($29 million after taxes) and a provision for restructuring
  of $20 million ($15 million after taxes). The third quarter results included
  a provision for restructuring of $386 million ($240 million after taxes).</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">** In 2000, the first
  quarter results included a provision for restructuring of $18 million ($11 million
  after taxes). The third quarter results included a gain on the sale of businesses
  of $402 million ($240 million after taxes) and a provision for restructuring
  of $16 million ($11 million after taxes). <br>
  _____________________________________________________________________________________________
  </font></p>
<p align="CENTER"></p>
<p align="CENTER"><font color="#000000">53</font></p>
<p align="CENTER"><font color="#000000"><u><font face="CG Times">REPORT OF INDEPENDENT
  ACCOUNTANTS</font></u></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">To the Board of Directors</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">and Stockholders of</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Bristol-Myers Squibb
  Company</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">In our opinion, the consolidated
  financial statements listed in the index appearing under Item 14(a)(1) on page
  56 present fairly, in all material respects, the financial position of Bristol-Myers
  Squibb Company and its subsidiaries at December 31, 2000, 1999 and 1998, and
  the results of their operations and their cash flows for the years then ended
  in conformity with accounting principles generally accepted in the United States
  of America. In addition, in our opinion, the financial statement schedule listed
  in the index appearing under Item 14(a)(2) on page 56 presents fairly, in all
  material respects, the information set forth therein when read in conjunction
  with the related consolidated financial statements. These financial statements
  and the financial statement schedule are the responsibility of the Company's
  management; our responsibility is to express an opinion on these financial statements
  and the financial statement schedule based on our audits. We conducted our audits
  of these statements in accordance with auditing standards generally accepted
  in the United States of America, which require that we plan and perform the
  audit to obtain reasonable assurance about whether the financial statements
  are free of material misstatement. An audit includes examining, on a test basis,
  evidence supporting the amounts and disclosures in the financial statements,
  assessing the accounting principles used and significant estimates made by management,
  and evaluating the overall financial statement presentation. We believe that
  our audits provide a reasonable basis for our opinion.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font color="#000000"><u><font face="CG Times">/s/ PricewaterhouseCoopers
  LLP</font></u></font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;PRICEWATERHOUSECOOPERS
  LLP</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">New York, New York </font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">January 24, 2001<br>
  _____________________________________________________________________________________________
  </font></p>
<p align="center"><font face="CG Times" color="#000000">54</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 9. CHANGES IN AND
  DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">None.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;<b><u>PART III</u></b></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 10. DIRECTORS AND
  EXECUTIVE OFFICERS OF THE REGISTRANT.</font></p>
<p align="JUSTIFY"></p>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">(a)&#9;Reference
      is made to the Proxy Statement for the Annual Meeting of Stockholders on
      May 1, 2001 with respect to the Directors of the Registrant which is incorporated
      herein by reference and made a part hereof in response to the information
      required by Item 10.</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">(b)&#9;The information
      required by Item 10 with respect to the Executive Officers of the Registrant
      has been included in Part IA of this Form 10-K Annual Report in reliance
      on General Instruction G of Form 10-K and Instruction 3 to Item 401(b) of
      Regulation SK</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY">&nbsp;</p>
  </dir>
</dir>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 11. EXECUTIVE COMPENSATION.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Reference is made to
  the Proxy Statement for the Annual Meeting of Stockholders on May 1, 2001 with
  respect to Executive Compensation which is incorporated herein by reference
  and made a part hereof in response to the information required by Item 11.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 12. SECURITY OWNERSHIP
  OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Reference is made to
  the Proxy Statement for the Annual Meeting of Stockholders on May 1, 2001 with
  respect to the security ownership of certain beneficial owners and management
  which is incorporated herein by reference and made a part hereof in response
  to information required by Item 12.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 13. CERTAIN RELATIONSHIPS
  AND RELATED TRANSACTIONS.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Reference is made to
  the Proxy Statement for the Annual Meeting of Stockholders on May 1, 2001 with
  respect to certain relationships and related transactions which is incorporated
  herein by reference and made a part hereof in response to the information required
  by Item 13. </font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"> </p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">55</font></p>
<p align="CENTER"><font color="#000000"><b><u><font face="CG Times">PART IV</font></u></b></font></p>
<p align="CENTER"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Item 14. EXHIBITS, FINANCIAL
  STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.</font></p>
<table width="87%" border="0" cellpadding="7">
  <tr>
    <td width="74%">&nbsp;</td>
    <td width="26%">
      <div align="right"><u>Page Number</u></div>
    </td>
  </tr>
  <tr>
    <td width="74%">(a)</td>
    <td width="26%">&nbsp;</td>
  </tr>
  <tr>
    <td width="74%">
      <blockquote>
        <p>1. Financial Statements</p>
      </blockquote>
    </td>
    <td width="26%">
      <div align="right">29-33</div>
    </td>
  </tr>
  <tr>
    <td width="74%">
      <blockquote>
        <blockquote>
          <p>Notes to Consolidated Financial Statements</p>
        </blockquote>
      </blockquote>
    </td>
    <td width="26%">
      <div align="right">34-53</div>
    </td>
  </tr>
  <tr>
    <td width="74%">
      <blockquote>
        <blockquote>
          <p>Report of Independent Accountants</p>
        </blockquote>
      </blockquote>
    </td>
    <td width="26%">
      <div align="right">54</div>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=657>
  <tr>
    <td width="71%" height=35>
      <p align="JUSTIFY"></p>
      <blockquote>
        <p><font face="CG Times">2. &#9;Financial Statement Schedules</font></p>
      </blockquote>
    </td>
    <td width="14%" height=35>
      <p align="CENTER"><font face="CG Times">Schedule <u>Number</u></font> </p>
    </td>
    <td width="14%" height=35>
      <p align="CENTER"><font face="CG Times">Page </font><u><font face="CG Times">Number</font></u></p>
      <p align="CENTER">
    </td>
  </tr>
  <tr>
    <td width="71%">
      <p><font face="CG Times">Valuation and qualifying accounts</font>
    </td>
    <td width="14%">
      <p align="CENTER"><font face="CG Times">II</font>
    </td>
    <td width="14%">
      <p align="CENTER"><font face="CG Times">S-1</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">All other schedules
      not included with this additional financial data are omitted because they
      are not applicable or the required information is included in the financial
      statements or notes thereto.</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY">&nbsp;</p>
  </dir>
</dir>
<p align="JUSTIFY"><font face="CG Times" color="#000000">3. Exhibit List</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Exhibits listed below
  are identified by numbers corresponding to the Exhibit Table of Item 601 of
  Regulation SK The Exhibits designated by two asterisks (**) are management contracts
  or compensatory plans or arrangements required to be filed pursuant to this
  Item 14. Unless otherwise indicated, all Exhibits are part of Commission File
  Number 1-1136.</font></p>
<p align="JUSTIFY"></p>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">3a.&#9;Restated Certificate
      of Incorporation of Bristol-Myers Squibb Company (incorporated herein by
      reference to Exhibit 4a to Registrant's Registration Statement on Form S-3,
      Registration Statement No. 33-33682, dated March 7, 1990, as amended through
      May 5, 1999 by Certificate of Amendment incorporated herein by reference
      to Exhibit 3a to Form 10-K for the fiscal year ended December 31,1999).</font></p>
    <p align="JUSTIFY"></p>
  </dir>
</dir>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">3b.&#9;Bylaws of
      Bristol-Myers Squibb Company, as amended through February 1, 2001, filed
      herewith.</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4a.&#9;Letter of
      Agreement dated March 28, 1984 (incorporated herein by reference to Exhibit
      4 to Form 10-K for the fiscal year ended December 31, 1983).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4b.&#9;Indenture,
      dated as of June 1, 1993, between Bristol-Myers Squibb Company and The Chase
      Manhattan Bank (National Association), as trustee (incorporated herein by
      reference to Exhibit 4.1 to the Form 8-K dated May 27, 1993, and filed on
      June 3, 1993).<br>
      _____________________________________________________________________________________________
      </font></p>
    <p align="center"><font color="#000000">56</font></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4c.&#9;Form of 7.15%
      Debenture Due 2023 of Bristol-Myers Squibb Company (incorporated herein
      by reference to Exhibit 4.2 to the Form 8-K dated May 27, 1993, and filed
      on June 3, 1993).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4d.&#9;Form of 6.80%
      Debenture Due 2026 of Bristol-Myers Squibb Company (incorporated herein
      by reference to Exhibit 4e to the Form 10-K for the fiscal year ended December
      31, 1996).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4e.&#9;Form of 6.875%
      Debenture Due 2097 of Bristol-Myers Squibb Company (incorporated herein
      by reference to Exhibit 4f to the Form 10-Q for the quarterly period ended
      September 30, 1997).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4f.&#9;Five Year
      Competitive Advance and Revolving Credit Facility Agreement dated as of
      March 17, 1998 among Bristol-Myers Squibb Company, the Borrowing Subsidiaries
      (as defined in the Agreement), the Lenders listed in Schedule 2.1 to the
      Agreement, The Chase Manhattan Bank as Administrative Agent and Citibank,
      N.A., as Administrative Agent (incorporated herein by reference to Exhibit
      4f to the Form 10-K for the fiscal year ended December 31, 1997).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">4g.&#9;364-Day Competitive
      Advance and Revolving Credit Facility agreement dated as of March 17, 1998
      among Bristol-Myers Squibb Company, the Borrowing Subsidiaries (as defined
      in the Agreement), the Lenders listed in Schedule 2.1 to the Agreement,
      The Chase Manhattan Bank as Administrative Agent and Citibank, N.A., as
      Administrative Agent (incorporated herein by reference to Exhibit 4g to
      the Form 10-K for the fiscal year ended December 31, 1997).</font></p>
    <p align="JUSTIFY"></p>
  </dir>
</dir>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10a.&#9;Bristol-Myers
      Squibb Company 1997 Stock Incentive Plan, effective as of May 6, 1997 and
      as amended effective November 3, 1998 (incorporated herein by reference
      to Exhibit 10a to the Form 10-K for the fiscal year ended December 31, 1998).
      </font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10b.&#9;Bristol-Myers
      Squibb Company Executive Performance Incentive Plan (incorporated herein
      by reference to Exhibit 10b to the Form 10-K for the fiscal year ended December
      31, 1996).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10c.&#9;Bristol-Myers
      Squibb Company 1983 Stock Option Plan, as amended and restated as of January
      1, 1997, as amended November 3, 1998 (incorporated herein by reference to
      Exhibit 10c to the Form 10-K for the fiscal year ended December 31, 1998).
      </font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10d.&#9;Squibb
      Corporation 1982 Option, Restricted Stock and Performance Unit Plan, as
      amended (incorporated herein by reference to Exhibit 10b to the Form 10-K
      for the fiscal year ended December 31, 1993).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10e.&#9;Squibb
      Corporation 1986 Option, Restricted Stock and Performance Unit Plan, as
      amended (as adopted, incorporated herein by reference to Exhibit 10k to
      the Squibb Corporation Form 10-K for the fiscal year ended December 31,
      1988, File No. 1-5514; as amended effective July 1, 1993, and incorporated
      herein by reference to Exhibit 10c to the Form 10-K for the fiscal year
      ended December 31, 1993).</font></p>
    <p align="JUSTIFY"></p>
  </dir>
</dir>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10f.&#9;Bristol-Myers
      Squibb Company Performance Incentive Plan, as amended (as adopted, incorporated
      herein by reference to Exhibit 2 to the Form 10-K for the fiscal year ended
      December 31, 1978; as amended as of January 8, 1990, incorporated herein
      by reference to Exhibit 19b to the Form 10-K for the fiscal year ended December
      31, 1990; as amended on April 2, 1991, incorporated herein by reference
      to Exhibit 19b to the Form 10-K for the fiscal year ended December 31, 1991;
      as amended effective January 1, 1994, incorporated herein by reference to
      Exhibit 10d to the Form 10-K for the fiscal year ended December 31, 1993;
      and as amended effective January 1, 1994, incorporated herein by reference
      to Exhibit 10d to the Form 10-K for the fiscal year ended December 31, 1994).<br>
      _____________________________________________________________________________________________
      </font></p>
    <p align="JUSTIFY"></p>
    <p align="center"><font face="CG Times" color="#000000">57</font></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10g.&#9;Benefit
      Equalization Plan of Bristol-Myers Squibb Company and its Subsidiary or
      Affiliated Corporations Participating in the Bristol-Myers Squibb Company
      Retirement Income Plan or the Bristol-Myers Squibb Puerto Rico, Inc. Retirement
      Income Plan, as amended (as amended and restated as of January 1, 1993,
      as amended effective October 1, 1993, incorporated herein by reference to
      Exhibit 10e to the Form 10-K for the fiscal year ended December 31, 1993;
      and as amended effective February 1, 1995, incorporated herein by reference
      to Exhibit 10e to the Form 10-K for the fiscal year ended December 31, 1996).</font></p>
    <p align="JUSTIFY"></p>
  </dir>
</dir>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10h.&#9;Benefit
      Equalization Plan of Bristol-Myers Squibb Company and its Subsidiary or
      Affiliated Corporations Participating in the Bristol-Myers Squibb Company
      Savings and Investment Program, as amended (as amended and restated as of
      May 1, 1990, incorporated herein by reference to Exhibit 19d to the Form
      10-K for the fiscal year ended December 31, 1990; as amended as of January
      1, 1991, incorporated herein by reference to Exhibit 19g to the Form 10-K
      for the fiscal year ended December 31, 1990; as amended as of January 1,
      1991, incorporated herein by reference to Exhibit 19e to the Form 10-K for
      the fiscal year ended December 31, 1991, as amended as of October 1, 1994,
      incorporated herein by reference to Exhibit 10f to the Form 10-K for the
      fiscal year ended December 31, 1994).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10i.&#9;Squibb
      Corporation Supplementary Pension Plan, as amended (as previously amended
      and restated, incorporated herein by reference to Exhibit 19g to the Form
      10-K for the fiscal year ended December 31, 1991; as amended as of September
      14, 1993, and incorporated herein by reference to Exhibit 10g to the Form
      10-K for the fiscal year ended December 31, 1993).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10j.&#9;Bristol-Myers
      Squibb Company Restricted Stock Award Plan, as amended (as adopted on November
      7, 1989, incorporated herein by reference to Exhibit 10t to the Form 10-K
      for the fiscal year ended December 31, 1989; as amended on December 4, 1990,
      incorporated herein by reference to Exhibit 19a to the Form 10-K for the
      fiscal year ended December 31, 1990; as amended effective July 1, 1993,
      incorporated herein by reference to Exhibit 10h to the Form 10-K for the
      fiscal year ended December 31, 1993; as amended effective December 6, 1994,
      incorporated herein by reference to Exhibit 10h to the Form 10-K for the
      fiscal year ended December 31, 1994).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10k.&#9;Bristol-Myers
      Squibb Company Retirement Income Plan for Non-Employee Directors, as amended
      to March 5, 1996 (incorporated herein by reference to Exhibit 10k to the
      Form 10-K for the fiscal year ended December 31, 1996).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10l.&#9;Bristol-Myers
      Squibb Company 1987 Deferred Compensation Plan for Non-Employee Directors,
      as amended to January 13, 1998 (incorporated herein by reference to Exhibit
      10l to the Form 10-K for the fiscal year ended December 31, 1997).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10m.Bristol-Myers
      Squibb Company Non-Employee Directors' Stock Option Plan, as amended (as
      approved by the Stockholders on May&nbsp;1, 1990, incorporated herein by
      reference to Exhibit 28 to Registration Statement No. 33-38587 on Form S-8;
      as amended May&nbsp;7, 1991, incorporated herein by reference to Exhibit
      19c to the Form 10-K for the fiscal year ended December 31, 1991), as amended
      January 12, 1999 (incorporated herein by reference to Exhibit 10m to the
      Form 10-K for the fiscal year ended December 31, 1998). <br>
      _____________________________________________________________________________________________
      </font></p>
    <p align="JUSTIFY"></p>
    <p align="center"><font face="CG Times" color="#000000">58</font></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10n.&#9;Squibb
      Corporation Deferral Plan for Fees of Outside Directors, as amended (as
      adopted, incorporated herein by reference to Exhibit 10e to the Squibb Corporation
      Form 10-K for the fiscal year ended December 31, 1987, File No. 1-5514;
      as amended effective December 31, 1991, incorporated herein by reference
      to Exhibit 10m to the Form 10-K for the fiscal year ended December 31, 1992).</font></p>
    <p align="JUSTIFY"></p>
  </dir>
</dir>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10o.&#9;Amendment
      to all of the Company's plans, agreements, legal documents and other writings,
      pursuant to action of the Board of Directors on October 3, 1989, to reflect
      the change of the Company's name to Bristol-Myers Squibb Company (incorporated
      herein by reference to Exhibit 10v to the Form 10-K for the fiscal year
      ended December 31, 1989).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10p.&#9;Employment
      agreement of March 12, 1999 for Charles A. Heimbold, Jr. (incorporated herein
      by reference to Exhibit 10p to the Form 10-K for the fiscal year ended December
      31, 1998).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10q. Form of Agreement,
      effective June 1, 1999, entered into between the Registrant and each of
      the following officers on the following dates: Peter R. Dolan, July 29,
      1999; Donald J. Hayden, Jr., July 30, 1999; Richard J. Lane, August 6, 1999;
      John L. McGoldrick, August 10, 1999; Michael F. Mee, July 28, 1999; Peter
      S. Ringrose, Ph.D., August 5, 1999; Stephen I. Sadove, July 29, 1999; Frederick
      S. Schiff, July 29, 1999; John L. Skule, August 5, 1999; and Charles G.
      Tharp, Ph.D., July 28, 1999; (incorporated herein by reference to Exhibit
      10q to the Form 10-Q for the quarterly period ended September 30, 1999).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">**10r. Form of Agreement,
      effective February 1, 2001, entered into between the Registrant and Kenneth
      E. Weg, filed herewith.</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">21.&#9;Subsidiaries
      of the Registrant (filed herewith).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">23.&#9;Consent of
      PricewaterhouseCoopers LLP (filed herewith).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">99.&#9;Additional
      Exhibit (filed herewith).</font></p>
    <p align="JUSTIFY"></p>
    <p align="JUSTIFY">&nbsp;</p>
  </dir>
</dir>
<p align="JUSTIFY"><font face="CG Times" color="#000000">(b) &#9;Reports on Form
  8-K</font></p>
<p align="JUSTIFY"></p>
<dir>
  <dir>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">A Form 8-K, as of
      January 24, 2001, was filed by the Company, including financial statements
      restated to present Clairol (which includes its Matrix Essentials, Inc.
      affiliate) and Zimmer as discontinued operations.</font></p>
    <p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
    <dir>
      <dir>
        <p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________&#9;</font></p>
        <p align="left"><font face="CG Times" color="#000000">59</font></p>
        <p align="JUSTIFY"></p>
      </dir>
    </dir>
  </dir>
</dir>
<p align="left"><font face="CG Times" color="#000000">_____________________________________________________________________________________________&#9;</font></p>
<p align="center"><font face="CG Times" color="#000000">59</font></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER"><font color="#000000"><u><font face="CG Times">SIGNATURES</font></u></font></p>
<p align="CENTER"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Pursuant to the requirements
  of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant
  has duly caused this Report to be signed on its behalf by the undersigned, thereunto
  duly authorized.</font></p>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<table cellspacing=0 border=0 cellpadding=7 width=686>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">
      <p align="left"><font face="CG Times">BRISTOL-MYERS SQUIBB COMPANY</font></p>
      <p align="JUSTIFY"><font face="CG Times"> (Registrant)</font></p>
      <p align="JUSTIFY">
    </td>
  </tr>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">
      <p align="JUSTIFY"><u><font face="CG Times"> By /s/ Charles A. Heimbold,
        Jr.</font></u></p>
      <p align="JUSTIFY">
    </td>
  </tr>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Charles A. Heimbold, Jr. </font></p>
      <p align="JUSTIFY"><font face="CG Times">Chairman of the Board and</font></p>
      <p align="JUSTIFY"><font face="CG Times">Chief Executive Officer</font>
    </td>
  </tr>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><u><font face="CG Times"> March 30, 2001</font></u>
    </td>
  </tr>
  <tr>
    <td width="50%" valign="TOP">&nbsp;</td>
    <td width="50%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"> Date</font>
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">Pursuant to the requirements
  of the Securities Exchange Act of 1934, this Report has been signed below by
  the following persons on behalf of the Registrant and in the capacities and
  on the dates indicated.</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=686>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"><u>Signature</u>&#9;</font>
    </td>
    <td width="30%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"><u>Title</u>&#9;</font>
    </td>
    <td width="37%" valign="TOP">
      <p align="JUSTIFY"><u><font face="CG Times">Date</font></u>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><br>
        <br>
      </p>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Charles A. Heimbold, Jr.</font></u>
    </td>
    <td width="30%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Chairman of the Board, Chief Executive
        Officer <br>
        And Director (Principal Executive Officer)</font> </p>
    </td>
    <td width="37%" valign="TOP">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><br>
        <br>
      </p>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%">
      <p align="JUSTIFY"><font face="CG Times"> (Charles A. Heimbold, Jr.)</font></p>
      <p align="left">
    </td>
    <td width="30%" valign="TOP">&nbsp;</td>
    <td width="37%" valign="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><br>
        <br>
      </p>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Michael F. Mee</font></u>
    </td>
    <td width="30%" valign="TOP">
      <p><font face="CG Times">Chief Financial Officer and Executive Vice President
        Corporate Staff (Principal Financial Officer)</font> </p>
    </td>
    <td width="37%" valign="TOP">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY"><br>
        <br>
      </p>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"> (Michael F. Mee)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="30%" valign="TOP">&nbsp;</td>
    <td width="37%" valign="TOP">&nbsp;</td>
  </tr>
  <tr>
    <td width="33%">
      <p align="JUSTIFY">&nbsp;</p>
      <p align="JUSTIFY">&nbsp;</p>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Frederick S. Schiff</font></u>
    </td>
    <td width="30%">
      <p align="JUSTIFY"><font face="CG Times">Controller and Senior Vice President,
        Financial Operations, Corporate Staff (Principal Accounting Officer)</font>
      </p>
    </td>
    <td width="37%">
      <p align="JUSTIFY"></p>
      <p align="JUSTIFY">&nbsp;</p>
      <p align="JUSTIFY">&nbsp;</p>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"> (Frederick S. Schiff)</font>
    </td>
    <td width="30%" valign="TOP">&nbsp;</td>
    <td width="37%" valign="TOP">&nbsp;</td>
  </tr>
</TABLE>
<p align="JUSTIFY"></p>
<p align="JUSTIFY"> </p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">60&#9;&#9;</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=686>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times"><u>Signature</u>&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times"><u>Title</u>&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">Date</font></u>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Robert E. Allen</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Robert E. Allen)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Lewis B. Campbell</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Lewis B. Campbell)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Vance D. Coffman</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Vance D. Coffman)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><u><font face="CG Times"><br>
        /s/ Peter R. Dolan</font></u>
    </td>
    <td width="33%" valign="TOP">
      <p><font face="CG Times">President, Chief Executive Officer-Designate and
        Director</font>
    </td>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Peter R. Dolan)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Ellen V. Futter</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Ellen V. Futter)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Louis V. Gerstner, Jr.</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Louis V. Gerstner, Jr.)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Laurie H. Glimcher, MD</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Laurie H. Glimcher, MD)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Leif Johansson</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (Leif Johansson)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ James D. Robinson III</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=48>
      <p align="JUSTIFY"><font face="CG Times"> (James D. Robinson III)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
    <td width="33%" valign="TOP" height=48>
      <p></p>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><u><font face="CG Times">/s/ Louis W. Sullivan, MD</font></u>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">Director&#9;</font>
    </td>
    <td width="33%" valign="TOP" height=26>
      <p align="JUSTIFY"><font face="CG Times">March 30, 2001</font>
    </td>
  </tr>
  <tr>
    <td width="33%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times"> (Louis W. Sullivan, MD)</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="33%" valign="TOP">&nbsp;</td>
    <td width="33%" valign="TOP">&nbsp;</td>
  </tr>
</TABLE>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">61</font></p>
<p align="JUSTIFY">&nbsp;</p>
<p align="CENTER"><font color="#000000"><u><font face="CG Times">EXHIBIT INDEX</font></u></font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">&#9;</font></p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">The Exhibits listed below
  are identified by numbers corresponding to the Exhibit Table of Item 601 of
  Regulation SK The Exhibits designed by two asterisks (**) are management contracts
  or compensatory plans or arrangements required to be filed pursuant to this
  Item 14. An asterisk (*) in the Page column indicates that the Exhibit has been
  previously filed with the Commission and is incorporated herein by reference.
  Unless otherwise indicated, all Exhibits are part of Commission File Number
  1-1136.</font></p>
<p align="JUSTIFY"></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr>
    <td width="15%" valign="TOP" height=21>
      <p><u><font face="CG Times">Exhibit No.</font></u>
    </td>
    <td width="69%" valign="TOP" height=21>
      <p><u><font face="CG Times">Description</font></u>
    </td>
    <td width="15%" valign="TOP" height=21>
      <p align="CENTER"><u><font face="CG Times">Page No.</font></u>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">3a.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Restated Certificate of Incorporation
        of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit
        4a to Registration Statement No. 33-33682 on Form S-3, dated March 7,
        1990, as amended through May 5, 1999 by Certificate of Amendment incorporated
        herein by reference to Exhibit 3a to Form 10-K for the fiscal year ended
        December 31,1999).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%">
      <p><font face="CG Times">3b.</font>
    </td>
    <td width="69%">
      <p align="JUSTIFY"><font face="CG Times">Bylaws of Bristol-Myers Squibb
        Company, as amended through February 1, 2001, filed herewith.</font></p>
    </td>
    <td width="15%">
      <p align="CENTER"><font face="CG Times" size="3">E-1-1</font></p>
      <p align="CENTER">
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">4a.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Letter of Agreement dated March
        28, 1984 &#9;(incorporated herein by reference to Exhibit 4 to Form 10-K
        for the fiscal year ended December 31,1983).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">4b.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Indenture, dated as of June 1,
        1993, between Bristol-Myers Squibb&#9;Company and The Chase Manhattan
        Bank (National Association), as trustee (incorporated herein by reference
        to Exhibit 4.1 to the Form 8-K dated May 27, 1993, and filed on June 3,
        1993).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%">
      <p><font face="CG Times">4c.</font>
    </td>
    <td width="69%">
      <p align="JUSTIFY"><font face="CG Times">Form of 7.15% Debenture Due 2023
        of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit
        4.2 to the Form 8-K dated May 27, 1993, and filed on June 3, 1993).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">4d.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Form of 6.80% Debenture Due 2026
        of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit
        4e to the Form 10-K for the fiscal year ended December 31, 1996).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">4e.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Form of 6.875% Debenture Due 2097
        of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit
        4f to the Form 10-Q for the quarterly period ended September 30, 1997).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
</TABLE>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">62</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"><u>Exhibit No.</u></font> </p>
    </td>
    <td width="69%" valign="TOP">
      <p><u><font face="CG Times">Description</font></u></p>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Page No.</font></u>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 4f.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Five Year Competitive Advance and
        Revolving Credit Facility Agreement dated as of March 17, 1998 among Bristol-Myers
        Squibb Company, the Borrowing Subsidiaries (as defined in the Agreement),
        the Lenders listed in Schedule 2.1 to the Agreement, The Chase Manhattan
        Bank as Administrative Agent and Citibank, N.A., as Administrative Agent.</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><font face="CG Times"> 4g.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">364-Day Competitive Advance and
        Revolving Credit Facility Agreement dated as of March 17, 1998 among Bristol-Myers
        Squibb Company, the Borrowing Subsidiaries (as defined in the Agreement),
        the Lenders listed in Schedule 2.1 to the Agreement, The Chase Manhattan
        Bank as Administrative Agent and Citibank, N.A., as Administrative Agent.</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10a.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company 1997
        Stock Incentive Plan, effective as of May 6, 1997 and as amended effective
        November 3, 1998 (incorporated herein by reference to Exhibit 10a to the
        Form 10-K for the fiscal year ended December 31, 1998).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10b</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company Executive
        Performance Incentive Plan (incorporated herein by reference to Exhibit
        10b to the Form 10-K for the fiscal year ended December 31, 1996).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10c.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company 1983
        Stock Option Plan, as amended and restated as of January 1, 1997, as amended
        November 3, 1998 (incorporated herein by reference to Exhibit 10c to the
        Form 10-K for the fiscal year ended December 31, 1998).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10d.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Squibb Corporation 1982 Option,
        Restricted Stock and&#9; Performance Unit Plan, as amended (incorporated
        by reference to Exhibit 10b to the Form 10-K for the fiscal year ended
        December 31, 1993).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10e.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Squibb Corporation 1986 Option,
        Restricted Stock and Performance Unit Plan, as amended (as adopted, incorporated
        herein by reference to Exhibit 10k to the Squibb Corporation Form 10-K
        for the fiscal year ended December 31, 1988, File No. 1-5514, as amended
        July 1, 1993, incorporated herein by reference to Exhibit 10c to the Form
        10-K for the fiscal year ended December 31, 1993).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
</TABLE>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">63</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr>
    <td width="15%" valign="TOP">
      <p><u><font face="CG Times">Exhibit No.</font></u> </p>
    </td>
    <td width="69%" valign="TOP">
      <p><u><font face="CG Times">Description</font></u></p>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Page No.</font></u>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10f.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company Performance
        Incentive Plan, as amended (as adopted, incorporated herein by reference
        to Exhibit 2 to the Form 10-K for the fiscal year ended December 31, 1978;
        as amended as of January 8, 1990, incorporated herein by reference to
        Exhibit 19b to the Form 10-K for the fiscal year ended December 31, 1990;
        as amended on April 2, 1991, incorporated herein by reference to Exhibit
        19b to the Form 10-K for the fiscal year ended December 31, 1991; as amended
        effective on January 1, 1994, and incorporated herein by reference to
        Exhibit 10d to the Form 10-K for the fiscal year ended December 31, 1994).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10g.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Benefit Equalization Plan of Bristol-Myers
        Squibb Company and its Subsidiary or Affiliated corporations Participating
        in the Bristol-Myers Squibb Company Retirement Income Plan or the Bristol-Myers
        Squibb Puerto Rico, Inc. Retirement Income Plan, as amended (as amended
        and restated as of January 1, 1993, as amended effective October 1, 1993,
        incorporated herein by reference to Exhibit 10e to the Form 10-K for the
        fiscal year ended December 31, 1993 and amended effective February 1,
        1995, incorporated by reference to Exhibit 10e to the Form 10-K for the
        fiscal year ended December 31, 1995).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10h</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Benefit Equalization Plan of Bristol-Myers
        Squibb Company an its Subsidiary or Affiliated Corporation Participating
        in the Bristol-Myers Squibb Company Savings and Investment Program, as
        amended (as amended and restated as of May 1, 1990, incorporated herein
        by reference to Exhibit 19d to the Form 10-K for the fiscal year ended
        December 31, 1990; as amended as of January 1, 1991, incorporated herein
        by reference to Exhibit 19g to the Form 10-K for the fiscal year ended
        December 31, 1990; as amended as of January 1, 1991, incorporated herein
        by reference to Exhibit 19e to the Form 10-K for the fiscal year ended
        December 31, 1991; as amended as of October 1, 1994, incorporated herein
        by reference to Exhibit 10f of the Form 10-K for the fiscal year ended
        December 31, 1994).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10i</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Squibb Corporation Supplementary
        Pension Plan, as amended (as previously amended and restated, incorporated
        herein by reference to Exhibit 19g to the Form 10-K for the fiscal year
        ended December 31, 1991; as amended on September 14, 1993, incorporated
        by reference to Exhibit 10g to the Form 10-K for the fiscal year ended
        December 31, 1993).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="99%" valign="TOP" colspan="3">
      <p><font face="CG Times">_____________________________________________________________________________________________</font></p>
      <p align="center"><font face="CG Times">64</font></p>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p><u><font face="CG Times">Exhibit No.</font></u>
    </td>
    <td width="69%" valign="TOP">
      <p><u><font face="CG Times">Description</font></u></p>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Page No.</font></u>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10j.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company Restricted
        Stock Award Plan, as amended (as adopted on November 7, 1989, incorporated
        herein by reference to Exhibit 10t to the Form 10-K for the fiscal year
        ended December 31, 1989; as amended on December 4, 1990, incorporated
        herein by reference to Exhibit 19a to the Form 10-K for the fiscal year
        ended December 31, 1990; as amended July 1, 1993, incorporated by reference
        to Exhibit 10h to the Form 10-K for the fiscal year ended December 31,
        1993; as amended effective December 6, 1994, incorporated by reference
        to Exhibit 10h to the Form 10-K for the fiscal year ended January 31,
        1994).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10k.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company Retirement
        Income Plan for Non-Employee Directors, as amended to March 5,1996 (incorporated
        herein by reference to Exhibit 10k to the Form 10-K for the fiscal year
        ended December 31, 1996).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10l.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company 1987
        Deferred Compensation Plan for Non-Employee Directors, as amended to January
        13, 1998 (incorporated herein by reference to Exhibit 10l to the Form
        10-K for the fiscal year ended December 31, 1997).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10m.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Bristol-Myers Squibb Company Non-Employee
        Directors' Stock&#9;Option Plan, as amended (as approved by the Stockholders
        on May 1, 1990, incorporated herein by reference to Exhibit 28 to Registration
        Statement No. 33-38587 on Form S-8; as amended May 7, 1991, incorporated
        herein by reference to Exhibit 19c to the Form 10-K for the fiscal year
        ended December 31, 1991; as amended January 12, 1999, incorporated herein
        by reference to Exhibit 10m to the Form 10-K for the fiscal year ended
        December 31, 1998; as amended May 2, 2000, incorporated herein by reference
        to Exhibit 10m to the Form 10-Q for the quarterly period ended March 31,
        2000).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10n.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Squibb Corporation Deferral Plan
        for Fees of Outside Directors, as amended (as adopted, incorporated herein
        by reference to Exhibit 10e to the Squibb Corporation Form 10-K for the
        fiscal year ended December 31, 1987, File No. 1-5514; as amended effective
        December 31, 1991, incorporated herein by reference to Exhibit 10m to
        the Form 10-K for the fiscal year ended December 31, 1992).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
</TABLE>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font face="CG Times" color="#000000">65</font></p>
<table cellspacing=0 border=0 cellpadding=7 width=624>
  <tr>
    <td width="15%" valign="TOP">
      <p><u><font face="CG Times">Exhibit No.</font></u> </p>
    </td>
    <td width="69%" valign="TOP">
      <p><u><font face="CG Times">Description</font></u></p>
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><u><font face="CG Times">Page No.</font></u>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10o.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Amendment to all of the Company's
        plans, agreements, legal documents and other writings, pursuant to action
        of the Board of Directors on October 3, 1989, to reflect the change of
        the Company's name to Bristol-Myers Squibb Company (incorporated herein
        by reference to Exhibit 10v to the Form 10-K for the fiscal year ended
        December 31, 1989).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10p.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Employment agreement of March 12,
        1999 for Charles A. Heimbold, Jr. (incorporated herein by reference to
        Exhibit 10p to the Form 10-K for the fiscal year ended December 31, 1998).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10q.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Form of Agreement, effective June
        1, 1999, entered into between the Registrant and each of the following
        officers on the following dates: Peter R. Dolan, July 29, 1999; Donald
        J. Hayden, Jr., July 30, 1999; Richard J. Lane, August 6, 1999; John L.
        McGoldrick, August 10, 1999; Michael F. Mee, July 28, 1999; Peter S. Ringrose,
        Ph.D., August 5, 1999; Stephen I. Sadove, July 29, 1999; Frederick S.
        Schiff, July 29, 1999; John L. Skule, August 5, 1999; and Charles G. Tharp,
        Ph.D., July 28, 1999. (incorporated herein by reference to Exhibit 10q
        to the Form 10-Q for the quarterly period ended September 30, 1999).</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="CENTER"><font face="CG Times" size="3">*</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">** 10r.</font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Form of Agreement, effective February
        1, 2001, entered into between the Registrant and Kenneth E. Weg, filed
        herewith.</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">E-2-1</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">21. </font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Subsidiaries of the Registrant</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">E-3-1</font>
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">23. </font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Consent of PricewaterhouseCoopers
        LLP.</font></p>
      <p align="JUSTIFY">
    </td>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">E-4-1</font></p>
      <p align="JUSTIFY">
    </td>
  </tr>
  <tr>
    <td width="15%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">99. </font>
    </td>
    <td width="69%" valign="TOP">
      <p align="JUSTIFY"><font face="CG Times">Additional Exhibit</font>
    </td>
    <td width="15%" valign="TOP">
      <p><font face="CG Times">E-5-1</font></p>
      <p align="JUSTIFY">
    </td>
  </tr>
</TABLE>
<p align="JUSTIFY">&nbsp;</p>
<p align="JUSTIFY"><font face="CG Times" color="#000000">_____________________________________________________________________________________________&#9;</font></p>
<p align="JUSTIFY"></p>
<dir>
  <p align="center"><font color="#000000">66&#9;<font face="CG Times">&#9;&#9;&#9;</font></font></p>
</dir>
<p align="center"><font face="CG Times" color="#000000">&#9;SCHEDULE II</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">&#9;---------------------</font></p>
<p align="CENTER"></p>
<p align="CENTER"><font face="CG Times" color="#000000">BRISTOL-MYERS SQUIBB COMPANY</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">VALUATION AND QUALIFYING
  ACCOUNTS</font></p>
<p align="CENTER"><font face="CG Times" color="#000000">(dollars in millions)</font></p>
<p align="CENTER"></p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER">&nbsp;</p>
<p align="CENTER">&nbsp;</p>
<table cellspacing=0 border=0 cellpadding=7 width=646>
  <tr bgcolor="" align="none">
    <td width="24%" valign="TOP" height="63" align="none"><b>
      <p><u><font face="CG Times"><br>
        <br>
        Description</font></u> </p>
      </b></td>
    <td width="20%" valign="TOP" height="63"><b>
      <p align="CENTER"> </p>
      <p align="CENTER"><br>
        Balance at <font face="CG Times">beginning Of <u>period</u></font> </p>
      </b></td>
    <td width="19%" valign="TOP" height="63"><b>
      <p align="CENTER">Additions charged to <font face="CG Times">costs and <br>
        <u>expenses</u></font> </p>
      </b></td>
    <td width="16%" valign="TOP" height="63"><b>
      <p align="CENTER"><br>
        Deductions -<font face="CG Times"> <br>
        bad debts <u>written off</u></font> </p>
      </b></td>
    <td width="21%" valign="TOP" height="63"><b>
      <p align="CENTER"></p>
      <p align="CENTER"><br>
        <br>
        Balance at <font face="CG Times">End <u>of period</u></font> </p>
      </b></td>
  </tr>
  <tr bgcolor="">
    <td valign="TOP" colspan="5" height="46" align="none">
      <p><font face="CG Times">Allowances for Discounts and Doubtful accounts:</font></p>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="24%" valign="TOP" align="none">
      <p><font face="CG Times">For the year ended December 31, 2000</font></p>
    </td>
    <td width="20%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$168</font>
    </td>
    <td width="19%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$37</font>
    </td>
    <td width="16%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$34</font>
    </td>
    <td width="21%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$171</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="24%" valign="TOP" align="none">
      <p><font face="CG Times">For the year ended December 31, 1999</font></p>
    </td>
    <td width="20%">
      <p align="CENTER"><font face="CG Times">$147</font>
    </td>
    <td width="19%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$65</font>
    </td>
    <td width="16%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$44</font>
    </td>
    <td width="21%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$168</font>
    </td>
  </tr>
  <tr bgcolor="">
    <td width="24%" valign="TOP" align="none">
      <p><font face="CG Times">For the year ended December 31, 1998</font></p>
    </td>
    <td width="20%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$109</font>
    </td>
    <td width="19%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$57</font>
    </td>
    <td width="16%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$19</font>
    </td>
    <td width="21%">
      <p align="CENTER"></p>
      <p align="CENTER"><font face="CG Times">$147</font>
    </td>
  </tr>
</TABLE>
<p><font face="CG Times" color="#000000">_____________________________________________________________________________________________</font></p>
<p align="center"><font color="#000000">S-1 </font></p>
<p>&nbsp;</p>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>2
<FILENAME>exhibit3b.htm
<TEXT>

<HTML>
<BODY LINK="#0000ff" VLINK="#800080">

<B><FONT FACE="Arial"><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">_______________________________________________________________</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">_________________</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">BYLAWS</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">As Adopted on November 1, 1965</P>
<P ALIGN="CENTER">And as Amended to February 1, 2001</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">________________</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">_______________________________________________________________</P>
</B></FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-1</P>
</FONT><P><HR></P>
<FONT FACE="Arial"><P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=4><P ALIGN="CENTER">&nbsp;</P>
</FONT><U><FONT FACE="Arial" SIZE=4><P ALIGN="CENTER">I N D E X</P>
</B></U></FONT><FONT FACE="Arial"><P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=672>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P ALIGN="CENTER"><U><FONT FACE="Arial">No.</U></FONT></TD>
<TD WIDTH="71%" VALIGN="TOP">
<U><FONT FACE="Arial"><P ALIGN="CENTER">SUBJECT</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT FACE="Arial"><P>Page</U></FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>1.&nbsp;</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Principal Office</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-5</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;2.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Other Offices</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-5</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;3.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Seal</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-5</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;4.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Date and Time</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-5 - E-1-6</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;5.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Place</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-7</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;6.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- No Action By Written Consent, Call</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-7</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;7.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Notice</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-7</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;8.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Quorum</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-7</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;9.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Presiding Officer and Secretary</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-8</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;10.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Voting</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-8</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;11.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Voting List</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-8 - E-1-9</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;12.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Annual Meeting of Shareholders -- Statement of Business and Condition of Company</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-9</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;13.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Meetings of Shareholders -- Inspectors of Election</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-9</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;14.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Powers</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-9</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;15.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Number, Election, Term, Resignation or Retirement, Removal and Filling Vacancies</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>&nbsp;</P>
<P>E-1-9 - E-1-11</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;16.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Location of Meetings and Books</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-11</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;17.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Scheduling of Regular Meetings</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-11</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;18.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Scheduling of Special Meetings</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-11</FONT></TD>
</TR>
</TABLE>

<FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-2</P>
</FONT><P><HR></P>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=672>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P ALIGN="CENTER"><U><FONT FACE="Arial">No.</U></FONT></TD>
<TD WIDTH="71%" VALIGN="TOP">
<U><FONT FACE="Arial"><P>SUBJECT</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT FACE="Arial"><P>Page</U></FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;19.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Waiver of Meeting Notice and Action by Consent</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-11</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;20.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Quorum for Meeting</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-12</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;21.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Meeting Procedure</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-12</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;22.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Fees</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-12</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;23.</TD>
<TD WIDTH="50%" VALIGN="TOP">
<FONT FACE="Arial"><P>Board of Directors -- Indemnification</FONT></TD>
<TD WIDTH="25%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-12 - E-1-13</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<P>&nbsp;24.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Committees of the Board -- Executive, Audit, Others</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-14 - E-1-15</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;25.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Committees of the Board -- Minutes and Reports</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-15</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;26.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-15</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;27.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Election and Term</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-15 - E-1-16</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;28.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Appointment of Other Officers, Committees or Agents</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-16</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;29.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Removal</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-16</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;30.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Resignation</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-16</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;31.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Unable to Perform Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-16</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;32.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Vacancy</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;33.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>The Chairman of the Board -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;34.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Vice Chairman of the Board -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;35.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Duties of President</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;36.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Vice Presidents -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;37.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>The Treasurer -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-17 - E-1-18</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;38.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>The Secretary -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-18</FONT></TD>
</TR>
</TABLE>

<FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-3</P>
</FONT><P><HR></P>
<FONT FACE="Arial"><P ALIGN="CENTER">&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=672>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P ALIGN="CENTER"><U><FONT FACE="Arial">No.</U></FONT></TD>
<TD WIDTH="71%" VALIGN="TOP">
<U><FONT FACE="Arial"><P>SUBJECT</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT FACE="Arial"><P>Page</U></FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;39.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>The Controller -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-18</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;40.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Assistant Treasurers and Assistant Secretaries -- Powers and Duties</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-18</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;41.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Officers -- Compensation</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-18</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;42.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Contracts, Other Instruments, Authority to Enter Into or Execute</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-19</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;43.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Loans and Negotiable Paper</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-19</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;44.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Checks, Drafts, etc.</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-19</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;45.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Banks -- Deposit of Funds</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-19</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;46.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Stock Certificates -- Form, Issuance</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-20</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;47.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Stock -- Transfer</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-20</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;48.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Stock Certificates -- Loss, Replacement</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-20</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;49.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Record Dates</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-21</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;50.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Registered Shareholders</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-21</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;51.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Fiscal Year</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-21</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;52.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Notices</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-22</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;53.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Notices -- Waiver</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-22</FONT></TD>
</TR>
<TR><TD WIDTH="11%" VALIGN="TOP">
<P>&nbsp;54.</TD>
<TD WIDTH="71%" VALIGN="TOP">
<FONT FACE="Arial"><P>Amendments of Bylaws</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT FACE="Arial"><P>E-1-22</FONT></TD>
</TR>
</TABLE>

<P ALIGN="CENTER">E-1-4</P>
<P><HR></P>
<FONT SIZE=2><P>&nbsp;</P>
</FONT><B><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BYLAWS</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">of</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U><P ALIGN="CENTER">OFFICES</B></U></P><DIR>

<DIR>
<P ALIGN="JUSTIFY">1.&#9;The registered office of the Company shall be in the City of Wilmington, County of New Castle, State of Delaware, and the name of the resident agent in charge thereof is The Corporation Trust Company.</P>
<P ALIGN="JUSTIFY">2.&#9;The Company may also have offices at such place or places as the Board of Directors may from time to time appoint or the business of the Company may require.</P>
<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">SEAL</P>
</B></U><P ALIGN="JUSTIFY">3.&#9;The corporate seal shall have inscribed thereon the name of the Company, the year of its organization and the words "Corporate Seal, Delaware." Said seal may be used in causing it or a facsimile thereof to be impressed or
affixed or reproduced or otherwise.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><U><P ALIGN="CENTER">MEETINGS OF SHAREHOLDERS</P></DIR>

<DIR>
</B></U><P ALIGN="JUSTIFY">4.&#9;The annual meeting of the shareholders for the election of directors and for the transaction of any other proper business shall be held at such time as the Board of Directors may determine. For nominations or other
business to be properly brought before any annual meeting by a shareholder, a shareholder must give timely notice in writing thereof to the Secretary of the Company and, in the case of business other than nominations, such other business must be a proper
matter for</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<DIR>
<DIR>
</DIR>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-5</P></DIR>


</FONT><P><HR></P>
<FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">&nbsp;</P>


</FONT><P ALIGN="JUSTIFY">shareholder action. To be considered timely, a shareholder's notice must be received by the Secretary at the principal executive offices of the Company not less than 120 calendar days before the date of the Company's proxy
statement released to shareholders in connection with the prior year's annual meeting. If the annual meeting for the election of directors is not held on the date designated therefor, the directors shall cause the meeting to be held as soon thereafter as
convenient. A shareholder's notice shall set forth: (a) as to each person whom the shareholder proposes to nominate for election or re-election as a director, all information relating to such person that is required to be disclosed in solicitations of
proxies for election of directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, including such person's written consent to being named in the proxy statement as a nominee and to serving as a director if elected; (b) as to any
 other business that the shareholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of
such shareholder and the beneficial owner, if any, on whose behalf the proposal is made and (c) as to the shareholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (i) the name and address of such
shareholder, as they appear on the Company's books, and of such beneficial owner, (ii) the number of shares of stock held of record and beneficially by such shareholder and such beneficial owner, (iii) the name in which all such shares of stock are
registered on the stock transfer books of the Company, (iv) a representation that the shareholder intends to appear at the meeting in person or by proxy to submit the business specified in such notice, (v) a brief description of the business desired to be
submitted
to the annual meeting, including the complete text of any resolutions intended to be presented at the annual meeting, and the reasons for conducting such business at the annual meeting, (vi) any personal or other material interest of the shareholder in
the business to be submitted, and (vii) all other information relating to the proposed business which may be required to be disclosed under applicable law. In addition, a shareholder seeking to submit such business at the meeting shall promptly provide
any other information reasonably requested by the Company. The chairman of the meeting shall determine all matters relating to the efficient conduct of the meeting, including, but not limited to, the items of business, as well as the maintenance of order
and decorum. The chairman shall, if the facts warrant, determine and declare that any putative business was not properly brought before the meeting in accordance with the procedures prescribed by this bylaw, in which case such business shall not be
transacted. No
 twithstanding the foregoing provisions of this bylaw, a shareholder who seeks to have any proposal included in the Company's proxy materials shall comply with the requirements of Rule 14a-8 under Regulation 14A of the Securities Exchange Act of 1934.</P>
</DIR>
</DIR>

</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-6</P>
</FONT>

<DIR>
<DIR>
<P ALIGN="JUSTIFY">5.&#9;Meetings of the shareholders may be held at such places either within or without the State of Delaware as the Board of Directors may determine.</P>
<P ALIGN="JUSTIFY">6.&#9;Any action required or permitted to be taken by the stockholders of the Company must be effected at a duly called annual or special meeting of such stockholders and may not be effected by any consent in writing by such
stockholders. Except as otherwise required by law and subject to the rights under Article FOURTH of the Certificate of Incorporation of the Company of the holders of any class or series of stock having a preference over the Common Stock as to dividends or
upon liquidation, special meetings of stockholders of the Company may be called only by the Chairman of the Board or by the Board of Directors pursuant to a resolution approved by a majority of the entire Board of Directors.</P>
<P ALIGN="JUSTIFY">7.&#9;
Except as hereinafter provided or as may be otherwise required by law, notice of the place, date and hour of holding each annual and special meeting of the shareholders shall be in writing and shall be delivered personally or mailed in a postage prepaid
envelope, not less than ten days before such meeting, to each person who appears on the books of the Company as a shareholder entitled to vote at such meeting, and to any shareholders who, by reason of any action proposed at such meeting, would be
entitled to have their shares appraised if such action were taken. The notice of every special meeting, besides stating the time and place of such meeting, shall state briefly the purpose or purposes thereof; and no business other than that specified in
such notice or germane thereto shall be transacted at the meeting, except with the unanimous consent in writing of the holders of record of all of the shares of the Company entitled to vote at such meeting. Notice of any meeting of shareholders
shall not be required to be given to any shareholder entitled to participate in any action proposed to be taken at such meeting who shall attend such meeting in person or by proxy or who before or after any such meeting shall waive notice thereof in
writing or by telegram, cable or wireless. Notice of any adjourned meeting need not be given.</P>



<P ALIGN="JUSTIFY">8.&#9;At all meetings of shareholders of the Company, except as otherwise provided by law, the holders of a majority in number of the outstanding shares of the Company, present in person or by proxy and entitled to vote thereat, shall
constitute a quorum for the transaction of business. In the absence of a quorum the holders of a majority in number of the shares of stock so present or represented and entitled to vote may adjourn the meeting from time to time until a quorum is present.
At any such adjourned meeting at which a quorum is present any business may be transacted which might have been transacted at the meeting as originally called.</P><DIR>

</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-7</P></DIR>
</DIR>
</DIR>

</FONT><P><HR></P>
<P ALIGN="CENTER">&nbsp;</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">9.&#9;The Chairman of the Board shall preside as chairman at every meeting of shareholders. The Chairman of the Board may designate another officer of the Company or any shareholder to preside as chairman of a meeting of shareholders
in place of the Chairman of the Board and in the absence of the Chairman of the Board and an officer or shareholder designated by the Chairman of the Board to preside as chairman of the meeting, the Board of Directors may designate an officer or
shareholder to preside as chairman of the meeting. In the event the Chairman of the Board and the Board of Directors fail to so designate a chairman of the meeting the shareholders may designate an officer or shareholder as chairman. The Secretary shall
act as secretary of the meeting, or, in the absence of the Secretary, the presiding officer shall appoint a secretary of the meeting.</P>
<P ALIGN="JUSTIFY">10.&#9;At each meeting of the shareholders every shareholder of record entitled to vote thereat shall be entitled to one vote for each share of the Company standing in that shareholder's name on the books of the Company provided that
no share of stock shall be voted at any election of directors which shall have been transferred on the books of the Company later than the record date announced by the Board of Directors or fixed by operation of these bylaws The vote on shares may be
given by the shareholder entitled thereto in person or by proxy duly appointed by an instrument in writing subscribed by such shareholder or that shareholder's duly authorized attorney (or in any other manner prescribed by the General Corporation Law of
the State of Delaware), and delivered to the secretary of the meeting; provided, however, that no proxy shall be valid after the expiration of three years from the date of its execution unless the shareholder executing it shall have specified therein the
length of t
 ime it is to continue in force, which shall be for some limited period. At all meetings of shareholders, a quorum being present, all matters, except as otherwise provided by law or by the Certificate of Incorporation of the Company or these bylaws,
shall be decided by the holders of a majority in number of the shares of stock of the Company present in person or by proxy and entitled to vote. A share vote may be by ballot and each ballot shall state the name of the shareholder voting and the number
of shares owned by that shareholder and shall be signed by such shareholder or by that shareholder's proxy. Except as otherwise required by law or by these bylaws all voting may be <U>viva</U> <U>voce</U>.</P>
<P ALIGN="JUSTIFY">11.&#9;The Secretary or other officer in charge of the stock ledger of the Company shall prepare and make at least ten days before every meeting of shareholders a complete list of the shareholders entitled to vote at the meeting
arranged in alphabetical order and showing the address of each shareholder and the number of shares registered in the name of each shareholder. Such list shall be open to the examination of any shareholder for any purpose germane to the meeting during
ordinary business hours for a period of at least ten days prior to the meeting either </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-8</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or if not so specified at the place where the meeting is to be held. The list shall also be produced and kept at
the time and place of the meeting during the whole time thereof and may be inspected by any shareholder who is present. The stock ledger shall be the only evidence as to who are the shareholders entitled to examine the stock ledger, the list required by
this bylaw, or the books of the Company or to vote in person or by proxy at any meeting of shareholders.</P>
<P ALIGN="JUSTIFY">12.&#9;The Board of Directors shall present at each annual meeting, and when called for by vote of the shareholders at any special meeting of the shareholders, a full and clear statement of the business and condition of the Company.</P>

<P ALIGN="JUSTIFY">13.&#9;At all elections of directors and when otherwise required by law, the chairman of the meeting shall appoint two inspectors of election. The inspectors shall be responsible for receiving, tabulating and reporting the result of
the votes taken. No director or candidate for the office of director shall be appointed such inspector. The chairman of the meeting shall open and close the polls.</P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>

<B><U><P ALIGN="CENTER">DIRECTORS</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">14.&#9;The property, business and affairs of the Company shall be managed by or under the direction of the Board of Directors, which may exercise all such powers of the Company and do all such lawful acts and things as are not
by statute or by the Certificate of Incorporation or by these bylaws directed or required to be exercised or done by the shareholders.</P>
<P ALIGN="JUSTIFY">15.(a)&#9;The Board of Directors shall consist of eleven directors. Directors need not be shareholders. The number of directors may be determined by a majority vote of the entire Board of Directors.</P>
<P ALIGN="JUSTIFY">&#9;(b)&#9;Except as otherwise provided by the Certificate of Incorporation, by these bylaws or by law, at each meeting of the shareholders for the election of directors at which a quorum shall be present, the persons receiving a
plurality of the votes cast shall be directors. Such election shall be by ballot.</P>
<P ALIGN="JUSTIFY">&#9;(c)&#9;The directors, other than those who may be elected by the holders of any class or series of stock having a preference over the Common Stock as to dividends or upon liquidation, shall be classified, with respect to the time
for which they severally hold office, into three classes, as nearly equal in number as possible, as determined by the Board of Directors, one class to be originally elected for a term expiring at the annual meeting of stockholders to be held in 1985, </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-9</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">another class to be originally elected for a term expiring at the annual meeting of stockholders to be held in 1986, and another class to be originally elected for a term expiring at the annual meeting of stockholders to be held in
1987, with the directors of each class to hold office until their successors are elected and qualified. At each annual meeting of the stockholders, the successors of the class of directors whose term expires at that meeting shall be elected to hold office
for a term expiring at the annual meeting of stockholders held in the third year following the year of their election. No decrease in the number of directors constituting the Board of Directors or change in the restrictions and qualifications for
directors shall shorten the term of any incumbent director.</P>
<P ALIGN="JUSTIFY">&#9;(d)&#9;Except as otherwise provided in the Certificate of Incorporation or in these bylaws, each director shall continue in office until the expiration of his term of office and until a successor shall have been elected and shall
have qualified, or until the director shall have resigned, or, in the case of a director who is an employee of the Company, until the director shall have resigned from employment with the Company or the director's employment shall have been terminated by
the Company. In addition, a director who is not an employee of the Company or who is the Chief Executive Officer of the Company or a retired Chief Executive Officer of the Company shall retire from the position of director at the Annual Meeting following
attainment of age 70; an employee who is a director of the Company (other than the Chief Executive Officer or a retired Chief Executive Officer) shall retire from the position of director on the effective date of the director's retirement as an employee
of the
Company. Any director of the Company may resign at any time by giving written notice to the Chairman of the Board or to the Secretary of the Company. Such resignation shall take effect at the time specified therein; and, unless otherwise specified
therein, the acceptance of such resignation shall not be necessary to make it effective. Exceptions to the requirements for the retirement of a director may be made by the Board of Directors.</P>
<P ALIGN="JUSTIFY">(e)&#9;Subject to the rights under Article FOURTH of the Certificate of Incorporation of any class or series of stock having a preference over the Common Stock as to dividends or upon liquidation to elect directors under specified
circumstances, any director or entire class of directors or the entire Board of Directors may be removed from office, with or without cause, only by the affirmative vote of the holders of at least 75% of the outstanding shares of stock of the Company
entitled to vote generally in the election of directors, voting together as a single class.</P>
<P ALIGN="JUSTIFY">(f)&#9;Subject to the rights under Article FOURTH of the Certificate of Incorporation of the Company of the holders of any class or series of stock having a preference over the Common Stock as to dividends or upon liquidation to elect
directors under specified circumstances, newly created </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-10</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">directorships resulting from any increase in the number of directors and any vacancies on the Board of Directors resulting from death, resignation, retirement, disqualification, removal or other cause shall be filled only by the
affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the
class of directors in which the new directorship was created or the vacancy occurred and until such director's successor shall have been elected and qualified.</P></DIR>
</DIR>

<OL START=16>


<DIR>
<P ALIGN="JUSTIFY">16.&#9;The directors may hold their meetings and keep the books of the Company at such place or places as they may from time to time determine.</P>
<P ALIGN="JUSTIFY">17.&#9;Regular meetings of the Board of Directors may be held at such time as may be fixed from time to time by resolution of the Board of Directors. Unless required by said resolution, notice of any such meeting need not be given.</P>



<P ALIGN="JUSTIFY">18.&#9;Special meetings of the Board of Directors shall be held whenever called by direction of the Chairman of the Board or any of three of the directors for the time being in office. Notice of each such special meeting shall be
mailed, postage prepaid, to each director, addressed to the director at the director's residence or usual place of business, at least two days before the day on which the meeting is to be held, or shall be sent to the director at such place by telegraph,
cable, or wireless, or be delivered personally or by telephone, not later than the day before the day on which the meeting is to be held. Every such notice shall state the time and place but, except as provided by these bylaws or by resolution of the
Board of Directors, need not state the purposes of the meetings.</P>
<P ALIGN="JUSTIFY">19.&#9;Anything in these bylaws or in any resolution adopted by the Board of Directors to the contrary notwithstanding, notice of any meeting of the Board of Directors need not be given to any director, if, before or after any such
meeting, notice thereof shall be waived by such director in writing or by telegraph, cable or wireless. Any meeting of the Board of Directors shall be a legal meeting without any notice having been given or regardless of the giving of any notice or the
adoption of any resolution in reference thereto, if all the directors shall be present thereat or shall have so waived notice thereof. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting, if
prior to such action a written consent thereto is signed by all members of the Board and such written consent is filed with the minutes of proceedings of the Board of Directors.</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-11</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">20.&#9;Five of the directors in office at the time of any regular or special meeting of the Board of Directors shall constitute a quorum for the transaction of business at such meeting and except as may be otherwise specifically
provided by statute or by the Certificate of Incorporation or by these bylaws, the act of a majority of the directors present at any such meeting at which a quorum is present shall be the act of the Board of Directors. In the absence of a quorum a
majority of the directors present may adjourn any meeting from time to time until a quorum is present. Notice of any adjourned meeting need not be given. The directors shall act only as a board and the individual directors shall have no power as such.</P>
<P ALIGN="JUSTIFY">21.&#9;At each meeting of the Board of Directors the Chairman of the Board shall preside. The Chairman of the Board may designate another member of the Board of Directors to preside as chairman of a meeting in place of the Chairman of
the Board, and in the absence of the Chairman of the Board and any member of the Board of Directors designated by the Chairman of the Board to preside as chairman of the meeting, a majority of the directors present may designate a member of the Board of
Directors as chairman to preside at the meeting. The Secretary of the Company or, in the absence of the Secretary, a person appointed by the chairman of the meeting, shall act as secretary of the Board of Directors. The Board of Directors may adopt such
rules and regulations for the conduct of their meetings and the management of the affairs of the Company as they shall deem proper and not inconsistent with the law or with these bylaws. At all meetings of the Board of Directors business shall be
transacted in s
 uch order as the Board of Directors may determine.</P>
<P ALIGN="JUSTIFY">22.&#9;Each director shall be paid such fee, if any, for each meeting of the Board attended and/or such annual fee as shall be determined from time to time by resolution of the Board of Directors, provided that nothing herein contained
shall be construed to prevent any director from serving the Company in any other capacity and receiving compensation therefor.</P>
<P ALIGN="JUSTIFY">23.(a)&#9;Definitions. As used herein, the term "director" shall include each present and former director of the Company and the term "officer" shall include each present and former officer of the Company as such, and the terms
"director" and "officer" shall also include each employee of the Company, who, at the Company's request, is serving or may have served as a director or officer of another corporation in which the Company owns directly or indirectly, shares of capital
stock or of which it is a creditor. The term "officer" also includes each assistant or divisional officer. The term "expenses" shall include, but not be limited to, reasonable amounts for attorney's fees, costs, disbursements and other expenses and the
amount or amounts of judgments, fines, penalties and other liabilities.</P>
<P ALIGN="JUSTIFY">(b)&#9;Indemnification Granted. Each director and officer shall be and hereby is indemnified by the Company, to the full extent permitted by law, against:</P><DIR>
<DIR>

</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-12</P></DIR>
</DIR>
</DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;expenses incurred or paid by the director or officer in connection with any claim made against such director or officer, or any actual or threatened action, suit or proceeding (civil, criminal, administrative, investigative or
other, including appeals and whether or not relating to a date prior to the adoption of this bylaw) in which such director or officer may be involved as a party or otherwise, by reason of being or having been a director or officer of the Company, or of
serving or having served at the request of the Company as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action taken or not taken by such director or officer in
such capacity, and</P>
<P ALIGN="JUSTIFY">(ii)&#9;the amount or amounts paid by the director or officer in settlement of any such claim, action, suit or proceeding or any judgment or order entered therein, however, notwithstanding anything to the contrary herein where a
director or officer seeks indemnification in connection with a proceeding voluntarily initiated by such director or officer the right to indemnification granted hereunder shall be limited to proceedings where such director or officer has been wholly
successful on the merits.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">(c)&#9;Miscellaneous.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;Expenses incurred and amounts paid in settlement with respect to any claim, action, suit or proceeding of the character described in paragraph (b)(i) above may be advanced by the Company prior to the final disposition thereof
upon receipt of an undertaking by or on behalf of the recipient to repay such amounts as shall not ultimately be determined to be payable to such recipient under this bylaw.</P>
<P ALIGN="JUSTIFY">(ii)&#9;The rights of indemnification herein provided for shall be severable, shall not be exclusive of other rights to which any director or officer now or hereafter may be entitled, shall continue as to a person who has ceased to be
an indemnified person and shall inure to the benefit of the heirs, executors, administrators and other legal representatives of such a person.</P>
<P ALIGN="JUSTIFY">(iii)&#9;The provisions of this bylaw shall be deemed to be a contract between the Company and each director or officer who serves in such capacity at any time while such bylaw is in effect.</P>
<P ALIGN="JUSTIFY">(iv)&#9;The Board of Directors shall have power on behalf of the Company to grant indemnification to any person other than a director or officer to such extent as the Board in its discretion may from time to time determine.</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-13</P></DIR>
</DIR>
</DIR>
</DIR>

</FONT><P><HR></P>
<B><U><P ALIGN="CENTER">COMMITTEES OF THE BOARD</B></U></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">24.(a)&#9;The Board of Directors may, by resolution or resolutions, passed by a majority of the whole Board of Directors, designate an Executive Committee (and may discontinue the same at any time) to consist of three or more of the
Directors of the Company. The members shall be appointed by the Board of Directors and shall hold office during the pleasure of the Board of Directors; provided, however, that in the absence or disqualification of any member of the Executive Committee,
the member or members thereof present at any meeting and not disqualified from voting, whether or not the member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any
such absent or disqualified member. The Executive Committee shall have and may exercise, during the intervals between the meetings of the Board of Directors, all of the powers of the Board of Directors in the management of the business and affairs of the
Comp
 any (and shall have power to authorize the seal of the Company to be affixed to all papers which may require it), except that the Executive Committee shall have no power to (i) elect Directors to fill any vacancies or appoint any officers; (ii) fix the
compensation of any officer or the compensation of any Director for serving on the Board of Directors or on any committee; (iii) declare any dividend or make any other distribution to the shareholders of the Company; (iv) submit to shareholders any action
that needs shareholder authorization; (v) amend or repeal the bylaws or adopt any new bylaw; (vi) amend or repeal any resolution of the Board of Directors which by its terms shall not be so amendable or repealable; (vii) take any final action with respect
to the acquisition or disposition of any business at a price in excess of $25,000,000.</P>
<P ALIGN="JUSTIFY">(b)&#9;The Board of Directors shall, by resolution or resolutions, passed by a majority of the whole Board of Directors designate an Audit Committee to consist of three or more non-employee directors of the Company free from any
relationship that, in the opinion of the Board of Directors, would interfere with the exercise of independent judgment as a Committee member. Any director who is a former employee of the Company may not serve on the Audit Committee. The members of the
Audit Committee shall be appointed by and hold office during the pleasure of the Board of Directors. A majority of the members of the Audit Committee will constitute a quorum for the transaction of business. It shall be the duty of the Audit Committee (i)
to recommend to the Board of Directors a firm of independent accountants to perform the examination of the annual financial statements of the Company; (ii) to review with the independent accountants and with the Controller the proposed scope of the annual
audit, past
audit experience, the Company's internal audit program, recently completed internal audits and other matters bearing upon the scope of the audit; (iii) to review with the independent accountants and with the Controller significant matters revealed </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-14</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">in the course of the audit of the annual financial statements of the Company; (iv) to review on a biennial basis that the Company's Standards of Business Conduct have been communicated by the Company to all key employees of the Company
and its subsidiaries throughout the world with a direction that all such key employees certify that they have read, understand and are not aware of any violation of the Standards of Business Conduct; (v) to review with the Controller any suggestions and
recommendations of the independent accountants concerning the internal control standards and the accounting procedures of the Company; (vi) to meet on a regular basis with a representative or representatives of the Internal Audit Department of the Company
and to review the Internal Audit Department's Reports of Operations; (vii) to report its activities and actions to the Board of Directors at least once each fiscal year.</P>
<P ALIGN="JUSTIFY">(c)&#9;The Board of Directors may, by resolution or resolutions passed by a majority of the whole Board of Directors, designate such other committees as may be deemed advisable (and may discontinue the same at any time), to consist of
two or more of the directors of the Company. The members shall be appointed by and shall hold office during the pleasure of the Board of Directors, and the Board of Directors shall prescribe the name or names of such committees, the number of their
members and their duties and powers.</P>
<P ALIGN="JUSTIFY">(d)&#9;Any action required or permitted to be taken at any meeting of any committee may be taken without a meeting, if prior to such action a written consent thereto is signed by all members of the committee and such written consent is
filed with the minutes of proceedings of the committee.</P></DIR>
</DIR>

<DIR>
<DIR>
<P ALIGN="JUSTIFY">25.&#9;All committees shall keep written minutes of their proceedings and report the same to the Board of Directors when required.</P>

<P ALIGN="JUSTIFY">&nbsp;</P>
<B><U><P ALIGN="CENTER">OFFICERS</P>
</B></U><P ALIGN="JUSTIFY">&nbsp;</P>

<P ALIGN="JUSTIFY">26.&#9;The officers of the Company shall be a Chairman of the Board, a Vice Chairman of the Board, a President, two or more Vice Presidents (which shall include Senior Vice President, Executive Vice President and other Vice President
titles), a Treasurer, a Secretary, a Controller, and such other officers as may be appointed in accordance with these bylaws. The Secretary and Treasurer may be the same person, or a Vice President may hold at the same time the office of Secretary,
Treasurer, or Controller.</P>
<P ALIGN="JUSTIFY">27.&#9;The officers of the Company shall be chosen by the Board of Directors. Each officer shall hold office until a successor shall have been duly chosen and shall have qualified or until the death </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-15</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>
<DIR>

<P ALIGN="JUSTIFY">or retirement of the officer or until the officer shall resign or shall have been removed in the manner hereinafter provided. The Chairman of the Board and the Vice Chairman of the Board shall be chosen from among the directors.</P>
<P ALIGN="JUSTIFY">28.&#9;The Board of Directors may appoint such other officers, committees or agents, as the business of the Company may require, including one or more Assistant Treasurers and one or more Assistant Secretaries, each of whom shall hold
office for such period, and have such authority and perform such duties as are provided in these bylaws or as the Board of Directors may from time to time determine. The Board of Directors may delegate to any officer or committee the power to appoint and
to remove any such subordinate officer or agent.</P></DIR>
</DIR>
<DIR>
<DIR>
<P ALIGN="JUSTIFY">29.&#9;Subject to the provisions of any written agreement, any officer may be removed, either with or without cause, by a vote of the majority of the whole Board of Directors at a regular meeting or a special meeting called for the
purpose. Any officer, except an officer elected by the Board of Directors, may also be removed, with or without cause, by any committee or superior officer upon whom such power of removal may be conferred by the Board of Directors.</LI></P>
<P ALIGN="JUSTIFY">30.&#9;Subject to the provisions of any written agreement, any officer may resign at any time by giving written notice to the Board of Directors, the Chairman of the Board or the Secretary of the Company. Any such resignation shall
take effect at the time specified therein; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.</LI></P>
<P ALIGN="JUSTIFY">31.&#9;
Except as otherwise provided in these bylaws, in the event any officer shall be unable to perform the duties of the office held, whether by reason of absence, disability or otherwise, the Chairman of the Board may designate another officer of the Company
to assume the duties of the officer who is unable to carry out the duties of the office; in the event the Chairman of the Board shall be absent and unable to perform the duties of the office of Chairman of the Board, the Chairman of the Board shall
designate another officer to assume the duties of the Chairman of the Board; if another officer has not been designated by the Chairman of the Board to assume the duties of the Chairman of the Board, then the Board of Directors shall designate another
officer to assume the duties of the Chairman of the Board; in the event the Chairman of the Board shall be disabled and unable to perform the duties of the office of Chairman of the Board, then the Board of Directors shall designate another offi
 cer to assume the duties of the Chairman of the Board. Any officer designated to assume the duties of another officer shall have all the powers of and be subject to all the restrictions imposed upon the officer whose duties have been assumed.</LI></P></OL>

<DIR>
<DIR>

</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-16</P></DIR>
</DIR>

</FONT><P><HR></P><DIR>


<P ALIGN="JUSTIFY">32.&#9;A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled for the unexpired portion of the term in the manner prescribed by these bylaws for the regular appointment or
election to such office.</P>
<P ALIGN="JUSTIFY">33.&#9;The Chairman of the Board shall be the chief executive officer of the Company and shall have general supervision of the business and operations of the Company, subject, however, to the control of the Board of Directors. The
Chairman of the Board shall preside at all meetings of the shareholders and of the Board of Directors. The Chairman of the Board shall perform all of the duties usually incumbent upon a chief executive officer of a corporation and incident to the office
of the Chairman of the Board. The Chairman of the Board shall also have such powers and perform such duties as are assigned by these bylaws and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as may from
time to time be assigned by the Board of Directors.</P>
<P ALIGN="JUSTIFY">34.&#9;The Vice Chairman shall have such powers and perform such duties as are assigned by these bylaws and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as from time to time may be
assigned by the Board of Directors or the Chairman of the Board.</P>
<P ALIGN="JUSTIFY">35.&#9;The President shall have such powers and perform such duties as are assigned by these bylaws and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as from time to time may be
assigned by the Board of Directors or the Chairman of the Board.</P>
<P ALIGN="JUSTIFY">36.&#9;Each Vice President shall have such powers and perform such duties as are assigned by these bylaws and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as from time to time may be
assigned by the Board of Directors or the Chairman of the Board.</P></DIR>



<DIR>
<P ALIGN="JUSTIFY">37.&#9 The Treasurer shall have charge and custody of, and be responsible for, all funds of the Company. The Treasurer shall regularly enter or cause to be entered in books to be kept by the Treasurer or under the Treasurer's direction
for this purpose full and adequate account of all moneys received or paid by the Treasurer for the account of the Company; the Treasurer shall exhibit such books of account and records to any of the directors of the Company at any time upon request at the
office of the Company where such books and records shall be kept and shall render a detailed statement of these accounts and records to the Board of Directors as often as it shall require the same. The Treasurer shall also have such powers and perform
such duties as are assigned the Treasurer by </P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-17</P>
</FONT><P><HR></P>
<P ALIGN="JUSTIFY">these bylaws and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as from time to time may be assigned by the Board of Directors.</P>
<P ALIGN="JUSTIFY">38.&#9
It shall be the duty of the Secretary to act as Secretary of all meetings of the Board of Directors and of the shareholders of the Company, and to keep the minutes of all such meetings in the proper book or books to be provided for that purpose; the
Secretary shall see that all notices required to be given by or for the Company or the Board of Directors or any committee are duly given and served; the Secretary shall be custodian of the seal of the Company and shall affix the seal, or cause it to be
affixed, to all documents, the execution of which on behalf of the Company, under its seal shall have been duly authorized in accordance with the provisions of these bylaws. The Secretary shall have charge of the share records and also of the other books,
records, and papers of the Company relating to its organization and management as a corporation and shall see that the reports, statements and other documents required by law are properly kept and filed; and shall in general perform all the
duties usually incident to the office of Secretary. The Secretary shall also have such powers and perform such duties as are assigned by these bylaws, and shall have such other powers and perform such other duties, not inconsistent with these bylaws, as
from time to time may be assigned by the Board of Directors.</P>


<P ALIGN="JUSTIFY">39.&#9;The Controller shall perform the usual duties pertaining to the office of the Controller. The Controller shall have charge of the supervision of the accounting system of the Company, including the preparation and filing of all
reports required by law to be made to any public authorities and officials, and shall also have such powers and perform such duties, not inconsistent with these bylaws, as from time to time may be assigned by the Board of Directors.</P>
<P ALIGN="JUSTIFY">40.&#9;The Assistant Treasurers and the Assistant Secretaries shall have such powers and perform such duties as are assigned to them by these bylaws and shall have such other powers and perform such other duties, not inconsistent with
these bylaws, as from time to time may be assigned to them by the Treasurer or the Secretary, respectively, or by the Board of Directors.</P>
<P ALIGN="JUSTIFY">41.&#9;The compensation of the Chairman of the Board, Vice Chairman of the Board, President, Vice President, Treasurer, Secretary and Controller shall be fixed by the Board of Directors. The compensation of such other officers as may
be appointed in accordance with the provisions of these bylaws may be fixed by the Chairman of the Board. No officer shall be prevented from receiving such compensation by reason of also being a director of the Company.</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-18</P></DIR>
</DIR>

</FONT><P><HR></P>
<B><U><P ALIGN="CENTER">CONTRACTS, CHECKS, DRAFTS, BANK ACCOUNTS, ETC.</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">42.&#9;The Board of Directors except as in these bylaws otherwise provided, may authorize any officer or officers, agent or agents, in the name of and on behalf of the Company, to enter into any contract or execute and deliver
any instrument, and such authority may be general or confined to specific instances; and, unless so authorized by the Board of Directors or expressly authorized by these bylaws, no officer or agent or employee shall have any power or authority to bind the
Company by any contract or engagement or to pledge its credit or to render it pecuniarily liable for any purpose or to any amount.</P>
<P ALIGN="JUSTIFY">43.&#9;No loans shall be contracted on behalf of the Company and no negotiable paper shall be issued in its name unless authorized by resolution of the Board of Directors. When authorized by the Board of Directors, any officer or agent
of the Company thereunto authorized may effect loans and advances at any time for the Company from any bank, trust company, or other institution, or from any firm, corporation or individual, and for such loans and advances may make, execute and deliver
promissory notes, bonds, or other certificates or evidences of indebtedness of the Company and, when authorized so to do, may pledge, hypothecate or transfer any securities or other property of the Company as security for any such loans or advances. Such
authority may be general or confined to specified instances.</P>
<P ALIGN="JUSTIFY">44.&#9;All checks, drafts and other orders for the payment of moneys out of the funds of the Company and all notes or other evidences of indebtedness of the Company shall be signed on behalf of the Company in such manner as shall from
time to time be determined by resolution of the Board of Directors.</P>
<P ALIGN="JUSTIFY">45.&#9;All funds of the Company not otherwise employed shall be deposited from time to time to the credit of the Company in such banks, trust companies or other depositories as the Board of Directors may select or as may be selected by
any officer or officers, agent or agents of the Company to whom such power may from time to time be delegated by the Board of Directors; and for the purpose of such deposit, the Chairman of the Board, the Vice Chairman of the Board, the President, a Vice
President, the Treasurer, the Controller, the Secretary or any other officer or agent or employee of the Company to whom such power may be delegated by the Board of Directors, may endorse, assign and deliver checks, drafts and other orders for the payment
of moneys which are payable to the order of the Company.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-19</P></DIR>
</DIR>

</FONT><P><HR></P>
<B><U><P ALIGN="CENTER">CERTIFICATES AND TRANSFERS OF SHARES</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">46.&#9;The shares of the Company shall be represented by certificates or shall be uncertificated. Each registered holder of shares, upon request to the Company, shall be provided with a certificate of stock, representing the
number of shares owned by such holder. Certificates for shares of the Company shall be in such form as shall be approved by the Board of Directors. Such certificates shall be numbered and registered in the order in which they are issued and shall be
signed by the Chairman of the Board, the Vice Chairman of the Board, the President or a Vice President and the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer. Where any such certificate is countersigned by a transfer agent,
other than the Company or its employee, or by a registrar, other than the Company or its employee, any other signature on such certificate may be a facsimile, engraved, stamped or printed. In the event that an officer whose facsimile signature appears on
such certif
icate ceases for any reason to hold the office indicated and the Company or its transfer agent has on hand a supply of share certificates bearing such officer's facsimile signature, such certificates may continue to be issued and registered until such
supply is exhausted.</P>
<P ALIGN="JUSTIFY">47.&#9;Transfers of shares of the Company shall be made only on the books of the Company by the holder thereof, or by the holder's attorney thereunto duly authorized and on either the surrender of the certificate or certificates for
such shares properly endorsed or upon receipt of proper transfer instructions from the registered owner of uncertificated shares. Every certificate surrendered to the Company shall be marked "Cancelled," with the date of cancellation, and no new
certificate shall be issued in exchange therefor until the old certificate has been surrendered and cancelled, except as hereinafter provided. Uncertificated shares shall be cancelled and issuance of new equivalent uncertificated shares shall be made to
the person entitled thereto and the transaction shall be recorded upon the books of the Company.</P>
<P ALIGN="JUSTIFY">48.&#9;The holder of any shares of the Company shall immediately notify the Company of any loss, destruction or mutilation of the certificate therefor and the Company may issue a new certificate in the place of any certificate
theretofore issued by it alleged to have been lost, destroyed or mutilated. The Board of Directors may, in its discretion, as conditions to the issue of any such new certificate, require the owner of the lost or destroyed certificate or the owner's legal
representatives to make proof satisfactory to the Board of Directors of the loss or destruction thereof and to give the Company a bond in such form, in such sum and with such surety or sureties as the Board of Directors may direct, to indemnify the
Company against any claim that may be made against it on account of any such certificate so alleged to have been lost or destroyed.</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">E-1-20</P>


</FONT><P><HR></P>
<B><U><P ALIGN="CENTER">DETERMINATION OF RECORD DATE</P>

</B></U><P ALIGN="JUSTIFY">49.&#9;In order that the Company may determine the shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or
allotment of any rights or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix in advance a record date which shall not be more than 60 nor
less than 10 days before the date of such meeting nor more than 60 days prior to any other action.</P>
<P ALIGN="JUSTIFY">If no record date is fixed:</P>
<P ALIGN="JUSTIFY">(i)&#9;The record date for determining shareholders entitled to notice of or </P>
<P ALIGN="JUSTIFY">to vote at a meeting of shareholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting
is held.</P>
<P ALIGN="JUSTIFY">(ii)&#9;The record date for determining shareholders for any other purpose</P>
<P ALIGN="JUSTIFY">shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>
<P ALIGN="JUSTIFY">A determination of shareholders of record entitled to notice of or to vote at a meeting of shareholders shall apply to any adjournment of the meeting provided, however, that the Board of Directors may fix a new record date for the
adjourned meeting.</P>
<B><U><P ALIGN="CENTER">REGISTERED SHAREHOLDERS</P>
</U><P ALIGN="JUSTIFY">&nbsp;</P>
</B><P ALIGN="JUSTIFY">50.&#9;The Company shall be entitled to treat the holder of record of any share or shares of stock as the holder in fact thereof and, accordingly, shall not be bound to recognize any equitable or other claim to or interest in such
share on the part of any other person, whether or not it shall have express or other notice thereof, save as expressly provided by the laws of Delaware.</P>
<B><U><P ALIGN="CENTER">FISCAL YEAR</P>
</B></U><P ALIGN="JUSTIFY">51.&#9;The fiscal year shall begin on the first day of January and end on the thirty-first day of December in each year.</P>

</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-21</P>
</FONT><P><HR></P>

<B><U><P ALIGN="CENTER">NOTICES</P>
</B></U><P ALIGN="JUSTIFY">52.&#9;Whenever under the provision of these bylaws notice is required to be given to any director or shareholder, it shall be construed to mean personal notice, but such notice may be given in writing, by mail, by depositing
the same in a post office or letter box, in a postpaid sealed wrapper, addressed to such director or shareholder at such address as appears on the books of the Company, or, in default of other address, to such director or shareholder, at the General Post
Office in the City of Wilmington, Delaware, and such notice shall be deemed to be given at the time when the same shall be thus mailed.</P>
<P ALIGN="JUSTIFY">53.&#9;Any notice required to be given under these bylaws may be waived in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein.</P></DIR>
</DIR>

<B><U><P ALIGN="CENTER">AMENDMENTS</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">54.&#9;Except as otherwise provided in the Certificate of Incorporation of the Company and consistent therewith, these bylaws may be altered, amended or repealed or new bylaws may be made by the affirmative vote of the holders
of record of a majority of the shares of the Company entitled to vote, at any annual or special meeting, provided that such proposed action shall be stated in the notice of such meeting, or, by a vote of the majority of the whole Board of Directors, at
any regular meeting without notice, or at any special meeting provided that notice of such proposed action shall be stated in the notice of such special meeting.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><FONT FACE="Arial" SIZE=2><P ALIGN="CENTER">E-1-22</P></DIR>
</DIR>

</FONT><P><HR></P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>exhibit10r.htm
<TEXT>

<HTML>

<BODY LINK="#0000ff" VLINK="#800080">

<U><P ALIGN="RIGHT">Exhibit 10r</P>
</U><P>&nbsp;</P>
<P>&nbsp;</P>
<P>C.G. Tharp&#9;&#9;&#9;&#9;&#9;&#9;<P ALIGN="RIGHT">December 6, 2000</P>
<P>K.E. Weg&#9;&#9;&#9;&#9;&#9;&#9;<B><P ALIGN="RIGHT">Retirement Arrangements</P>
</B><P>C.A. Heimbold, Jr.</P>
<P>&nbsp;</P>
<P>As we discussed, you will retire from the Company on February 1, 2001 ("retirement date"). Outlined below are the various payments and benefits you would normally receive corresponding to your retirement date of February 1, 2001. Additionally, I have
outlined the supplemental payments and benefits which the Company will provide to you.</P>
<B><U><P>Retirement Benefits</P>
<OL>

</B></U><LI>Based upon the service and earnings you will have as of February 1, 2001, your retirement benefits will be provided under the provisions of the Retirement Income Plan.</LI>
<LI>All of your outstanding stock option awards, which have been outstanding for at least one year, will vest in full upon retirement and you will be treated under the Plan provisions relating to retirees.</LI>
<LI>As a retiree, you will be eligible to participate in the Company's retiree medical plan and you will have life insurance coverage equal to one times your base salary until age 65. After age 65, the level of life insurance coverage decreases to
$6,000. At retirement, and until age 70, the company also makes one times pay voluntary life insurance available to those who had at least two times pay coverage immediately prior to retirement. Upon the attainment of age 65, this optional coverage is
limited to $50,000.</LI></OL>

<B><U><P>Supplemental Payments and Benefits</P>
<OL>

</B></U><LI>The Bristol-Myers Squibb Board of Directors' Charitable Contributions Program requires that management directors remain with the Company until normal retirement age (age 65) in order to vest in the program. However, we will seek Board of
Directors approval for you to continue to participate in the Program so that the $300,000 gift to the Fox Chase Cancer Center and the $200,000 gift to Dartmouth College will vest upon your retirement. This matter will be reviewed with the Board and once a
determination is made we will notify you off their decision.</LI>
<LI>To allow the company to draw upon your experience and expertise, you will be retained as a consultant for a period of two years following your retirement date at an annual retainer of $100,000. The details of this consulting arrangement will be
forwarded to you under separate cover.</LI>
<LI>Per your request, the Company will provide office and secretarial support in Princeton, New Jersey (or another location should your plans change) for as long as you should desire such support.</LI>
<LI>Financial counseling and tax preparation services will be provided for a period of two years following your retirement date.</LI>
<LI>You will retain use of your current Company provided automobile for a period of two years following your retirement date.</LI></OL>

<P>Ken, we would be happy to discuss any questions you may have regarding the items outlined above.</P>
<P>If you accept the terms of this agreement, please sign the agreement, retain a copy for your records, and return the original to me.</P>
<P>&#9;&#9;&#9;&#9;&#9;</P>
<P>&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;</P>
<P>&#9;&#9;&#9;&#9;&#9;&#9;&#9;</FONT><U>By /s/ Charles G. Tharp</FONT><FONT FACE="Arial"> </P>
</U><P>&#9;&#9;&#9;&#9;&#9;&#9; Charles G. Tharp</P>
<P>&#9;&#9;&#9;&#9;&#9;&#9;&#9;Senior Vice President</P>
<P>&#9;&#9;&#9;&#9;&#9;&#9;&#9;Human Resources</P>
<P>&nbsp;</P>
<P>Agreed to:</P>
<P>&nbsp;</P>
</FONT><U><FONT FACE="CG Times"><P>By /s/ Kenneth E. Weg</P>
</U></FONT><FONT FACE="Arial"><P>Kenneth E. Weg</P>
<P>&nbsp;</P>
<U><P>12/18/00</U> </P>
<P>Date&#9;&#9;&#9;&#9; </P>
<P>&#9;&#9;&#9;&#9;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P ALIGN="RIGHT">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;December 6, 2000</P>
<P>Kenneth E. Weg</P>
<P>12 Boudinot Street</P>
<P>Princeton, NJ 08540</P>
<P>&nbsp;</P>
<P ALIGN="JUSTIFY">Dear Ken:</P>
<P ALIGN="JUSTIFY">This letter sets for the terms of your Consulting Agreement with Bristol-Myers Squibb Company ("the Company").</P>
<P ALIGN="JUSTIFY">Your services shall consist of consulting, assisting and advising on subjects in your area of expertise pertaining to general management, business operations and other matters. Specific projects will be identified for you by Charles A.
Heimbold, Jr., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Company, and upon his retirement, his successor, or their designees, based on mutual agreement as to their nature and substance, and taking into consideration your
availability.</P>
<P ALIGN="JUSTIFY">This agreement shall be in effect for a twenty-four month period commencing February 1, 2001 and ending February 1, 2003. Your consulting fee during that two-year period shall be one hundred thousand dollars ($100,000) per year
representing 30 consulting days per year, and will be paid in quarterly installments at the end of each three-month period. Should your services be needed for more than 30 days during any one-year period, your fee will be $3,333.34 per day. You will
receive full reimbursement for all reasonable expenses (e.g. travel and entertainment) you incur in rendering services under this Agreement provided you provide documentation of such expenses in accordance with the usual practices of the Company.</P>
<P ALIGN="JUSTIFY">Any amounts paid pursuant to this agreement shall be in addition to any amounts, funds, proceeds, benefits and awards due or to become due to you from the Company as a result of your prior employment by the Company or under any
separate agreement with the Company.</P>
<P ALIGN="JUSTIFY">It is understood that during the course of your consulting you may be exposed to material and information that is confidential to the Company. All such material and information, whether tangible or intangible, made available, disclosed
or otherwise known to you as a result of your services under this agreement or by reason of your prior employment with the Company, shall be considered the sole property of the Company, shall be used by you only for the benefit of the Company during the
term of this Agreement, and shall not be disclosed to others except with the Company's prior approval. This obligation of confidentiality shall survive the termination of this Agreement. Upon termination of this Agreement you shall promptly return all
material, data and documents which you may then have in your possession as a result of your services under the Agreement.</P>
<P ALIGN="JUSTIFY">It is understood that your status shall be that of independent contractor and not of agent or employee of the Company. In this connection, you will not be entitled to any employee benefits from the Company as a result of this Agreement
or the services rendered under it. You further agree that during the terms of this Agreement you will not accept employment with or provide any services to anyone who is a competitor of Bristol-Myers Squibb Company without the prior approval of the Company.
 </P>
<P ALIGN="JUSTIFY">Finally, you are reminded of the continuing nature of your obligation to maintain in confidence and not to make use of information concerning the Company's business or affairs of any nature that is not otherwise a matter of public
record. This obligation which you acknowledged and agreed to in the agreement concerning confidentiality that you executed when your employment with the Company began, continues after the termination of your employment.</P>
<P ALIGN="JUSTIFY">Please acknowledge your understanding of and agreement to the provisions of this Consulting Agreement by signing below.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;Very truly yours,</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;</FONT><U><FONT FACE="CG Times">By /s/ Charles G. Tharp</U></FONT><FONT FACE="Arial"> </P>
<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;Charles G. Tharp</P>
<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;Senior Vice President</P>
<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;Human Resources</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">AGREED TO AND ACCEPTED:</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><U><FONT FACE="CG Times"><P ALIGN="JUSTIFY">By /s/ Kenneth E. Weg</U></FONT><FONT FACE="Arial">__</P>
<P ALIGN="JUSTIFY">KENNETH E. WEG</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U><P>12/18/00 </P>
</U><P ALIGN="JUSTIFY">DATE&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;&#9;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>exhibit21.htm
<TEXT>

<HTML>

<BODY LINK="#0000ff" VLINK="#800080">

<FONT FACE="CG Times"><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="RIGHT">&#9;&#9;&#9;&#9;&#9;&#9;<U>Exhibit 21</P>
</U><P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>2309 Realty Corporation </P>
<P>3130827 CANADA INC. </P>
<P>345 Park Corporation </P>
<P>77 Wilson St., Corp. </P>
<P>A.G. Medical Services, P.A. </P>
<P>Alive &amp; Well, Inc. </P>
<P>Allard Laboratories, Inc. </P>
<P>Allard Labs Acquisition LLC </P>
<P>AMCARE Limited</P>
<P>Apothecon BV </P>
<P>Apothecon Farmaceutica Ltda. </P>
<P>Apothecon, Inc. </P>
<P>Apothecon, S.A. </P>
<P>Astel Laboratoires S.A.R.L. </P>
<P>B-MS GeneRx </P>
<P>B. L. Pharmaceuticals (Proprietary) Limited </P>
<P>Blisa Acquisition LLC </P>
<P>Blisa, Inc. </P>
<P>BMS Holdings </P>
<P>BMS Investco SAS </P>
<P>BMS Music Company</P>
<P>BMS Pharmaceutical Korea Limited </P>
<P>BMS-Generiques SA </P>
<P>BMSF SAS</P>
<P>BMSIC Pharma Handels GmbH &amp; Co. KG </P>
<P>BMSIC Pharma-Handels Verwaltungs GmbH </P>
<P>Boclaro Inc. </P>
<P>Bristol (Iran) S.A. </P>
<P>Bristol Arzneimittel G.m.b.H. </P>
<P>Bristol Caribbean, Inc. </P>
<P>Bristol Foundation </P>
<P>Bristol Iran Private Company Limited </P>
<P>Bristol Laboratories Corporation </P>
<P>Bristol Laboratories Inc. </P>
<P>Bristol Laboratories International, S.A. </P>
<P>Bristol Laboratories Medical Information Systems Inc. </P>
<P>Bristol Pharmaceutical Information Center, S.A. </P>
<P>Bristol Pharmaceuticals K.K.</P>
<P>Bristol-Myers (Bangladesh) Inc. </P>
<P>Bristol-Myers (Japan) Limited </P>
<P>Bristol-Myers (Private) Limited</P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>Bristol-Myers (Zaire) Ltd.</P>
<P>Bristol-Myers Award Superannuation Pty. Ltd.</P>
<P>Bristol-Myers Barceloneta, Inc. </P>
<P>Bristol-Myers Company Limited </P>
<P>Bristol-Myers de Mexico, S. de R. L. de C.V. </P>
<P>Bristol-Myers Lion Ltd. </P>
<P>Bristol-Myers Middle East S.A.L. </P>
<P>Bristol-Myers Nederland Inc. </P>
<P>Bristol-Myers Oncology Therapeutic Network, Inc. </P>
<P>Bristol-Myers Overseas Corporation </P>
<P>Bristol-Myers Overseas Corporation (Guam Branch) </P>
<P>Bristol-Myers Overseas Corporation (Korea - Branch) </P>
<P>Bristol-Myers Pakistan (Pvt.) Limited </P>
<P>Bristol-Myers S.A. </P>
<P>Bristol-Myers Squibb (China) Investment Co., Ltd. </P>
<P>Bristol-Myers Squibb (Hong Kong) Limited</P>
<P>Bristol-Myers Squibb (Israel) Limited</P>
<P>Bristol-Myers Squibb (Malaysia) Sendirian Berhad </P>
<P>Bristol-Myers Squibb (N.Z.) Limited </P>
<P>Bristol-Myers Squibb (Phil.) Inc. </P>
<P>Bristol-Myers Squibb (Proprietary) Limited </P>
<P>Bristol-Myers Squibb (Russia) </P>
<P>Bristol-Myers Squibb (Shanghai) Trading Co. Limited</P>
<P>Bristol-Myers Squibb (Singapore) Pte. Limited </P>
<P>Bristol-Myers Squibb (Taiwan) Ltd. </P>
<P>Bristol-Myers Squibb (Thailand) Ltd. </P>
<P>Bristol-Myers Squibb (West Indies) Ltd. </P>
<P>Bristol-Myers Squibb A.E.B.E. </P>
<P>Bristol-Myers Squibb A.G. </P>
<P>Bristol-Myers Squibb Aktiebolag </P>
<P>Bristol-Myers Squibb Argentina, S.A. </P>
<P>Bristol-Myers Squibb Asia/Pacific, Inc. (Singapore - Branch) </P>
<P>Bristol-Myers Squibb Auslandsbeteiligungs Holding, GmbH </P>
<P>Bristol-Myers Squibb Australia Pty. Ltd. </P>
<P>Bristol-Myers Squibb B.V. </P>
<P>Bristol-Myers Squibb Barceloneta Holdings, L.L.C.</P>
<P>Bristol-Myers Squibb Belgium, S.A. </P>
<P>Bristol-Myers Squibb Brasil, S.A. </P>
<P>Bristol-Myers Squibb Bulgaria EOOD </P>
<P>Bristol-Myers Squibb Business Services Limited </P>
<P>Bristol-Myers Squibb Canada Inc. </P>
<P>Bristol-Myers Squibb Caribbean Company</P>
<P>Bristol-Myers Squibb Caribbean Holdings, L.L.C. </P>
<P>Bristol-Myers Squibb de Colombia S.A. </P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>Bristol-Myers Squibb de Costa Rica, S.A. </P>
<P>Bristol-Myers Squibb de Guatemala, S. A. </P>
<P>Bristol-Myers Squibb de Mexico, S de R.L. de C.V. </P>
<P>Bristol-Myers Squibb de Venezuela, S.A. </P>
<P>Bristol-Myers Squibb Delta Holdings, L.L.C. </P>
<P>Bristol-Myers Squibb Dominicana, S.A. </P>
<P>Bristol-Myers Squibb Ecuador C.A. </P>
<P>Bristol-Myers Squibb Eesti Aktsiaselts</P>
<P>Bristol-Myers Squibb EOOD</P>
<P>Bristol-Myers Squibb Europa PLC </P>
<P>Bristol-Myers Squibb Europe Headquarters SARL </P>
<P>Bristol-Myers Squibb Export SA (Slovak Republic) </P>
<P>Bristol-Myers Squibb Export SA </P>
<P>Bristol-Myers Squibb Farmaceutica Portuguesa Limitada </P>
<P>Bristol-Myers Squibb Finance Ltd.</P>
<P>Bristol-Myers Squibb Foreign Sales Corporation </P>
<P>Bristol-Myers Squibb G.m.b.H. </P>
<P>Bristol-Myers Squibb Ges. m.b.H. </P>
<P>Bristol-Myers Squibb Global Properties Ltd. </P>
<P>Bristol-Myers Squibb Holding Germany GMBH </P>
<P>Bristol-Myers Squibb Holdings B.V. </P>
<P>Bristol-Myers Squibb Holdings Limited </P>
<P>Bristol-Myers Squibb Holdings Limited (Ireland - Branch) </P>
<P>Bristol-Myers Squibb Holdings Limited (Kenya - Branch) </P>
<P>Bristol-Myers Squibb Ilaclari Limited Sirketi </P>
<P>Bristol-Myers Squibb Ilaclari, Inc. </P>
<P>Bristol-Myers Squibb Ilaclari, Inc. (Turkey - Branch) </P>
<P>Bristol-Myers Squibb International Company </P>
<P>Bristol-Myers Squibb International Corporation </P>
<P>Bristol-Myers Squibb International Corporation (Belgium - Branch) </P>
<P>Bristol-Myers Squibb International Corporation (Egypt - Branch) </P>
<P>Bristol-Myers Squibb International Corporation (Spain - Branch) </P>
<P>Bristol-Myers Squibb International Corporation (BMSICII) </P>
<P>Bristol-Myers Squibb International Insurance Company </P>
<P>Bristol-Myers Squibb International Limited </P>
<P>Bristol-Myers Squibb Investco, Inc. </P>
<P>Bristol-Myers Squibb Italia Finance SRL </P>
<P>Bristol-Myers Squibb K.K. </P>
<P>Bristol-Myers Squibb Korea Ltd. </P>
<P>Bristol-Myers Squibb Laboratories Company </P>
<P>Bristol-Myers Squibb Manufacturing </P>
<P>Bristol-Myers Squibb Manufacturing Company </P>
<P>Bristol-Myers Squibb Manufacturing Holdings, L.L.C.</P>
<P>Bristol-Myers Squibb MEA GmbH</P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>Bristol-Myers Squibb MEA GmbH (Saudi Arabia - Branch) </P>
<P>Bristol-Myers Squibb MEA GmbH (Egypt - Branch) </P>
<P>Bristol-Myers Squibb Norway Ltd. </P>
<P>Bristol-Myers Squibb Pakistan (Pvt.) Ltd. </P>
<P>Bristol-Myers Squibb Peru S.A. </P>
<P>Bristol-Myers Squibb Pharmaceuticals Limited (England) </P>
<P>Bristol-Myers Squibb Pharmaceuticals Limited (Ireland) </P>
<P>Bristol-Myers Squibb Products S.A. </P>
<P>Bristol-Myers Squibb Puerto Rico, Inc. </P>
<P>Bristol-Myers Squibb Research Foundation Africa </P>
<P>Bristol-Myers Squibb S.p.A.</P>
<P>Bristol-Myers Squibb Securitization L.P.</P>
<P>Bristol-Myers Squibb Service Ltd. </P>
<P>Bristol-Myers Squibb Slovakia s r.o. </P>
<P>Bristol-Myers Squibb Sp. z o.o. </P>
<P>Bristol-Myers Squibb Spol. s r.o. </P>
<P>Bristol-Myers Squibb Superannuation Plan Pty. Ltd. </P>
<P>Bristol-Myers Squibb UPSA Tunisie</P>
<P>Bristol-Myers Squibb Zentrum uer Forschung Und Fortbildung Im </P>
<P>Gesundheitswesen G.m.b.H. </P>
<P>Bristol-Myers Squibb, S.A. </P>
<P>Cancer Research, Inc. </P>
<P>CJG Partners, L.P. </P>
<P>Clairol (China) Ltd. </P>
<P>Clairol Brazil Ltda.</P>
<P>Clairol GmbH.</P>
<P>Clairol Incorporated </P>
<P>Clairol International S.r.l. </P>
<P>Clairol Limited</P>
<P>Clairol Properties, Inc. </P>
<P>Comercializadora RPM, S. De R.L. De C.V. </P>
<P>Compania Bristol-Myers Squibb de Centro America (El Salvador Branch) </P>
<P>Compania Bristol-Myers Squibb de Centro America (Honduras Branch) </P>
<P>Compania Bristol-Myers Squibb de Centro America (Nicaragua Branch) </P>
<P>Compania Bristol-Myers Squibb de Centro America (Panama Branch) </P>
<P>Convatec Limited </P>
<P>ConvaTec Praha spol. s r.o. </P>
<P>Convatec Spot s r.o. </P>
<P>Convatec Vertriebs G.m.b.H. </P>
<P>Convatec, S.A. </P>
<P>CRBM GIE </P>
<P>Duart Industries, Ltd. </P>
<P>E. R. Squibb &amp; Sons de Venezuela, C.A. </P>
<P>E. R. Squibb &amp; Sons Inter-American (Chile - Branch) </P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST </P>
</FONT><FONT FACE="CG Times" SIZE=2><P>E. R. Squibb &amp; Sons Inter-American Corporation </P>
<P>E. R. Squibb &amp; Sons Inter-American Corporation (Colombia - Branch) </P>
<P>E. R. Squibb &amp; Sons Inter-American Corporation (PRico - Branch) </P>
<P>E. R. Squibb &amp; Sons Limited </P>
<P>E. R. Squibb &amp; Sons, L.L.C. </P>
<P>Elektrochemische Ges.Hirschfelde M.b.H. </P>
<P>ESS Partners, L.P. </P>
<P>EWI Corporation </P>
<P>G.I.E. Centre de Recherche de Biologie Moleculaire </P>
<P>G.I.E. Institut de Recherche Squibb </P>
<P>Grove Insurance Company Ltd. </P>
<P>Grove Limited </P>
<P>Grove Products (Far East) Limited </P>
<P>Grove Products (Far East) Limited (India - Branch) </P>
<P>Heyden Farmaceutica Portugesa Limitada </P>
<P>Iris Acquisition Corp. </P>
<P>JG Partners, L.P. </P>
<P>Kingsdown Medical Consultants Limited </P>
<P>KPMG</P>
<P>Laboratoire Oberlin </P>
<P>Laboratoires Convatec S.A. </P>
<P>Laboratoires Guieu France S.a.r.l. </P>
<P>Laboratoires UPSA, SAS </P>
<P>Lawrence Laboratories </P>
<P>Linson Investments Limited </P>
<P>Linson Pharma Inc. </P>
<P>Listo B.V.</P>
<P>Little Sycamore Limited </P>
<P>Mead Johnson &amp; Company </P>
<P>Mead Johnson (Guangzhou) Ltd. </P>
<P>Mead Johnson (Manufacturing) Jamaica Limited </P>
<P>Mead Johnson A.E.B.E. </P>
<P>Mead Johnson B.V. </P>
<P>Mead Johnson de Mexico, S. de R.L. de C.V. </P>
<P>Mead Johnson Farmaceutica Limitada </P>
<P>Mead Johnson International Limited (Argentine - Branch) </P>
<P>Mead Johnson International Limited (Canada) </P>
<P>Mead Johnson International Limited (Colombia - Branch) </P>
<P>Mead Johnson Jamaica Ltd. </P>
<P>Mead Johnson Limited </P>
<P>Mead Johnson Nutritional GmbH </P>
<P>MEC Subsidiary Corporation </P>
<P>Medical Engineering Corporation </P>
<P>Monarch Crown Corporation </P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>NOVACARE Limited</P>
<P>O.o.o. Bristol-Myers Squibb</P>
<P>O.o.o. Bristol-Myers Squibb Manufacturing</P>
<P>Oncogen Limited Partnership </P>
<P>Oncology Therapeutics Network Automated Technologies, Inc. </P>
<P>Oncology Therapeutics Network Corporation </P>
<P>Oncology Therapeutics Network Joint Venture, L.P. </P>
<P>Osmat S.A. </P>
<P>OTN Funding Corp.</P>
<P>OTN Online, Inc. </P>
<P>OTN Parent Corp. </P>
<P>Oy Bristol-Myers Squibb (Finland) AB </P>
<P>P. T. Squibb Indonesia Tbk</P>
<P>Pharmagen </P>
<P>Pharmavit Praha spol. S.r.o. </P>
<P>Pharmavit Rt. </P>
<P>PRB Partners, L.P. </P>
<P>Princeton Pharmaceuticals, S.A. </P>
<P>Recherche et Propriete Industrielle </P>
<P>Redmond Products de Mexico, S. De R.L. De C.V. </P>
<P>Redmond Products Distributing, Inc. </P>
<P>Redmond Products International, Inc. </P>
<P>Redmond Products, Inc. </P>
<P>Route 22 Real Estate Holding Corporation </P>
<P>RPI Management, Inc. </P>
<P>Salorpharma G.m.b.H. </P>
<P>Sanofi Pharma Bristol-Myers Squibb SNC </P>
<P>Schuppert Meubelen Holten B.V. </P>
<P>Sino-American Shanghai Squibb Pharmaceuticals Limited </P>
<P>Societe Francaise de Complements Alimentaires (S.O.F.C.A.)</P>
<P>Sphinx Holdings Company, Inc. </P>
<P>Squibb (Far East) Limited </P>
<P>Squibb (Far East) Limited (Taiwan - Branch) </P>
<P>Squibb (Nigeria) Limited </P>
<P>Squibb (Thailand) Limited </P>
<P>Squibb ApS </P>
<P>Squibb Convatec Medical Products Co. Ltd. </P>
<P>Squibb Development Limited </P>
<P>Squibb Farmaceutica Portuguesa, Limitada </P>
<P>Squibb Industria Farmaceutica, S.A. </P>
<P>Squibb Manufacturing, Inc. </P>
<P>Squibb Middle East S.A. (Egypt - Branch) </P>
<P>Squibb Middle East S.A. (Jordan - Branch) </P>
<P>Squibb Middle East S.A. (Panama) </P>
</FONT><FONT FACE="CG Times"><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">BRISTOL-MYERS SQUIBB COMPANY</P>
<P ALIGN="CENTER">SUBSIDIARY LIST</P>
</FONT><FONT FACE="CG Times" SIZE=2><P>Squibb Overseas Investments, Inc. </P>
<P>Squibb Pacific Limited </P>
<P>Squibb Pharma G.m.b.H. </P>
<P>Squibb Properties, Inc. </P>
<P>Squibb Surgicare Limited </P>
<P>Squibb-von Heyden G.m.b.H. </P>
<P>Stamford Holdings B.V. </P>
<P>Swords Holdings I, L.L.C. </P>
<P>Swords Holdings II, L.L.C. </P>
<P>Swords Laboratories </P>
<P>T S V Corporation </P>
<P>Tallosa, S.A. </P>
<P>The B-M Group (Proprietary) Limited </P>
<P>Unterstuetzungskasse Bristol-Myers Squibb G.m.b.H.</P>
<P>UPSA CONSEIL</P>
<P>UPSA S.p.a. </P>
<P>Upsamedica LDA </P>
<P>Von Heyden Pharma G.m.b.H. </P>
<P>Wallingford Research, Inc. </P>
<P>Westwood-Intrafin, S.A. </P>
<P>Westwood-Squibb Holdings, Inc. </P>
<P>Westwood-Squibb Pharmaceuticals, Inc. </P>
<P>Zimmer B.V. </P>
<P>Zimmer Caribe, Inc. </P>
<P>Zimmer Chirurgie G.m.b.H. </P>
<P>Zimmer Europe Limited </P>
<P>Zimmer K.K</P>
<P>Zimmer Limited </P>
<P>Zimmer New Zealand Limited </P>
<P>Zimmer of Canada Limited </P>
<P>Zimmer Pte. Ltd. </P>
<P>Zimmer S. A. S.(France) </P>
<P>Zimmer S.A. (Spain) </P>
<P>Zimmer S.R.L. </P>
<P>Zimmer SAS </P>
<P>Zimmer, Inc. </P>
<P>Zimmer - 1 L.L.C.</P>
<P>Zimmer - 2 L.L.C.</P>
<P>Zimmer - 3 L.L.C.</P>
<P>Zimmer - 4 L.L.C.</P>
<P>Zimmer - 5 L.L.C.</P>
<P>Zimmer - 6 L.L.C.</P>
<P ALIGN="JUSTIFY">&#9;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>exhibit23.htm
<TEXT>

<HTML>

<BODY LINK="#0000ff" VLINK="#800080">
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<U><FONT FACE="CG Times"><P ALIGN="RIGHT">Exhibit 23</P></font></u></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<FONT FACE="CG Times">
<P ALIGN="JUSTIFY">&#9;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U><P ALIGN="CENTER">CONSENT OF INDEPENDENT ACCOUNTANTS</P>
</U><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-30856, 33-38411, 33-38587, 33-44788, 333-47403, 33-52691, 33-30756-02, 33-58187, and 333-02873), Form S-4 (No. 333-09519), Form S-3
(Nos. 33-33682, 33-62496 and 333-49227) of Bristol-Myers Squibb Company of our report dated January 24, 2001 relating to the financial statements and the financial statement schedule, which appears in this Form 10-K.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><U>/s/ PricewaterhouseCoopers LLP</U></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
PRICEWATERHOUSECOOPERS LLP<p></P>
<P ALIGN="JUSTIFY">New York, New York</P>
<P ALIGN="JUSTIFY">March 30, 2001</P>
<p></P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>6
<FILENAME>exhibit99.htm
<TEXT>

<HTML>
<BODY>

<FONT FACE="CG Times"><P ALIGN="RIGHT"></P>
<P ALIGN="RIGHT">&#9;<U>Exhibit 99</P>
</U><P ALIGN="JUSTIFY">&#9;</P>
<P ALIGN="JUSTIFY">CAUTIONARY STATEMENT PURSUANT TO PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 - &quot;SAFE HARBOR&quot; FOR FORWARD LOOKING STATEMENTS.</P>
<P ALIGN="JUSTIFY"></P>
</FONT><FONT FACE="CG Times" SIZE=3><P ALIGN="JUSTIFY">This Form 10-K Annual Report, and other written and oral statement that the Company makes from time to time, contain certain &quot;forward-looking&quot; statements&quot; all of which are subject to
risks and uncertainties.  One can identify these forward-looking statements by the fact they use words such as &quot;anticipate&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;project,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;believe&quot;
and others words of similar meaning and expression in connection with any discussion of future operating or financial performance.  One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current
facts. These statements are likely to relate to, among other things, the Company's goals, plans and projections regarding its financial position, results of operations, market position and product development, which are based on current expectations that
involve in
herit risks and uncertainties, including factors that could delay, divert or change any of them in the next several years.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Although it is not possible to predict or identify all factors, they may include the following:</P>

<UL>
<P ALIGN="JUSTIFY"><LI>New government laws and regulations, such as (i) health care reform initiatives in the United States at the state and federal level and in other countries; (ii) changes in the FDA and foreign regulatory approval processes that may
cause delays in approving, or prevent the approval of new products; (iii) tax changes such as the phasing out of tax benefits heretofore available in the United States and certain foreign countries, and (iv) new laws, regulations and judicial decisions
affecting pricing or marketing.</LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Competitive factors, such as (i) new products developed by competitors that have lower prices or superior performance features or which are otherwise competitive with the Company's current products; (ii) generic competition as the
Company's products mature and patents expire on products; (iii) technological advances and patents attained by competitors, and (iv) problems with licensors, suppliers and distributors. </LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Difficulties and delays inherent in product development, manufacturing, and sale, such as (i) products that may appear promising in development may fail to reach market for numerous reasons, including efficacy or safety concerns,
the inability to obtain necessary regulatory approval, and the difficulty or excessive cost to manufacture; (ii) seizure or recall of products; (iii) the failure to obtain, the imposition of limitations on the use of, or loss of patent and other
intellectual property rights, and (iv) manufacturing or distribution problems.  </LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Legal difficulties, any of which can preclude or delay commercialization of products or adversely affect profitability, including (i) patent disputes; (ii) adverse decisions in litigation including the breast implant cases and
other product liability cases; (iii) the inability to obtain adequate insurance with respect to this type of liability; (iv) recalls of pharmaceutical products or forced closing of manufacturing plants; (v) government investigations; (vi) claims asserting
securities law violations, and (vi) environmental matters.</LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Increasing pricing pressures worldwide, including rules and practices of managed care groups and institutional and governmental purchasers, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and
healthcare reform, pharmaceutical reimbursement and pricing in general.</LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Economic factors over which the Company has no control such as changes of business and economic conditions including, but not limited to, changes in interest rates and fluctuation of foreign currency exchange rates.  </LI></P></UL>

<P ALIGN="JUSTIFY"></P>

<UL>
<P ALIGN="JUSTIFY"><LI>Changes in accounting standards promulgated by the Financial Accounting Standards Board, the Securities and Exchange Commission or the American Institute of Certified Public Accountants.</LI></P></UL>

<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">No assurance can be given that any goal or plan set forth in forward looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. The Company
undertakes no obligation to release publicly any revisions to forward looking-statements as a result of future events or developments.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><FONT SIZE=3><P>&nbsp;</P>
</FONT><FONT FACE="CG Times"><P ALIGN="JUSTIFY">&nbsp;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
